

**Jacques E. Bradwejn, MD, FRCPC, ABPN**  
**Faculty of Medicine**  
**University of Ottawa**

Email: jacques.bradwejn@uottawa.ca

**CURRICULUM VITAE**

**Education:**

1974 B.Sc. (Honours) Biochemistry. McGill University, Canada  
1978 M.D. University of Sherbrooke, Canada  
1982 Diploma in Psychiatry, McGill University, Canada

**Internship and Residencies:**

1978-1979 Internship in Internal Medicine, University of Sherbrooke, Canada  
1979-1982 Residency in Psychiatry, Allan Memorial Institute, McGill University, Canada

**Research Fellowships:**

1982-1983 Psychopharmacology, Supervisor Dr Guy Chouinard, Allan Memorial Institute, McGill University, Canada  
1983-1985 FRSQ Fellowship - Neurophysiology and Psychopharmacology, Supervisor Dr. Claude de Montigny, Université de Montréal, Canada

**Executive Education:**

2001- 2004 Wharton Certificate of Professional Development. The Wharton School, University of Pennsylvania, USA  
2001-2006 Ongoing professional development in areas of Conflict Resolution and Mediation, Leadership, Strategic Planning, Board Governance, Human Resources Management at the Royal Ottawa Health Care Group, The Ottawa Hospital and The University of Ottawa, Canada  
2002-2003 Executive Coaching, sponsored by the Faculty of Medicine, University of Ottawa, Canada  
2005 Wharton Executive Coaching Workshop. The Wharton School, University of Pennsylvania, USA  
2005-2008 Wharton Fellows Program member, USA  
2008 Executive Development Seminar for Deans Phase I & II. Association of American Medical Colleges (AAMC)/Harvard Medical School, USA  
2012 Directors Consortium, Stanford Graduate School of Business, Stanford University, Palo Alto, California

**Certifications:**

1982 Fellow of the College of Physicians & Surgeons of Québec (CSPQ)  
1982 Fellow of the Royal College of Physicians & Surgeons of Canada (FRCPC)  
1983 American Board of Psychiatry and Neurology, Certificate #25072

**Licensures:**

Medical Council of Canada Certificate Number: 47422  
Québec Medical Permit Number: 79171  
Ontario Medical License Number: 68519  
Shanghai Medical License, Renji Hospital, Shanghai: 6992

**Academic Appointments:**

1985-1989 Assistant Professor, Department of Psychiatry, Faculty of Medicine, McGill University, Canada  
 1989-1995 Associate Professor, Department of Psychiatry, Faculty of Medicine, McGill University, Canada  
 1995-1998 Professor, Department of Psychiatry, Faculty of Medicine, University of Toronto, Canada  
 1998-2019 Professor, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Canada  
 1998-2006 Chair, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Canada  
 1999- Professor (Adjunct Appointment), Department of Psychiatry, Queen's University  
 2006-2007 Acting Dean, Faculty of Medicine, University of Ottawa, Canada  
 2007-2017 Dean, Faculty of Medicine, University of Ottawa, Canada  
 2011-2019 Professor (Cross-Appointment), Faculty of Education, University of Ottawa  
 2014- Visiting Professor, Shanghai Jiao Tong School of Medicine, Shanghai, China  
 2019- Professor Emeritus, Faculty of Medicine, University of Ottawa  
 2019- Full Professor, Clinical, of Psychiatry, Faculty of Medicine, Université de Montréal

### **Hospital Appointments:**

1982-1984 Assistant Psychiatrist, Royal Victoria Hospital, Montréal, Canada  
 1984-1985 Assistant Psychiatrist, Louis H. Lafontaine Hospital, Montréal, Canada  
 1985-1995 Psychiatrist, St Mary's Hospital, Montréal, Canada  
 1995-1998 Psychiatrist, Clarke Institute of Psychiatry, Toronto, Canada  
 1998- Psychiatrist, Royal Ottawa Health Care Group, Ottawa, Canada  
 1999-2006 Psychiatrist, The Ottawa Hospital, Ottawa, Canada  
 2018- Psychiatrist, Renji Hospital, Shanghai, China

### **Major Administrative Responsibilities (selected):**

1984-1985 Director, Affective Disorders Clinic, Louis H. Lafontaine Hospital, Montréal, Canada  
 1985-1995 Director, Division of Psychopharmacology, St Mary's Hospital, Montréal, Canada  
 1995-1998 Head, Psychobiology and Clinical Trials Research Unit in Anxiety, Clarke Institute of Psychiatry, Toronto, Canada  
 1998-2006 Chair, Department of Psychiatry, Faculty of Medicine, University of Ottawa, Canada  
 1998-2006 Psychiatrist-in-Chief, Royal Ottawa Health Care Group, Ottawa, Canada  
 1999-2006 Head of Psychiatry, The Ottawa Hospital, Ottawa, Canada  
 2006-2007 Acting Dean, Faculty of Medicine, University of Ottawa, Canada  
 2007-2017 Dean, Faculty of Medicine, University of Ottawa, Canada  
 2015- Founding Dean, Ottawa Shanghai Joint School of Medicine  
 2017- Presidential Advisor, China Partnerships, University of Ottawa

### **Awards and Honours:**

1983-1985 Fellowship, Fonds de la Recherche en Santé du Québec (FRSQ), Québec, Canada  
 1991 Best Teacher Award, McGill Psychiatry Residents, Montréal, Canada  
 1991 Young Investigator Award, Canadian College of Neuropsychopharmacology (CCNP)  
 1994 Educational Prize from the Hospital Association of Québec for the Video: "Trouble panique: trouble cache ", Canada  
 1996 Nomination, Best Teacher, Resident Association, University of Toronto, Canada  
 1997 Janssen-Ortho Award for Innovation in Research in Neuropsychopharmacology, Canadian College of Neuropsychopharmacology (CCNP)  
 2015-2020 Foreign Expert, Overseas Master Program, State Administration of Foreign Experts Affairs, People Republic of China  
 2105 Doctorat Honoris Causa (Honorary Doctorate), université Claude Bernard Lyon 1, France  
 2019- Certification, High Level Talents (Category A). People Republic of China

### **Teaching Experience (Selected):**

1982-1984 Weekly seminars on psychiatric diagnosis and psychopharmacology for residents III and IV. Allan Memorial Institute, McGill University

1984-1985 Supervisor, Senior resident rotation in psychopharmacology, Louis H. Lafontaine Hospital, Université de Montréal, Psychopharmacology lecture to senior residents, Université de Montréal, Department of Psychiatry

1985-1995 Supervisor, senior resident rotation (R III, R IV) in psychopharmacology research, St. Mary's Hospital, McGill University

1985-1995 Teaching to medical students, interns and residents, McGill University, Psychopharmacology supervision, St. Mary's Hospital

1988-1995 Supervisor, Master's Program in Psychiatry, McGill University

1989-1994 Block Chairman, Diploma Course in Psychiatry, McGill University. Block F: Psychopharmacology and Biological Psychiatry

1992-1995 Supervisor, Research Fellowships in Psychiatry, McGill University

1995-1998 Supervisor, Research Residents, Fellows and PhD Candidates, University of Toronto

1998-2006 Supervisor, Research Residents and Fellows, University of Ottawa

1998-2007 Lecturer, Annual Review Course in Psychiatry, University of Ottawa

### **Major Hospital Committee Assignments (Selected):**

1985-1988 Member, St. Mary's Hospital Research Committee

1986-1995 Member, Executive Committee, Department of Psychiatry, St. Mary's Hospital

1988-1994 Chairman, St. Mary's Hospital Research Committee

1988-1995 Member, St. Mary's Hospital Research Ethics Committee

1995-1997 Member, Research Advisory Committee, Clarke Institute of Psychiatry

1995-1997 Chairman, Pharmacy and Therapeutics Committee, Clarke Institute of Psychiatry

1998-2006 Member, Board of Trustees, Royal Ottawa Health Care Group

1998-2006 Member, Program Committee of the Board, Royal Ottawa Health Care Group

1998-2005 Member, Management Committee, Royal Ottawa Health Care

1998-2006 Member, Executive of the Associates-in-Psychiatry, Royal Ottawa Health Care Group

1998-2006 Member, Foundation Board, Royal Ottawa Health Care Group

2000-2006 Chair, Medical Advisory Committee, Royal Ottawa Health Care Group

2000-2006 Member, Senior Management Team, The Ottawa Hospital

2000-2006 Member, Medical Advisory Committee, The Ottawa Hospital

2000-2006 Member, Executive Medical Advisory Committee, The Ottawa Hospital

2000-2006 Member, New Development Committee (as Executive Committee Board Member, Royal Ottawa Health Care Group, new hospital building project (P3 - Private-Public Partnership) \$123 million

2003-2005 Member, Clinical Priorities Setting Committee, The Ottawa Hospital

2004 Member, Selection Committee for the CEO position of the Royal Ottawa Health Care Group

2005-2006 Co-Chair, Leadership Team, Royal Ottawa Health Care Group

2006- Member, Board of Trustees, Association of Faculties of Medicine of Canada

2006- Member, Council of Ontario Faculties of Medicine

2009- Chair, Nominating Committee of the Board of Trustees, Association of Faculties of Medicine of Canada

2006- Member, Board of Trustees, The Ottawa Hospital

2006- Member, Resource Committee of the Board of Trustees, The Ottawa Hospital

2006- Member, Board of Trustees, The Ottawa Health Research Institute

2008- Member, Board of Trustees, Children Hospital of Eastern Ontario

2009- Chair, Governance Committee of the Board of Trustees, Association of Faculties of Medicine of Canada

2010- Co-Chair, Education and Research Committee of the Board of Trustees, The Ottawa Hospital

### **Major University Committee Assignments (Selected):**

1984-1986	Member, Task force on psychiatric curriculum for medical students, Faculty of Medicine, McGill University
1985-1989	Member, McGill University Coordinating Committee for Research in Psychiatry
1985-1990	Member, McGill University Research Training Building Space Committee
1986-1994	Member, Psychiatry Research Day Committee, McGill University
1989-1994	Chairman, McGill University Coordinating Committee for Research in Psychiatry
1989-1994	Member, McGill University Management Committee of the Department of Psychiatry
1998	Member, Clinical Chairs' Executive, Faculty of Medicine, University of Ottawa
1998-2006	Member, Advisory Board, Faculty of Medicine, University of Ottawa
1998-2006	Member, Finance Committee, Faculty of Medicine, University of Ottawa
2000	Member of Selection Committee for the Chair of the Division of Palliative Care, 2002 Member of the Selection Committee for the CEO of the Institute of Mental Health Research
2003	Member of the Selection Committee for the holder of the Endowed Chair of Mood Disorder Research, University of Ottawa
2002-2005	Member, "Setting Directions" strategic directions Committee, Faculty of Medicine, University of Ottawa
2004-2006	Member of the Selection Committee for the Division of Neurology
2005-2006	Member, Board of Governors, Alternate Funding Plan, Royal Ottawa Health Care Group Academic Medical Organization (ROHCGAMO)
2005-2006	Member, Alternate Funding Plan Committee, The Ottawa Hospital Department of Psychiatry
2006-2008	Peer Elected Chair Member, Board of Governors, The Ottawa Hospital Academic Medical Organization (TOHAMO)
2006-	Member, Senate, University of Ottawa
2006-	Chair, Advisory Board, Faculty of Medicine, University of Ottawa
2006-	Chair, Faculty Council, Faculty of Medicine, University of Ottawa
2006-	Chair, Leadership Team, Faculty of Medicine, University of Ottawa
2009-2011	Member, Comité Directeur à la planification stratégique (Task Force, Strategic Planning), University of Ottawa
2010-2011	Member, Governance Review, University of Ottawa
2010-2011	Chair-Elect, College des Doyens (Dean's College), University of Ottawa
2011-2012	Chair, College des Doyens (Dean's College), University of Ottawa
2011-	Member, Communication Committee, University of Ottawa
2011-2012	Member, ad hoc Committee on University Research Chairs

### **Major Government Committee Assignments (Selected):**

2000-2003	Member, Champlain District Mental Health Implementation Task Force, appointed by the Minister of Health and Long Term Care of the province of Ontario, Canada
2000-2003	Member, Executive Committee, Champlain District Mental Health Implementation Task Force, Ministry of Health and Long Term Care of the province of Ontario, Canada
2000-2002	Chair, Human Resources Sub-Committee, Mental Health Implementation Task Force, Ministry of Health and Long Term Care of Ontario, Canada
2000-2003	Member, East Region Ministry of Health Long Term Care Integration Advisory Group, Ministry of Health and Long Term Care of Ontario, Canada
2003-2006	Chair, Mental Health Bed Utilization Group for the Champlain District of Ontario, Canada
2004	Member, Advisory Board, Ontario Center of Excellence, Canada
2005	Member, Federal Advisory Commission on Chronic Illness, Canada
2004-2006	Member, Advisory Committee, Ontario Center of Excellence for Child and Youth, Canada
2005-2006	Member, Champlain Mental Health Network Mental Health

2006- Member, Council of Ontario Faculties of Medicine, Canada

**Major Granting Agency Committee Assignments (Selected):**

1990-1992 Member, Medical Research Council of Canada, MRC Fellowship-Clinician Committee  
1992 Member, Comité d'Évaluation, Réseau de Santé Mentale du Fond de la Recherche en Santé du Québec  
1992-1993 President, Grant Evaluation Committee, Pharmacologie, Pharmaceutique, Équipe FRSQ  
1993-1994 President, Grant Evaluation Committee, Pharmacologie et Pharmaco-Épidémiologie, FRSQ  
1995-1996 Member, Clinical Trials Committee, Medical Research Council of Canada  
2000-2002 Canadian Institute of Health Research, Internal Reviewer, University-Industry Committee  
2001 Member, Canadian Institute of Health Research, Junior Investigation Awards  
2010 Member, Programme des projets de développement stratégique innovants du FRSQ

**Major Granting Agency External Reviewer Assignments (Selected):**

1985- Ontario Mental Health Foundation  
1987- Fond de la Recherche en Santé du Québec  
1987 British Columbia Lung Association  
1988-1991 Association des Médecins Psychiatres du Québec  
1990- Canadian Psychiatric Research Foundation  
1990-2000 Medical Research Council of Canada  
2000- Canadian Institute of Health Research

**Advisory assignments (Selected):**

1990 Consultant, CNS Division, Health Protection Branch, Health and Welfare Canada  
1997-2000 Scientific Advisor for the Office of Alternative Medicine, National Institute of Health, USA  
1997-2000 Expert Advisor for the National Institute of Health, USA. Sponsored clinical trial on the efficacy of Hypericum in major depression, National Institute of Mental Health, USA. Advisor, Office for Alternative Medicine, National Institute of Health, Washington, USA  
2006-2009 Member, Advisory Board, Institute of Neurosciences, Mental Health and Addiction, Canadian Institute of Health Research  
2018- Senior Advisor, Consultation-Liaison Psychosomatic Medicine, Academic Group of the Chinese Society of Psychosomatic Medicine

**Other Organizations (selected):**

1991-1995 Founding Member and President, Association Troubles Anxieux Québec (ATAQ)  
1992-1994 Councillor, Canadian College of Neuropsychopharmacology  
1992-1995 Member, Executive Committee, Psychopharmacology Section, Canadian Psychiatric Association  
1994-1996 Vice President, Canadian College of Neuropsychopharmacology  
1998- Founding Member of ONTRAC (Ontario Network for the Treatment and Research of Anxiety Conditions)  
2000 Member, Program Committee, 2000 Gordon Research Conference on Neuronal Cholecystokinin, Queens College, Oxford, UK  
1996-1998 President Elect, Canadian College of Neuropsychopharmacology (CCNP)  
1998-2000 President, Canadian College of Neuropsychopharmacology (CCNP)  
2000-2002 Past President, Canadian College of Neuropsychopharmacology (CCNP)  
2000 Chief Surveyor for a department of Psychiatry, The Royal College of Physicians and Surgeons of Canada  
2004-2007 Chair, Association of Chairs of Psychiatry of Canada (ACPC)  
2008 Chair of Survey Team for a Faculty of Medicine, Committee on Accreditation of Canadian Medical Schools (CACMS) and the Liaison Committee on Medical Education (LCME)

2010-2012 Chair, Governance Committee, Association of Faculties of Medicine of Canada (AFMC)  
 2011-2012 Chair-Elect, Board of Directors, Association of Faculties of Medicine of Canada (AFMC)  
 2012-2014 Chair, Board of Directors, Association of Faculties of Medicine of Canada (AFMC)  
 2014- Past Chair, Board of Directors, Association of Faculties of Medicine of Canada (AFMC)  
 2014 Chair of Survey Team for a Faculty of Medicine, Committee on Accreditation of Canadian Medical Schools (CACMS) and the Liaison Committee on Medical Education (LCME)

### **Editorial Boards:**

1988-1990 Member, Editorial Committee of the Canadian Medical Association for the publication of the first edition of the CMA Drug Compendium, (January 1990). Responsible for psychopharmacology.  
 1990-1995 Member, Editorial Advisory Board, Canadian Review of Affective Disorders  
 1993- Associate Editor, Anxiety  
 1992-2000 Associate Editor, Journal of Psychiatry and Neurosciences  
 1998-2002 Associate Editor, Neuropeptide  
 2011- Member, Comité scientifique international, Annales Médico-Psychologiques

### **Ad Hoc Reviewer:**

1989- Reviewer, Canadian Journal of Psychiatry  
 1989 Reviewer, La Lettre Médicale  
 1990- Reviewer, Progress in Neuropsychopharmacology and Biological Psychiatry  
 1990- Reviewer, Journal of Psychiatry and Neurosciences  
 1992- Reviewer, Psychiatry Research  
 1992- Reviewer, Biological Psychiatry  
 1994 Reviewer, M/S medicine science  
 1995 Reviewer, Journal of Clinical Psychopharmacology

### **Membership in Professional Societies:**

1985-2004 Member, Society for Neuroscience  
 1986- Member, Canadian College of Neuropsychopharmacology (CCNP)  
 1986- Member, Canadian Psychiatry Association  
 1986 Member, New York Academy of Sciences  
 1988-2003 Member, International Society of Psychoneuroendocrinology

### **Major Research Interests:**

Psychobiology and treatment of anxiety disorders.  
 The role of CCK in the neurobiology of panic disorder.  
 Novel psychotherapeutic approaches for anxiety and mood disorders.

### **Peer-Reviewed Funding (selected, excluding supervisor roles):**

1983-1985 Bradwejn, J. Fellowship Award, - Fonds de la Recherche en Santé du Québec. \$54,000  
 1989-1991 Bradwejn, J. Medical Research Council of Canada: The Role of Cholecystokinin in Specific Psychiatric Disorders (MA-10502). \$70,000  
 1990-1992 Bradwejn J. Medical Research Council of Canada: Cholecystokinin-Tetrapeptide as a Provocation Agent for Research in Panic Disorders (MA-11006). \$67,680  
 1992-1994 Boulenger JP, Bradwejn J, Jolicoeur F, Palmour R. Fonds de la Recherche en Santé du Québec: Multidisciplinary Research Team in Anxiety. \$190,600  
 1994-1996 Bradwejn J, Boulenger J. Fonds de la Recherche en Santé du Québec: Création et coordination d'un réseau anxieux. \$100,000  
 1995-1996 Bradwejn J and Bichet D. Medical Research Council of Canada: The role of the B-adrenergic system in CCK-4-induced panic attacks (MA-12849). \$81,000

- 1995-1999 Vaccarino F, Baker G, Bradwejn J, Gutkowska J, Kennedy S, Martin I, Palmour R. Medical Research Council of Canada: Cholecystokinin and anxiety: Neurobiological and behavioural characterization (GR-13306). \$107,564/year
- 1995-1999 Bradwejn J, Kennedy S, Gutkowska J, Palmour R, Vaccarino F. Medical Research Council of Canada: Cholecystokinin and anxiety: neurobiological and behavioural characterization, Project 1: clinical studies (GR-13306). \$207,346/year
- 1995-1996 Flint A, Bradwejn J, Vaccarino J. The Research Institute of the Queen Elizabeth Hospital. The effects of aging on cholecystokinin-induced panic. \$62,000
- 1996-1997 Flint A, Bradwejn J, Vaccarino F, Koszycki D. The Research Institute of the Queen Elizabeth Hospital: The effects of aging on the cholecystokinin system. \$103, 558
- 1996-1997 Bradwejn J, Caille G. Medical Research Council of Canada-Pharmaceutical Manufacturers Association of Canada Health Program: The role of 5HT3 receptors in CCK-4 panic. (PA-13595). \$180,640
- 1999-2002 Bradwejn J, Koszycki D, Segal Z., Canadian Institute of Health Research, Pharmaceutical Manufacturers Association of Canada. Sertraline vs. Self-Administered CBT in Panic Disorder. \$540, 975 (Total with Industry matching: \$3,130,000.)
- 2000 Pappas B., Anisman H, Ravindran A, Merali Z., Bradwejn J., Koszycki D. Canadian Foundation for Innovation. Center for Behavioural Sciences, Center for the Behavioral, Molecular and Clinical Study of Neuronal Dysfunction: Carleton Institute of Neuroscience, Royal Ottawa Hospital, University of Ottawa. \$665,576
- 2001-2004 Macciardi F., Bradwejn J, Kennedy, J., Koszycki D. Canadian Institutes of Health Research. Genetic Factors in Panic Disorder. \$388,938
- 2003-2005 Koszycki D, Bradwejn J., Canadian Institutes of Health Research, CCKB Receptor Polymorphism and Vulnerability to CCK-4 induced Panic Attacks in Healthy Subjects. \$141,364
- 2004-2005 Koszycki D, Bradwejn J, Flament M. Children at risk for panic disorder. University of Ottawa Medical Research Fund. \$ 33,793
- 2004-2005 Bradwejn J, Koszycki D, Shlik J. Randomized trial on the efficacy of cognitive behaviour therapy and mindfulness meditation in generalized social anxiety disorder: A pilot study. University of Ottawa Medical Research Fund. \$34,863
- 2004-2005 Shlik J, Koszycki D, Bradwejn J, Albert P. Clinical and biogenetic characteristics of treatment resistance in anxiety disorders. University of Ottawa Medical Research fund. \$29, 999
- 2004-2006 Swenson R, Busing N, Mercer J, Bradwejn J, Kates N. C.T. Lamont Primary Health Care Research Centre Grants: Primary Health Care Transition Fund. Shared Mental Health Care Linking General Hospital Acute Care Mental Health Services with Comprehensive Family Medicine Groups. \$760,000
- 2004-2008 Koszycki D, Bradwejn J, Flament M. Children at risk for panic disorder. Canadian Institutes of Health Research. \$214,509
- 2005-2006 Koszycki D, Bradwejn J, Bisslerbe J-C, Blier P, Antochi S. Randomized controlled trial on the efficacy of interpersonal psychotherapy in depressed women undergoing infertility treatment. University Medical Research Fund. \$34,069
- 2007-2008 Yang Q (PI), Co-Is in alphabetical order: Bradwejn J, Fergusson D, Koren G, Walker MC, Wen S. Canadian Institutes of Health Research. Perinatal outcomes in pregnancy women treated with antidepressants. \$71,564
- 2008-2009 Balfour D, Cameron B (PIs), Co-Is among 20 Co-Is. Canadian Behavioural Medicine Research Training Program in HIV. \$5000
- 2008-2013 Koszycki D (PI), Co-Is in alphabetic order: Bradwejn J, Flament M, Gow R, Merali Z, Schneider B, Taljaard M. Canadian Institutes of Health Research. Children at Risk for Panic Disorder. \$642,015
- 2015-2019 Koszycki D (PI), Co-Is in alphabetic order: Bradwejn J, Grimes D, Taljaard M, Tasca G. Canadian Institutes of Health Research. Interpersonal Psychotherapy with Depressed Patients with

Parkinson's Disease. \$360,456.

## Publications:

**Google Scholar citations (all time): 7524, h-index: 46**

1. FONTAINE R, **BRADWEJN J** (1981). The effects of benzodiazepines. Letter, Am J Psychiatry, 138: 536.
2. CHOUINARD G, BOISVERT D, **BRADWEJN J** (1982). Tardive dyskinesia in a non-psychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J, 126: 821-822.
3. CHOUINARD G, **BRADWEJN J** (1982). Reversible and irreversible tardive dyskinesia: A case report. Am J Psychiatry, 139(3): 360-362.
4. CHOUINARD G, CREESE I, BOISVERT D, ANNABLE L, **BRADWEJN J**, JONES B (1982). High neuroleptic plasma levels in patients manifesting super-sensitivity psychosis. Biol Psychiatry, 7 (7): 849-852.
5. CHOUINARD G, YOUNG SN, **BRADWEJN J**, ANNABLE L (1983). Tryptophan in the treatment of depression and mania. In: van Praag and Mendlewicz (Eds.): Adv Biol Psychiatry, Vol. 10, 47-66. Basel: Karger.
6. CHOUINARD G, **BRADWEJN J**, ANNABLE L, JONES BD, ROSS-CHOUINARD A (1984). Withdrawal symptoms after long-term treatment with low potency neuroleptics. J Clin Psychiatry, 45 (12): 500-502.
7. CHOUINARD G, ANNABLE L, **BRADWEJN J** (1984). An early phase II clinical trial of tomoxetine (L 139603) in the treatment of newly admitted depressed patients. Psychopharmacology, 83: 126-128, 1984.
8. CHOUINARD G, ANNABLE L, CAMPBELL W, BOISVERT D, **BRADWEJN J** (1984). A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacology Bull, 20: 108-109.
9. **BRADWEJN J**, DE MONTIGNY C (1984). Benzodiazepines antagonize cholecystokinin- induced activation of rat hippocampal neurons. Nature, 312: 363-364.
10. **BRADWEJN J**, DOWDALL M, INY L (1985). Meditation and psychotherapy, a rationale for the integration of dynamic psychotherapy, the relaxation response and mindfulness meditation. Letter, Am J Psychiatry, 142 (10): 1226-1227.
11. CHOUINARD G, ANNABLE L, **BRADWEJN J**, LABONTE A, JONES B, MERCIER P, BELANGER MC (1985). An early phase II clinical trial with follow-up of tomoxetine (L 139603) in the treatment of newly admitted depressed patients. Psychopharmacology Bull, 21: 73-76.
12. **BRADWEJN J**, DE MONTIGNY C (1985). Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: A microiontophoretic study in the rat. Eur J Pharmacology, 112: 415-418.
13. **BRADWEJN J**, DE MONTIGNY C (1985). Antagonism of cholecystokinin-induced activation by benzodiazepine receptor agonists: Microiontophoretic studies in the rat hippocampus. N.Y. Acad Sci, 448: 575-580.
14. METERISSIAN G, **BRADWEJN J** (1989). Adequate trials of pharmacotherapy. Letter, Am. J. Psychiatry, 146 (4): 562.
15. KARKANIAS CD, BLOCK GA, REINES S, **BRADWEJN J** (1989). Neurobiology of panic disorder. Letter, Am J Psychiatry, 146 (10): 1357.
16. **BRADWEJN, J** (1989). Depression: Pharmacological treatment. Psychiat J Univ Ottawa, 14: 372-374.
17. METERISSIAN G, **BRADWEJN J** (1989). Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacology, 9: 334-339. (R.D. Jones Award of the Canadian Psychiatric Association, 1989)



18. **BRADWEJN J, KOSZYCKI D, METERISSIAN G (1990).** Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry, 35: 83-85.
19. **BRADWEJN J (1990).** Fear and Phobias 2: Treatments and Variables Affecting Course and Outcome. Iver Hand, Hans- Ulrich Wittchen (editors). Springer-Verlag, Berlin Heidelberg, 1988. Review, Can J Psychiatry, 35: 454-455.
20. SHRIQUI C, **BRADWEJN J, JONES B, BLANCHARD A. (1990).** Alpha-tocopherol in the treatment of tardive dyskinesia. Movement Disorders, 5 (suppl 1): 58.
21. **BRADWEJN J, METERISSIAN G (1990).** Adequacy of pharmacological treatment. Letter, Am J Psychiatry, 147: 953-954.
22. SHRIQUI C, **BRADWEJN J, JONES BD (1990).** Tardive dyskinesia: Legal and preventative aspects. Can J Psychiatry, 35: 576-580.
23. **BRADWEJN J, SHRIQUI C, KOSZYCKI D (1990).** Double blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacology, 10: 403-408. *Selected for review in the section on Psychopharmacology of the "Year Book of Psychiatry And Applied Mental Health 1992" (Mosby Yearbook), pp.253-254, 1992.*
24. BOURIN M, **BRADWEJN J (1991).** Hypothèses biochimiques de l'action des antidépresseurs. Psychologie Médicale, 22: 1519-1522.
25. **BRADWEJN J, KOSZYCKI D, PAYEUR R (1991).** CCK-4 and irritable bowel syndrome. Letter, Am J Psychiatry, 148: 277-278.
26. **BRADWEJN J, KOSZYCKI D (1991).** Comparison of CO<sub>2</sub>-induced panic attacks with cholecystokinin-induced panic attacks in panic disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 15: 237-239.
27. BOURIN M, **BRADWEJN J, COUETOUX-DUTERTRE A (1991).** Neurobiologie de l'anxiété et mode d'action des anxiolytiques. Psychiatrie Française, 22: 51-73.
28. BOURIN M, **BRADWEJN J (1991).** Aspects cliniques et neurobiologiques de l'administration à long terme des psychotropes. Can J Psychiatry, 36: 260-264.
29. **BRADWEJN J, KOSZYCKI D, SHRIQUI C (1991).** Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: clinical and behavioral results. Arch Gen Psychiatry, 48: 603-610 (*Selected for review in the section on Psychopharmacology of the "Year Book of Psychiatry And Applied Mental Health 1993" (Mosby Yearbook), pp. 47-48, 1993.*)
30. KOSZYCKI D, **BRADWEJN J, BOURIN M (1991).** Comparison of the effects of cholecystokinin and carbon dioxide in healthy volunteers. Eur Neuropharmacology, 1: 137-141.
31. HASCOET M, BOURIN M, **BRADWEJN J (1991).** Behavioral models in mice, implication of the alpha noradrenergic system. Progress in Neuropsychopharmacology and Biological Psychiatry, 15: 825-840.
32. **BRADWEJN J, KOSZYCKI D, BOURIN M (1991).** Dose ranging study of the effect of CCK-4 in healthy volunteers. J Psychiatry & Neuroscience, 16: 91-95.
33. KENNEDY S, **BRADWEJN J, KUSALIC M.(1991).** Pharmacological treatment of bipolar depression. International Clinical Psychopharmacology, 6: suppl. 1, 53-72.
34. BOURIN M, **BRADWEJN J, KOSZYCKI D (1991).** Cholecystokinin and panic disorders. Eur Neuropsychopharmacology 1: 389-391.
35. BOURIN M, COLOMBEL MC, MALINGE M, **BRADWEJN J (1991).** Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry & Neuroscience, 16: 199-203.
36. BOURIN M, **BRADWEJN J, KOSZYCKI D (1991).** La cholécystokinine est-elle le support biologique des attaques de panique? L'Encéphale, 17: 475-479.

37. SHRIQUI C, **BRADWEJN J**, JONES B, ANNABLE L (1991). Alpha-tocopherol in the treatment of tardive dyskinesia. Am J Psychiatry, 149: 391-393.
38. BOURIN M, LE MELLEDO JM, **BRADWEJN J** (1991). Dosage de la concentration plasmatique d'un antidépresseur dans le cadre de la surveillance du traitement d'un déprimé. Synapse, No spécial, décembre, 74-81.
39. **BRADWEJN J**, KOSZYCKI D, COUETOUX-DUTERTRE, BOURIN M, PALMOUR R, ERVIN F (1992). The cholecystokinin hypothesis of anxiety and panic: a review. J Psychopharmacology 6: 345-351.
40. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BOURIN M, BORTHWICK H (1992). Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry, 149: 962-964.
41. BOURIN M, HASCOET M, MANSOURI B, COLOMBEL MC, **BRADWEJN J** (1992). Comparison of behavioral effects of single and repeated administration of four benzodiazepines in three mice behavioral models. J Psychiatry & Neuroscience, 17: 72-77.
42. BOURIN M, **BRADWEJN J** (1992). Les antagonistes de la cholecystokinine: anxiolytiques de demain? Path Biol, 40: n.3, 215-217.
43. BOURIN M, **BRADWEJN J** (1992). Gli antagonisti della colecistokinina: ansiolitici de domani? Psichiatria e Medicina, 6, 2: 23-25.
44. BOURIN M, **BRADWEJN J** (1992). Pharmacologie clinique des benzodiazépines hypnotiques. La Lettre du pharmacologue, 6: 90-93.
45. BOURIN M, **BRADWEJN J** (1992). Pharmacologie du stress. Psychologie Médicale, 24: 3-4.
46. BOURIN M, LE MELLEDO J M, **BRADWEJN J** (1992). Pharmacologie expérimentale et clinique des psychostimulants. Neuropsychopharmacologie, Masson Eds.
47. **BRADWEJN J**, KOSZYCKI D, COUETOUX-DUTERTRE, ANNABLE L (1992). A dose-ranging study of the behavioral & cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol Psychiatry, 32: 903-912.
48. BOURIN M, **BRADWEJN J** (1993). Les antagonistes de la cholécystokinine: anxiolytiques ou antipsychotiques? Lettre du Pharmacologue, 7: 41-43.
49. **BRADWEJN J** (1993). Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Can J Psychiatry, 38: S109-S113.
50. HARRO J, VASAR E, **BRADWEJN J** (1993). Cholecystokinin in animal and human research on anxiety. Trends in Pharmacological Sciences, 14: 244-249.
51. **BRADWEJN J** (1993). Neurobiological investigations on the role of cholecystokinin in panic disorder. J Psychiatry & Neuroscience 18: 178-188.
52. KUSALIC M, ENGELSMANN F, **BRADWEJN J** (1993). Thyroid functioning during treatment for depression. J Psychiatry & Neuroscience, 18: 260-263.
53. LE MELLEDO J-M, **BRADWEJN J** (1993). Les nouveaux développements dans la psychopharmacologie des troubles anxieux. Le Clinicien, 8: 73-86.
54. BOURIN M, **BRADWEJN J** (1993). Le basi biochimiche dei farmaci anti-stress. Psichiatria & Medicina, 3: 21-23.
55. PAYEUR R, NIXON MK, BOURIN M, **BRADWEJN J**, LEGRAND ML (1993). The potential role of cholecystokinin in schizophrenia: a review and update. Eur Psychiatry, 8: 67-78.
56. KOSZYCKI D, COX B, **BRADWEJN J** (1993). Anxiety Sensitivity and Response to Cholecystokinin Tetrapeptide in Healthy Volunteers. Am J Psychiatry, 150: 1881-1883. (Selected for review in the section on Clinical Psychiatry of the "Year Book of Psychiatry and Applied Mental Health 1995" (Mosby Yearbook), pp. 304, 1995.)

57. CHOUINARD G, SAXENA B, NAIR NPV, KUTCHER SP, BAKISH D, **BRADWEJN J**, KENNEDY S, SHARMA VS, REMICK RE, KUKHA-MAHAMAD SA, BEAUCLAIR L, SNAITH J, D'SOUZA J (1993). Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clinical Neuropsychopharmacology, 16: 551-554.
58. BOURIN M, **BRADWEJN J**, VASAR E, PALMOUR R (1993). CCK provocation as a research tool in panic disorder. Eur Neuropsychopharmacology, 3: 253-256.
59. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, PARADIS M, BOURIN M (1994). Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology, 114: 257-261.
60. **BRADWEJN J**, KOSZYCKI D (1994). Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry, 151: 261-263. (Selected for review in the section on *Biological Psychiatry of the "Year Book of Psychiatry and Applied Mental Health 1993" (Mosby Yearbook)*, pp. 426-427, 1995.)
61. VASAR A, LANG A, HARRO J, KUKS S, VOLKE V, SIHVER S., BOURIN M, **BRADWEJN J**, MANNISTO P (1994). Subdiaphragmatic vagotomy does not prevent the antiexploratory effect of caerulein in the elevated plus-maze. Neuropeptides, 26: 39-45.
62. **BRADWEJN J**, KOSZYCKI D (1994). The cholecystokinin hypothesis of panic disorder. NY Acad Sciences, 713: 273-282.
63. MANNISTO PT, LANG A, HARRO J, PEURANEN E, **BRADWEJN J**, VASAR E (1994). Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn-Smiedeberg's Arch Pharmacology, 349: 478-484.
64. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, ANNABLE L (1994). The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry, 51: 486-493. (Selected for review in the section on *Psychopharmacology of the "Year Book of Psychiatry and Applied Mental Health 1996 (Mosby Yearbook)*, pp.475-476.)
65. VASAR E, LANG A, HARRO J, BOURIN M, **BRADWEJN J** (1994). Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology, 33: 729-735.
66. CHOUINARD G, SAXENA BM, NAIR NPV, KUTCHER SP, BAKISH D, **BRADWEJN J**, KENNEDY SH, SHARMA V, REMICK RA, KUKHA-MOHAMAD SA, BELANGER MC, SNAITH J, BEAUCLAIR L, POHLMANN H, D'SOUZA J (1994). A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor in the treatment of major depression. J Affective Disorders, 32: 105-114.
67. LANG A, SOOSAAR A, KOKS S, VOLKE V, BOURIN M, **BRADWEJN J**, VASAR E (1994). Pharmacological Comparison of Antipsychotic Drugs and -Antagonists in Rodents. Pharmacology and Therapeutics, 75: 222-227.
68. BOULENGER JP, CADIEUX A, **BRADWEJN J**, JERABEK I, JOLICOEUR F, LAVALLÉE YJ (1994). Neuropeptide Y plasma concentrations in panic disorders and CCK-4-induced panic attacks. Canada. Physiol. Pharmacol., 72 (suppl. 1): 411.
69. SAFADI G, **BRADWEJN J** (1995). Relationship of panic disorder to posttraumatic stress disorder (letter). Arch Gen Psychiatry, 52: 76-77.
70. **BRADWEJN J**, KOSZYCKI D, PARADIS M, REECE P, HINTON J, SEDMAN R (1995). The effects of CI-988 on CCK-4-induced panic symptoms in healthy volunteers. Biol Psychiatry, 38: 742-746.
71. LANG A, VASAR E, HARRO J, SOOSAR A, KOKS S, VOLKE V, ORELAND L, BOURIN M, **BRADWEJN J**, MANNISTO P (1995). Role of N-Methyl-D-Aspartic Acid and cholecystokinin in apomorphine-induced

- aggressive behavior in rats. Naunyn-Schmedieberg Archive of Pharmacology, 351: 363-370.
72. VOLKE V, KÖKS S, VASAR E, BOURIN M, **BRADWEJN J**, MANNISTO PT (1995). Inhibition of nitric oxide synthase causes anxiolytic-like behavior in an elevated plus-maze. NeuroReport 6: 1285-1288.
  73. LE MELLEDO JM, **BRADWEJN J**, KOSZYCKI D, BICHET D (1995). Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Archives of General Psychiatry, 52: 605-606.
  74. KOSZYCKI D, **BRADWEJN J**, COX B (1995). Anxiety sensitivity and cholecystokinin-tetrapeptide challenge-reply. Am J Psychiatry, 152: 300-301.
  75. BENKELFAT C, **BRADWEJN J**, MEYER E, ELLENBOGEN M, MILOT S, GJEDDE A, EVAN S (1995). Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry, 152: 1180-1184.
  76. BATES J, **BRADWEJN J** (1995). Ventilatory response to cholecystokinin tetrapeptide in anaesthetized dogs. NeuroReport, 6: 2513-2517.
  77. HARRO J, ORELAND L, VASAR E, **BRADWEJN J** (1995). Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacology, 5: 447-455.
  78. BOURIN M, MALINGE M, **BRADWEJN J** (1995). Cholecystokinine et trouble panique. L'Information Psychiatrique, 71: 981-986.
  79. ZACHARKO R, KOSZYCKI D, MENDEALLA P, **BRADWEJN J** (1995). Behavioral, neurochemical, anatomical, and electrophysiological correlates of panic disorder. Multiple transmitter interactions and neuropeptide colocalization. Prog Neurobiology, 47: 371-423.
  80. SAFADI G, **BRADWEJN J** (1995). Relationship of panic disorder to posttraumatic stress disorder (letter). Arch Gen Psychiatry, 52: 76-77.
  81. KOSZYCKI D, ZACHARKO RM, LE MELLEDO JM, YOUNG S, **BRADWEJN J** (1996). Effect of acute tryptophan depletion on behavioral, cardiovascular and hormonal sensitivity to cholecystokinin-tetrapeptide in healthy volunteers. Biol Psychiatry: 40, 648-655.
  82. FRANKLAND PW, JOSSELYN S, **BRADWEJN J**, VACCARINO F, YEOMANS J (1996). Intracerebroventricular infusion of the CCK-B receptor agonist pentagastrin potentiates acoustic startle. Brain Research, 773: 129-132.
  83. BOURIN M, MALINGE M, VASAR E, **BRADWEJN J** (1996). Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol, 10: 116-126.
  84. KOSZYCKI D, **BRADWEJN J**, ZACHARKO R (1996). Personality correlates of behavioral response to CCK-4 in patients with panic disorder. Psychiatry Research, 62: 131-138. *Selected for review in La Lettre du Psychiatre 5:3, 1996.*
  85. GASTON L, BRUNET A, KOSZYCKI D, **BRADWEJN J** (1996). MMPI profiles of acute and chronic PTSD in a civilian sample. J Traumatic Stress, 9: 817-824.
  86. ALUOJA A, SHLIK J, VASAR V, KINGISEPP PH, JAGOMAGI K, VASAR V, **BRADWEJN J** (1997). Emotional and cognitive factors associated with response to CCK-4 in healthy volunteers. Psychiatry Research, 66: 59-67.
  87. FRANKLAND PW, JOSSELYN S, **BRADWEJN J**, VACCARINO F, YEOMANS J (1997). Activation of amygdala CCK-B receptors potentiates the acoustic startle response in the rat. J Neuroscience, 17: 1838-1847.
  88. BRAWMAN-MINTZER O, LYDIARD RB, **BRADWEJN J**, VILLAREAL G, KNAPP R, EMMANUEL N, BALLENGER J (1997). Pentagastrin effects in patients with generalized anxiety disorder. Am J Psychiatry, 154: 700-702.

89. SHLIK J, VASAR V, ALUOJA A, KINGISEPP P-H, JAGOMÄGI K, VASAR E, RÄGO L, **BRADWEJN J** (1997). The effects of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry, 42: 206-212.
90. **BRADWEJN J** (1997). (As part of the International Multicenter Clinical Trial Group on Moclobemide in Social Phobia). Moclobemide in Social Phobia, A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci, 247: 71-80.
91. SHLIK J, VASAR E, **BRADWEJN J** (1997). Cholecystokinin and Psychiatric Disorders. Role in Aetiology and Potential of Receptor Antagonists in Therapy. ADIS International, CNS Drugs, 8: 134-152.
92. MERANI S, PALMOUR RM, **BRADWEJN J**, BEREZOWSKA I, GUTKOWSKA J (1997). Development of a Sensitive and Specific Assay System for Cholecystokinin. Peptides, 18: 869-875.
93. SHLIK J, ALUOJA A, VASAR V, VASAR E, PODAR T, **BRADWEJN J** (1997). Effects of citalopram treatment on behavioral, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiat Neuroscience, 22: 332-340.
94. SHLIK J, ALUOJA A, VASAR V, VASAR E, **BRADWEJN J** (1997). Koletsüstokiniin-tetrapeptiidi psühho-füsioloogilise toime võrdlev uuring tervetel ja paanikahäiretega patsientidel. Teooria ja praktika, Eesti Arst, 6, 483-490.
95. BOURIN M, BAKER G, **BRADWEJN J** (1998). The neurobiology of panic disorder. J Psychosomatic Research, 44: 163-180.
96. **BRADWEJN J**, LEGRAND JM, KOSZYCKI D, BATES J, BOURIN M (1998). Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry, 155: 280-282.
97. FLINT A, **BRADWEJN J**, VACCARINO FJ, KOSZYCKI D (1998). The effect of aging on cholecystokinin-induced panic. Am J Psychiatry, 155: 283-285.
98. GASTON L, BRUNET A, KOSZYCKI D, **BRADWEJN J** (1998). J MMPI scales for diagnosing acute and chronic PTSD in civilians. Traumatic Stress, 11: 355-365.
99. KOSZYCKI D, ZACHARKO RM, LE MELLEDO J-M, **BRADWEJN J** (1998). Behavioral, cardiovascular and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: A comparison of panickers and non-panickers. Depression and Anxiety, 8: 1-7.
100. LE MELLEDO JM, **BRADWEJN J**, KOSZYCKI D, BICHET M (1998). The effect of B- Noradrenergic system in CCK-4 induced panic symptoms. Biol Psychiatry, 44: 364-366.
101. SHLIK J, KOSZYCKI D, **BRADWEJN J** (1998). Decrease in short-term memory function induced by CCK-4 in healthy volunteers. Peptides, 19: 969-975.
102. DEPOT M, MERANI S, **BRADWEJN J**, MUKHERJEE J, CAILLE J, GUTKOWSKA J, CAILLE G (1998). Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. Psychiatry & Neuroscience, 23: 298-304.
103. SHLIK, J. VASAR, E, **BRADWEJN, J** (1998). Cholecystokinin and Psychiatric Disorders: Role in Aetiology and Potential of Receptor Antagonists in Therapy. Disease Management Review - Depression. Auckland: Adis International.
104. DEPOT M, MERANI S, **BRADWEJN J**, MUKHERJEE J, CAILLE J, GUTKOWSKA J, CAILLE G (1999). Acute and chronic role of 5-HT<sub>3</sub> neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology, 20: 177-187.
105. LE MELLEDO JM, MERANI S, KOSZYCKI D, BELLAVANCE F, PALMOUR RM, STEINBERG S, BICHET DG, GUTKOWSKA J, **BRADWEJN J** (1999). Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology, 20: 81- 91.

106. JERABEK I, BOULENGER JP, **BRADWEJN J**, DRUMHELLER A, LAVALLEE YJ, JOLICOEUR F (1999). CCK4-Induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacology, 9: 149-155.
107. JERABEK I, BOULENGER JP, **BRADWEJN J**, DRUMHELLER A, LAVALLEE YJ, JOLICOEUR F (1999). CCK4-Induced panic in healthy subjects II: neurochemical correlates. Eur Neuropsychopharmacology, 9: 157-164.
108. JAVANMARD M, SHLIK J, KENNEDY SH, VACCARINO FJ, HOULE S, **BRADWEJN J** (1999). Neuroanatomical correlates of CCK-4-induced panic attacks in healthy humans: A time course study. Biol Psychiatry, 45, 7: 872-882.
109. KENNEDY JL, **BRADWEJN J**, KOSZYCKI D, KING N, CROWE R, VINCENT J, FOURIE O (1999). Investigation of CCK system genes in panic disorder. Molecular Psychiatry, 4: 206-209.
110. SHLIK J, ZHOU Y, KOSZYCKI D, VACCARINO F, **BRADWEJN J** (1999). Effects of CCK-4 infusion on the acoustic startle response in healthy volunteers. Psychopharmacology, 13: 385-390.
111. NOBLE F, WANK SA, CRAWLEY JN, **BRADWEJN J**, SEROOGY KB, HAMON M, ROQUES BP (2000). International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacological Reviews, 51: 745-781.
112. **BRADWEJN J**, ZHOU Y, KOSZYCKI D, SHLIK J (2000). A double-blind, placebo-controlled study on the effects of Gotu-Kola (*Centella asiatica*) on acoustic startle response in healthy subjects. Clinical Psychopharmacology, 20 6: 680-684.
113. FLINT AJ, KOSZYCKI D, **BRADWEJN J**, VACCARINO FJ (2000). Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects. Psychoneuroendocrinology, 25: 633-647.
114. LE MELLÉDO J-M, ARTHUR H, DALTON J, WOO C, LIPTON N, BELLAVANCE F, KOSZYCKI D, BOULENGER J-P, **BRADWEJN J** (2001). The influence of type A behaviour pattern on the response to the panicogenic agent CCK-4. Psychosomatic Research. 51: 513-520.
115. KOSZYCKI D, **BRADWEJN J** (2001). Anxiety sensitivity does not predict fearful responding to 35% carbon dioxide in patients with panic disorder. Psychiatry Research, 101: 137-143.
116. LE MELLEDO J-M., **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET DG (2001). Arginine vasopressin and oxytocin response to CCK-4. Peptides, 22: 1349-1357.
117. **BRADWEJN J**, KOSZYCKI D (2001). Cholecystokinin and panic disorder: Past and future clinical research strategies. Scand J Clin Lab Invest, 61 234: 19-27.
118. FLINT AJ, **BRADWEJN J**, VACCARINO F, GUTKOWSKA J, PALMOUR R, KOSZYCKI D (2002). Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system. Neuropsychopharmacology, 27 7: 664-671.
119. KATZMAN MA, DUFFIN J, SHLIK J, **BRADWEJN J** (2002). The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers. Neuropsychopharmacology, 26 6: 824-831.
120. KNOTT V, MAHONEY C, GUNNARSSON T, **BRADWEJN J**, SHLIK J (2002). Acute cholecystokinin effects on event-related potentials in healthy volunteers. J Human Psychopharmacology, 17: 285-291.
121. SWENSON JR, **BRADWEJN J** (2002). Mental Health Reform and Evolution of General Psychiatry in Ontario. Can J Psychiatry, 47 7: 644-651.
122. KNOTT V, MAHONEY C, **BRADWEJN J**, SHLIK J, GUNNARSSON T (2003). Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27: 179-184.
123. GUNNARSSON T, MAHONEY C, SHLIK J, **BRADWEJN J**, KNOTT V (2003). Acute effects of cholecystokinin-tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.

- Pharmacopsychiatry, 36: 181-186.
124. KOSZYCKI D, COPEN J, **BRADWEJN J** (2004). Sensitivity to cholecystokinin-tetrapeptide in major depression: Behavioral and cardiovascular findings. J. Affective Disorders, 80: 285-290.
  125. KNOTT V, MAHONEY C, GUNNARSSON T, **BRADWEJN J**, SHLIK J (2003). Acute cholecystokinin effects on event-related potentials in healthy volunteers. Human Psychopharmacology, 17: 285-29.
  126. KATZMAN M, KOSZYCKI D, **BRADWEJN J** (2004). Effects of CCK-tetrapeptide in patient with social phobia and obsessive compulsive disorder. Depression and Anxiety. 20: 51-58.
  127. ROTHE C, KOSZYCKI D, **BRADWEJN J**, KING N, DE LUCA V, SHAIKH S, FRANKE P, GARRITSEN H, FRITZE J, KENNEDY JL (2004). Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neuroscience Letter, 363: 276-279.
  128. BANN MC, PARKER CB, **BRADWEJN J**, DAVIDSON JRT, VITIELLO B, GADDE KM (2004). Assessing Patient Beliefs in a Clinical Trial of Hypericum Perforatum in Major Depression. Depression and Anxiety, 20: 114-122.
  129. LIEBOWITZ M, MANGANO R, **BRADWEJN J**, ASNIS G (2005). Venlafaxine ER Generalized Social Anxiety. Journal of Clinical Psychiatry, 66: 238-247.
  130. **BRADWEJN J**, AHOKAS A, STEIN D, SALINAS E, EMILIEN G, WHITAKER T (2005). Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. British Journal of Psychiatry, 187: 352-359.
  131. KOSZYCKI D, TORRES S, SWAIN J, **BRADWEJN J** (2005). Central cholecystokinin activity in irritable bowel syndrome, panic disorder and normal controls. Psychosomatic Medicine, 67: 590-594.
  132. THARMALINGAM S, KING N, DE LUCA V, ROTHE C, KOSZYCKI D, **BRADWEJN J**, MACCIARDI F, KENNEDY JL (2006). Investigation of the Corticotropin-Releasing hormone Receptor 2 Gene in Panic Disorder. Psychiatric Genetics, 16: 93-97.
  133. ROTHE C, KOSZYCKI D, **BRADWEJN J**, KING N, DELUCA V, THARMALINGAM S, MACCIARDI F, DECKERT J, KENNEDY J (2006). Association of the Val 158 Met Catechol- O-methyltransferase genetic polymorphism with panic disorder. Neuropsychopharmacology, 10: 2237-2242.
  134. XIE RH, HE G, LUI A, **BRADWEJN J**, WALKER M, WEN SW (2007). Fetal gender and postpartum depression in a cohort of Chinese women. Soc Sci Med., 65: 680-684.
  135. KOSZYCKI D, BENDER M, SHLIK J, **BRADWEJN J** (2007). Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav. Res. Ther., 45: 2518-2526.
  136. BISSADA H, TASCA GA, BARBER AM, **BRADWEJN J** (2008). Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry, 165: 1281-1288.

137. KOSZYCKI D, RAAB K, ALDOSARY F, **BRADWEJN J** (2010). A multifaith spiritually based intervention for generalized anxiety disorder: a pilot randomized trial. *J Clin Psychol.* 66: 430-41.
138. KOSZYCKI D, TALJAARD M, SEGAL Z, **BRADWEJN J** (2011). A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. *Psychol Med.* 13: 1-11.
139. TASCA G, KEATING L, MAXWELLS H, HARES S, TRINNEER A, BARBER AM, BRADWEJN J, BISSADA H (2011). Predictors of treatment acceptance and of participation in a randomized controlled trial among women with anorexia nervosa. *European Eating Disorders Review.* Wiley Online Publication (ePub).
140. ZWANZGER P, **BRADWEJN J**, DIEMER J, MARSHALL RW, KOSZYCKI D (2012). Differences in Saccadic Eye Movements in Subjects at High and Low Risk for Panic Disorder. *Curr Pharm Des.* 2012 May 24. [Epub ahead of print] PubMed PMID: 22632478.
141. ZWANZGER P, DOMSCHKE K, **BRADWEJN J** (2012). Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. *Depress Anxiety.* 2012 May 2. doi: 10.1002/da.21919. [Epub ahead of print] PubMed PMID: 22553078.
142. KOSZYCKI D, BISSERBE JC, BLIER P, **BRADWEJN J**, MARKOWITZ J (2012). Interpersonal psychotherapy versus brief supportive therapy for depressed infertile women: first pilot randomized controlled trial. *Arch Womens Ment Health.* 2012 Jun;15(3):193-201. Epub 2012 Apr 12. PubMed PMID: 22526405.
143. KOSZYCKI D, PRICHARD Z, FIOCCO AJ, SHLIK J, KENNEDY JL, **BRADWEJN J** (2012). CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers. *Peptides.* 2012 May;35(1):9-13. Epub 2012 Mar 10. PubMed PMID: 22414867.
144. KOSZYCKI D, BILODEAU C, ZWANZGER P, SCHNEIDER B, FLAMENT MF, **BRADWEJN J** (2013). Parental bonds in children at high and low familial risk for panic disorder. *Child Psychiatry & Human Development* 44 (2), 278-289.
145. WISEMAN L, **BRADWEJN J**, WESTBROEK EM (2014). A new leadership curriculum: the multiplication of intelligence. *Academic Medicine* 89 (3), 376-379.
146. KOSZYCKI D, BILODEAU C, RAAB-MAYO K, **BRADWEJN J** (2014). A Multifaith Spiritually Based Intervention Versus Supportive Therapy for Generalized Anxiety Disorder: A Pilot Randomized Controlled Trial. *Journal of clinical psychology* 70 (6), 489-509.
147. BILODEAU C, **BRADWEJN J**, KOSZYCKI D (2015). Impaired Facial Affect Perception in Unaffected Children at Familial Risk for Panic Disorder. *Child Psychiatry & Human Development* 46 (5), 715-724.
148. FAUCHER J, KOSZYCKI D, **BRADWEJN J**, MERALI Z, BIELAJEW C (2016). Effects of CBT Versus MBSR Treatment on Social Stress Reactions in Social Anxiety Disorder. *Mindfulness* (7): 514–526.
148. DANILEWICZ M, **BRADWEJN J**, KOSZYCKI D (2016). A pilot feasibility study of a peer-led mindfulness program for medical students. *Canadian Medical Education Journal* 7 (1), e31-37
149. KOSZYCKI D, THAKE J, MAVOUNZA C, DAOUST JP, TALJAARD M, **BRADWEJN J** (2016). Preliminary Investigation of a Mindfulness-Based Intervention for Social Anxiety Disorder That Integrates Compassion Meditation and Mindful Exposure. *The Journal of Alternative and Complementary Medicine.* 22:363-374.
150. **BRADWEJN J** (2017). A Unique Partnership between a Chinese and Canadian Faculty of Medicine to advance medical education and research in the world. *Journal of World Education (Chinese)* July 2017.
151. EL AMIRI S, KOSZYCKI D, TALJAARD M, SEGAL Z, **BRADWEJN J** (2018). Impact of etiological models of illness on baseline clinical characteristics and response to treatment in patients with panic disorder. *Psychiatry Research.* 264: 264-155.
152. DANILEWICZ M, KOSZYCKI D, MACLEAN H, SANCHEZ M, GONSALVES C, ARCHIBALD D, **BRADWEJN J** (2018). Feasibility and effectiveness of an online mindfulness meditation program for medical students. *Canadian medical education journal.* 9: 15-25.
153. KOSZYCKI D, TALJAARD M, BIELAJEW C, GOW R, BRADWEJN J (2019). Stress reactivity in healthy child offspring of parents with anxiety disorders. *Psychiatry Research.* 272: 756-764.

## Book Chapters:



1. CHOUINARD G, ANNABLE L, CAMPBELL W, BOISVERT D, **BRADWEJN J** (1985). A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. In Pichot P et al. (Eds.): Psychiatry: The state of the art, Vol. 3. Plenum Publishing Corporation.
2. **BRADWEJN J** (1990). Psychopharmacology Section. In The Canadian Medical Association's Guide to Prescription and Over the Counter Drugs. Reader's Digest.
3. **BRADWEJN J**, KOSZYCKI D, PAYEUR (1991). Cholecystokinin-tetrapeptide: A provocation agent for research in panic disorders? In Briley M & File S (Eds.), New Concepts in Anxiety. MacMillan Press, pp. 313-319.
4. BOURIN M, LE MELLEDO, **BRADWEJN J** (1991). Propriétés pharmacologiques et pharmacocinétiques des médicaments sédatifs. In Veille et Sommeil, Journées de l'Enseignement Post Universitaire d'Anesthésiologie et Réanimation. Arnette Paris, pp. 119-140.
5. **BRADWEJN J**, KOSZYCKI D (1992). CCK-4 and panic attacks in man. In Dourish CT, Cooper SJ, Iversen SD & Iversen LL(Eds), Multiple Cholecystokinin Receptors in the CNS. Oxford University Press, pp. 121-131.
6. BOURIN M, **BRADWEJN J** (1992). Clinical pertinence of pharmacokinetics of benzodiazepines. Journal de Pharmacie Clinique. In Bres J, Panis G (Eds.), Pharmacocinétique de la recherche à la clinique. John Libbey Eurotext , pp. 99-112.
7. BOURIN M, **BRADWEJN J** (1992). Cholecystokinine et attaques de panique. In Meyer P, Jaillon P (Eds), Méthodes en pharmacologie clinique. Masson, pp. 167-170.
8. **BRADWEJN J**, KOSZYCKI D (1992). CCK-4 and panic attacks in man. In Iversen SD, Dourish CT and Cooper SJ (Eds), Multiple Cholecystokinin Receptors in Man. Oxford University Press, Oxford, England, pp. 121-131.
9. BOURIN M, KOSZYCKI D, **BRADWEJN J** (1993). Psychopharmacological models of normal aging. In Macher JP, Crocq MA (Eds), New Prospects on Psychiatry: The Bio-Clinical Interface. Developments in Psychiatry. Vol 9, pp. 161-170.
10. **BRADWEJN J**, KOSZYCKI D, BOURIN M, PAYEUR R (1993). Cholecystokinin and panic disorders. In Montgomery SA (Ed), The Psychopharmacology of Panic. Oxford University Press, pp. 110-117.
11. LE MELLEDO JM, **BRADWEJN J** (1993). Psychopharmacology of Depression. In Y. Lapiere (Ed), Pharmacotherapy of Depression. Pharmalibri, Montréal, pp. 25-46.
12. BOURIN M, **BRADWEJN J**, NIXON MK (1993). Provocation agents and the biology of panic attacks. In Anxiety: Neurobiology, Clinic and Therapeutic Perspectives.
13. PARADIS M, **BRADWEJN J** (1993). Pathologie mentale et IMAO. In Les IMAO. (M Bourin Ed.), Collection Les Grands Médicaments. Ellipses, Paris, pp. 13-28.
14. **BRADWEJN J**, KOSZYCKI D, BOURIN M, PAYEUR R (1993). Cholecystokinin and panic disorders. In Montgomery SA (Ed.), The Psychopharmacology of Panic. Oxford University Press, pp. 110-117.
15. BOURIN M, KOSZYCKI D, **BRADWEJN J** (1993). Psychopharmacological models of normal aging. In Macher JP & Crocq MA (Eds), New Prospects on Psychiatry: The Bio-Clinical Interface. Developments in Psychiatry.
16. **BRADWEJN J** ( 1994). The role of CCK in panic: clinical research. In Beigel A, Lopez Ibor JJ, Costa JA (Eds), Past, Present and Future of Psychiatry. World Congress of Psychiatry, 1: pp. 29-33.
17. **BRADWEJN J**, KOSZYCKI D (1994). The cholecystokinin hypothesis of panic disorder. Annals of the New York Academy of Sciences, 713, pp. 273-282.
18. **BRADWEJN J**, KOSZYCKI D (1995). Cholecystokinin and panic disorder. In Asnis G & van Pragg H (Eds), Panic Disorder, Clinical, Biological and Treatment Aspects. Wiley-Interscience Publication, John Wiley and Sons, New York Press. Chapter 10, pp. 233-254.
19. **BRADWEJN J** (1995). Cholecystokinin and Panic Disorder. In Bradwejn J & Vasar E (Eds), Cholecystokinin and Anxiety: From Neuron to Behavior. Molecular Biology Intelligence Unit. Biomedical Publishers. Springer Verlag.
20. HARRO J, VASAR E, KOSZYCKI D, **BRADWEJN J** (1995). Cholecystokinin in panic and anxiety

- disorders. In Pankseep J. (Ed), Advances in Biological Psychiatry. JAI Press Inc., Connecticut, pp. 235-262.
21. **BRADWEJN J**, KOSZYCKI D, VASAR E, PALMOUR R, VACCARINO F (2000). Cholecystokinin Antagonists in Panic and Anxiety Disorders. In Halbreich U & Montgomery SA (Eds), Pharmacotherapy for Mood, Anxiety and Cognitive Disorders. American Psychiatric Press, pp. 411-437.
  22. **BRADWEJN J**, KOSZYCKI D (2000). Abnormal CCK function: a pathophysiological model for panic disorder and gastrointestinal disorders? Evolving pathophysiological models of functional GI disorders: implications for new drug development. Health Education Alliance Inc., New York, NY, pp. 89-91.
  23. LEMELLEDO J-M, LEGRAND J-M, **BRADWEJN J**, DUFOUR N (2001). Anxiolytiques et hypnotiques. In Morin, G. (Ed.), Psychiatrie Clinique Une approche bio-psycho-sociale Tome II. Gaëtan Morin Éditeur ltée., pp. 1138-1159.
  24. **BRADWEJN J**, KOSZYCKI D (2002). Panic Disorder. In Raker RE and Bope ET(Eds), Conn's Current Therapy, W.B. Saunders Company. St. Louis, MO, pp. 1144-1146.
  25. SWAIN J, SHLIK J, KOSZYCKI D, **BRADWEJN J** (2003). Pharmacological challenge agents in anxiety. In D. Nutt and J. Ballengers (eds.), Anxiety Disorders. Blackwell Science, Oxford England, pp. 269-295.

#### **Books Edited:**

1. **BRADWEJN J** (Ed) (1992). Generalized Anxiety Disorder In Family Practice: Guide for Diagnosis and Treatment. Publication of the Canadian Medical Association. Grosvenor House (publishers), Montréal.
2. **BRADWEJN J**, VASAR E (Eds) (1995). "Cholecystokinin and Anxiety, from Neuron to Behavior". Book, Molecular Biology Intelligence Unit. Biomedical Publishers. Springer Verlag, August.

#### **Abstracts:**

1. CHOUINARD G, CREESE I, BOISVERT D, ANNABLE L, **BRADWEJN J**. Super-sensitivity psychosis and plasma neuroleptic levels measured by radio receptor assay. Scientific program of the 36th Annual Convention, Society for Biological Psychiatry, New Orleans, LA p. 48, 1981.
2. CHOUINARD G, CREESE I, BOISVERT D, ANNABLE L, **BRADWEJN J**. High neuroleptic plasma levels in patients manifesting super-sensitivity psychosis. 3<sup>rd</sup> World Congress of Biological Psychiatry, Stockholm, Sweden, No F-76, 1981.
3. CHOUINARD G, ANNABLE L, ROSS-CHOUINARD A, **BRADWEJN J**, OLIVIER M, FONTAINE R. Piracetam in elderly psychiatric patients. 11<sup>th</sup> Annual Meeting, American Aging Association (Age), New York, NY, September 24-26, 1981.
4. CHOUINARD G, CREESE I, BOISVERT D, ANNABLE L, **BRADWEJN J**. High neuroleptic plasma levels in patients manifesting super-sensitivity psychosis. Annual Meeting, CPA, Winnipeg, MB, September 21-25, 1981.
5. CHOUINARD G, YOUNG SN, ANNABLE L, **BRADWEJN J**. Antimanic effect of clonazepam. 37<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, Toronto, ON, p. 101, 1982.
6. DONGIER M, **BRADWEJN J**. Schizophreniform psychosis: Diagnostic criteria? Syllabus and scientific proceedings of the 135<sup>th</sup> Annual Meeting, American Psychiatric Association (APA), p. 25-26, 1982.
7. CHOUINARD G, YOUNG SN, ANNABLE L, **BRADWEJN J**. Clonazepam in acute mania. Abstract - Canadian College of Neuropsychopharmacology (CCNP) 5<sup>th</sup> Annual Meeting, Québec, QC, p. 29, 1982.
8. CHOUINARD G, ANNABLE L, ROSS-CHOUINARD A, **BRADWEJN J**. Tardive dyskinesia: A five-year epidemiological study. Syllabus and scientific proceedings of the 135<sup>th</sup> Annual Meeting, APA, No 68F, p. 172, 1982.
9. CHOUINARD G, ANNABLE L, ROSS-CHOUINARD A, **BRADWEJN J**. Central anticholinergics and tardive dyskinesia. Syllabus and scientific proceedings of the 135<sup>th</sup> Annual Meeting, APA, No 10C, p. 47, 1982.
10. **BRADWEJN J**, JONES BD, ANNABLE L, CHOUINARD G. Relapse or therapeutic rebound upon anti-

- depressant withdrawal. Syllabus and scientific proceedings of the 135<sup>th</sup> Annual Meeting, APA, No 82E, p. 202, 1982.
11. CHOUINARD G, YOUNG SN, ANNABLE L, **BRADWEJN J**. Antimanic effect of clonazepam. Scientific proceedings of the 32<sup>nd</sup> Annual Meeting, CPA, No 55, pp. 74-75, 1982.
  12. FONTAINE R, CHOUINARD G, ANNABLE L, **BRADWEJN J**. Alprazolam in the treatment of anxiety and panic disorders. Scientific proceedings of the 32<sup>nd</sup> Annual Meeting, CPA, No 56, pp. 75-76, 1982.
  13. REMILLARD GM, ANDERMANN F, DEMERS L, BRADWEJN J. Homosexuality and limbic epilepsy. XVIII Canadian Congress of Neurological Sciences, St. John's, NL, June 1983.
  14. REMILLARD G, ANDERMANN F, **BRADWEJN J**, DEMERS L. Homosexuality and limbic epilepsy: A study of twelve patients. Eastern Association of Electroencephalography (EAEEG), St-Adele, QC, March 3-5, 1983.
  15. **BRADWEJN J**, JONES BD, ANNABLE L, CREESE I, CHOUINARD G. Effect of alcohol on extrapyramidal symptoms and neuroleptic blood levels. Scientific program of the 38<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, No 69, p. 103, 1983.
  16. JONES BD, **BRADWEJN J**, CHOUINARD G, ANNABLE L, YOUNG SN. Paradoxical therapeutic response to antidepressant withdrawal. Scientific program of the 38<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, No 45, p. 79, 1983.
  17. CHOUINARD G, BOISVERT D, **BRADWEJN J**. Tardive dyskinesia in nonpsychiatric patient due to short-term use of neuroleptic/anticholinergic combination drug. International Synopses Publications, Psychiatry Digest, p. 7, 1983.
  18. CHOUINARD G, ANNABLE L, CAMPBELL W, BOISVERT D, **BRADWEJN J**. Haloperidol decanoate in the prevention of relapse in schizophrenia. VII World Congress of Psychiatry, Vienna, Austria, No S-615, p. 145, 1983.
  19. SOUSA-POZA JF, EAGLE R, **BRADWEJN J**, ROHRBERG R. Anaclitic states and neuroses. VII World Congress of Psychiatry, Vienna, Austria, No F-257, p. 314, 1983.
  20. CHOUINARD G, ANNABLE L, CAMPBELL W, BOISVERT D, **BRADWEJN J**. Haloperidol decanoate in the maintenance treatment of schizophrenia. Scientific program of the 33<sup>rd</sup> Annual Meeting, CPA, No 66, 1983.
  21. SOUSA-POZA JF, **BRADWEJN J**. Attachment, information theory and neuroses. Scientific program of the 33<sup>rd</sup> Annual Meeting, CPA, No 58, 1983.
  22. CHOUINARD G, YOUNG SN, ANNABLE L, **BRADWEJN J**. L-tryptophan in acute mania. CCNP 6<sup>th</sup> Annual Meeting, Saskatoon, SK, p. 92, 1983.
  23. **BRADWEJN J**, ANNABLE L, JONES BD, CREESE I, CHOUINARD G. Alcohol and neuroleptic blood level in schizophrenic outpatients. CCNP 6<sup>th</sup> Annual Meeting, Saskatoon, SK, p. 93, 1983.
  24. **BRADWEJN J**, SOUSA-POZA JF, ROHRBERG R. The neurobiology of attachment. 14<sup>th</sup> C.I.N.P. Congress. Abstracts No F-311, p. 312, 1984.
  25. **BRADWEJN J**, DE MONTIGNY C. Selective suppression of cholecystokinin-induced activation of hippocampal pyramidal neurons by benzodiazepines and PK 8165: A microiontophoretic study in the rat. 14<sup>th</sup> C.I.N.P. Congress. Abstracts No P-241, p. 556, 1984.
  26. **BRADWEJN J**, DE MONTIGNY C. Activation of benzodiazepine receptors suppresses cholecystokinin-induced excitation of hippocampal pyramidal neurons: A microiontophoretic study in the rat. 14<sup>th</sup> Annual Meeting, Society for Neuroscience, Anaheim, CA, Neurosci. Abst. 241.12, p. 812, 1984.
  27. **BRADWEJN J**, DE MONTIGNY C. Suppression of cholecystokinin-induced excitation of CNS neurons: A mechanism for the anxiolytic action of benzodiazepine receptor agonists? Scientific Proceedings of the

- 35<sup>th</sup> Annual Meeting, CPA, No 16, pp. 20-21, 1985.
28. **BRADWEJN J**, DE MONTIGNY C. The effect of benzodiazepines on cholecystokinin-induced excitation of rat hippocampal pyramidal neurons appears not to be mediated by the potentiation of GAMMA-aminobutyric acid. 15<sup>th</sup> Annual Meeting, Society for Neuroscience, Dallas (TX), Neurosci. Abst. No 6.4, p. 8, 1985.
  29. **BRADWEJN J**, METERISSIAN G, KOSZYCKI D. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. CCNP 11<sup>th</sup> Annual Meeting, Montréal, QC, p. 74, May 1988.
  30. **BRADWEJN J**, METERISSIAN G, KOSZYCKI D. Cholecystokinin induces panic in panic disorder. New Research Program and Abstracts, 141<sup>st</sup> Annual Meeting of the APA, Montréal, QC, p. 25, May 1988.
  31. **BRADWEJN J**, METERISSIAN G, KOSZYCKI D. The effects of cholecystokinin in panic disorder. Psychopharmacology, Abstracts of the XVIth CINP Congress, Munich, Germany, vol. 96, p. 184, 1988.
  32. **BRADWEJN J**, METERISSIAN G, KOSZYCKI D. A videotaped demonstration of cholecystokinin-induced panic attack. Scientific Program of the 38<sup>th</sup> Meeting of the CPA, Halifax, NS, p. 61, 1988.
  33. METERISSIAN G, **BRADWEJN J**. Comparative studies of pharmacotherapy and psychotherapy and of their combination in depression: Was adequate pharmacotherapy provided? Scientific Program of the 38<sup>th</sup> Meeting of the CPA, p. 24, 1988.
  34. **BRADWEJN J**, METERISSIAN G, KOSZYCKI D. Cholecystokinin-tetrapeptide induces panic attacks in patients suffering from panic disorder. Abstracts of the 18<sup>th</sup> Annual Meeting of the Society for Neuroscience, p. 291, 1988.
  35. SHRIQUI C, **BRADWEJN J**. Dyskinesie tardive: Aspects légaux. Association des psychiatres du Québec, 23<sup>e</sup> réunion annuelle, May 1989.
  36. **BRADWEJN J**, METERISSIAN G, SHRIQUI C, KOSZYCKI D. Comparison of clonazepam and lorazepam in mania. New Research Program and Abstracts, 142<sup>nd</sup> Meeting of the APA, San Francisco, NR 273, p. 152, May 1989.
  37. **BRADWEJN J**, KOSZYCKI D, METERISSIAN G, SHRIQUI C. Cholecystokinin panic: Patient control differences. New Research Program and Abstracts, 142<sup>nd</sup> Meeting of the APA, San Francisco, NR 334, p. 183, May 1989.
  38. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J. CO<sub>2</sub> response profile: Panic disorder and agoraphobia. New Research Program and Abstracts, 142<sup>nd</sup> Meeting of the APA, San Francisco, NR 332, p. 182, May 1989.
  39. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C, METERISSIAN G. Cholecystokinin in panic disorder and healthy volunteers. British Association of Psychopharmacology CCNP Joint Annual Meeting, Cambridge, England, No. 74, p. 23, July 1989.
  40. **BRADWEJN J**, KOSZYCKI D, METERISSIAN G, SHRIQUI C. Videotape demonstration of a panic attack induced by cholecystokinin-tetrapeptide in healthy volunteers. 39<sup>th</sup> Annual Meeting of the CPA, St. John's, NL, No. 4, p. 13, September 1989.
  41. SHRIQUI C, **BRADWEJN J**, JONES B. Tardive dyskinesia: Legal and preventive aspects. 39<sup>th</sup> Annual Meeting of the CPA, St. John's, NL, No. 32, p. 61, September 1989.
  42. KOSZYCKI D, **BRADWEJN J**, CAMPBELL JF. Somatic, affective and cognitive responses to a single inhalation of 35% CO<sub>2</sub>. 39<sup>th</sup> Annual Meeting of the CPA, St. John's, NL, No. 45, p. 91, September 1989.
  43. **BRADWEJN J**, SHRIQUI C, METERISSIAN G, KOSZYCKI D. The antimanic actions of clonazepam and lorazepam: A comparison. 39<sup>th</sup> Annual Meeting of the CPA, St. John's, NL, No. 81, p.143, September 1989.
  44. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C, METERISSIAN G. Specificity of action of CCK-tetrapeptide in

- panic disorder. Abstracts of the 19<sup>th</sup> Annual Meeting of the Society for Neuroscience, Phoenix, Arizona, 4493, p.1122, November 1989.
- No.
45. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J. CO<sub>2</sub> response profiles in panic disorder subtype. International Symposium on New Concepts in Anxiety. Castres, France, No. P14, p.42, April 1990.
46. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. A new concept in anxiety: The role of cholecystokinin in the neurobiology of panic disorder. International Symposium on New Concepts in Anxiety. Castres, France, No. P3, p.41, April 1990.
47. SHRIQUI C, **BRADWEJN J**, JONES B, BLANCHARD A. Alpha-tocopherol in tardive dyskinesia. Regional Congress - World Federation of Society for Biological Psychiatry. Casablanca, Morocco, February 1990.
48. **BRADWEJN J**, SHRIQUI C, METERISSIAN G, KOSZYCKI D. A double-blind comparison of clonazepam and lorazepam in acute mania. Regional Congress - World Federation of Society for Biological Psychiatry. Casablanca, Morocco, February 1990.
49. SHRIQUI C, **BRADWEJN J**, JONES B. Tardive dyskinesia: Legal and preventive aspects. Regional Congress - World Federation of Society for Biological Psychiatry. Casablanca, Morocco, February 1990.
50. SHRIQUI C, **BRADWEJN J**, JONES B, BLANCHARD A. Alpha-tocopherol in tardive dyskinesia. First International Congress of Movement Disorders. Washington, DC, April 1990.
51. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. CCK-4 versus CO<sub>2</sub> panic attacks in panic disorder. New Research Program and Abstracts, 143<sup>rd</sup> Meeting of the APA, NY, NR 282 p.154, May 1990.
52. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Cholecystokinin panic: Panic disorder versus agoraphobia. New Research Program and Abstracts, 143<sup>rd</sup> Meeting of the APA, NY, NR 283 p.154, May 1990.
53. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Dose ranging study of CCK-4 in healthy volunteers. New Research Program and Abstracts, 143<sup>rd</sup> Meeting of the APA, NY, NR 284 p.155, May 1990.
54. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J. Psychological correlates of response to inhalation of thirty-five percent CO<sub>2</sub>. New Research Program and Abstracts, 143<sup>rd</sup> Meeting of the APA, NY, NR 285 p.155, May 1990.
55. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. A comparison of the panicogenic effects of cholecystokinin and CO<sub>2</sub> in panic disorder. 13<sup>th</sup> Annual Scientific Meeting, CCNP, Banff, AB, p.85, June 1990.
56. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J. Differential response to CO<sub>2</sub> in panic disorder. 13<sup>th</sup> Annual Scientific Meeting, CCNP, Banff, AB, p.86, June 1990.
57. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Dose-ranging study of the effects of cholecystokinin-tetrapeptide in healthy volunteers. 13<sup>th</sup> Annual Scientific Meeting, CCNP, Banff, AB, p.87, June 1990.
58. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Comparison of cholecystokinin-induced panic attacks in panic disorder and agoraphobia. 13<sup>th</sup> Annual Scientific Meeting, CCNP, Banff, AB, p.79, June 1990.
59. PAYEUR R, **BRADWEJN J**. The role of neuropeptides in anxiety. 40<sup>th</sup> Annual Meeting of the CPA, Toronto, ON, No. 72, p.95, September 1990.
60. SHRIQUI C, **BRADWEJN J**, JONES B, BLANCHARD A. Alpha-tocopherol in the treatment of tardive dyskinesia. 40<sup>th</sup> Annual Meeting of the CPA, Toronto, ON, No. 131, p.162, September 1990.
61. **BRADWEJN J**, SHRIQUI C, METERISSIAN G, KOSZYCKI D. The antimanic action of clonazepam and lorazepam: A comparison. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.51, September 1990.
62. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J. Differential response to CO<sub>2</sub> in panic disorders. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.116, September 1990.
63. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Cholecystokinin-induced panic attacks: A comparison in panic disorder and agoraphobia. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.116, September 1990.
64. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. A dose-ranging study of the panicogenic effect of

- cholecystokinin- tetrapeptide in healthy volunteers. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.162, September 1990.
65. **BRADWEJN J**, KOSZYCKI D, CAMPBELL JF. Comparison of the effects of cholecystokinin-tetrapeptide and of 35% CO<sub>2</sub> in panic disorder. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.163, September 1990.
  66. KOSZYCKI D, **BRADWEJN J**, CAMPBELL JF. Psychological correlates of carbon dioxide. 17<sup>th</sup> Congress of CINP, Kyoto, Japan, Vol. 1, p.162, September 1990.
  67. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Specificity of action of cholecystokinin tetrapeptide in panic disorders. Association of Anxiety Disorders of America annual meeting. NR 404. Chicago, IL, April 7, 1991.
  68. SHRIQUI C, **BRADWEJN J**, JONES B, ANNABLE L. Vitamin E in the Treatment of Tardive Dyskinesia. New Research Program and Abstracts, 144<sup>th</sup> Meeting of the APA, New Orleans, LA, NR 80 p.67, May 13, 1991.
  69. ERVIN F, PALMOUR R, **BRADWEJN, J**. A New Primate Model for Panic Disorder. New Research Program and Abstracts, 144<sup>th</sup> Meeting of the APA, New Orleans, LA, NR 216 p. 100, May 14, 1991.
  70. KOSZYCKI D, **BRADWEJN J**, BOURIN M (1991). Comparison of Cholecystokinin- tetrapeptide and carbon dioxide in normals. New Research Program and Abstracts, 144<sup>th</sup> Meeting of the APA, New Orleans, LA, NR 367 p. 136, May 14, 1991.
  71. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BORTHWICK H. Replication of action of cholecystokinin-tetrapeptide in panic disordered patients. New Research Program and Abstracts, 144<sup>th</sup> Meeting of the APA, New Orleans, LA, NR 367 p. 136, May 14, 1991.
  72. BOURIN M, MANSOURI B, HASCOET M, **BRADWEJN J**. Benzodiazepines compared using three mice models. New Research Program and Abstracts, 144<sup>th</sup> Meeting of the APA, New Orleans, LA, NR 335 p. 128, May 14, 1991.
  73. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BORTHWICK H. Study of the repetition of action of CCK-4 in panic disorder. 14<sup>th</sup> Annual Scientific Meeting, CCNP, Hamilton, ON, p.21, June 4, 1991.
  74. KOSZYCKI D, **BRADWEJN J**, BOURIN M. Comparison of the panicogenic effects of CCK-4 and CO<sub>2</sub> in normal controls. 14<sup>th</sup> Annual Scientific Meeting, CCNP, Hamilton, ON, p.22, June 4, 1991.
  75. BOURIN M, MANSOURI B, HASCOET M, **BRADWEJN J**. Four benzodiazepines compared using three mice models of behaviour. 14<sup>th</sup> Annual Scientific Meeting, CCNP, Hamilton, ON, p.49, June 5, 1991.
  76. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J, BOURIN M. Comparison of MMPI profiles in users and non users of benzodiazepine in a panic disorder population. 14<sup>th</sup> Annual Scientific Meeting, CCNP, Hamilton, ON, p.50, June 5, 1991.
  77. SHRIQUI CL, **BRADWEJN J**, JONES B, ANNABLE L. Alpha-tocopherol in the treatment of tardive dyskinesia. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, p.226S, June 9-14, 1991.
  78. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Cholecystokinin panic: Panic disorder vs. agoraphobia. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, Biological Psychiatry p.289S, June 9-14, 1991.
  79. HASCOET M, BOURIN M, **BRADWEJN J**. The anticonflict effect of 5-HT drugs acting on serotonin system. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, Biological Psychiatry p.326S, June 9-14, 1991.
  80. KOSZYCKI D, **BRADWEJN J**, BOURIN M. CCK-4 versus CO<sub>2</sub> in Normal Controls. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, Biological Psychiatry p.423S, June 9-14, 1991.

81. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BORTHWICK H. Repetition of action of CCK-4 in panic disorder. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, Biological Psychiatry p.426S, June 9-14, 1991.
82. ERVIN FR, PALMOUR RM, **BRADWEJN J**. A new primate model for panic disorder. V<sup>th</sup> Congress of the World Federation of Society for Biological Psychiatry, Florence, Italy, Biological Psychiatry p.430S, June 9-14, 1991.
83. **BRADWEJN J**. Cholecystokinin and panic attacks. Invited Speaker. British Association of Psychopharmacology, York, England, p. 38, July 21-24, 1991.
84. KOSZYCKI D, **BRADWEJN J**, BOURIN M. Comparison of the panicogenic effects of CCK-4 and CO<sub>2</sub> in normal controls. British Association of Psychopharmacology, York, England, p. 49, July 21-24, 1991.
85. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J, BOURIN M. Comparison of MMPI profiles in users and non users of benzodiazepines in a panic disorder population. British Association of Psychopharmacology, York, England, p. 50, July 21-24, 1991.
86. BOURIN M, MANSOURI B, HASCOET M, **BRADWEJN J**. Four benzodiazepines compared using 3 mice models of behaviour. British Association of Psychopharmacology, York, England, July 21-24, 1991.
87. BOURIN M, **BRADWEJN J**, BENKELFAT C, MEYERS E, PALMOUR R, VASAR E. The role of cholecystokinin in anxiety disorders. Workshop, Third World Congress of Neuroscience, IBRO. W34, p12, Montréal, QC, August 8, 1991.
88. BOURIN M, MANSOURI B, HASCOET M, **BRADWEJN J**. Benzodiazepines compared using mice models. Third World Congress of Neuroscience, IBRO, N P31.19, p211. Montréal, QC, August 7, 1991.
89. KOSZYCKI D, **BRADWEJN J**, BOURIN M. Comparison of the panicogenic effects of CCK-4 and CO<sub>2</sub> in normal controls. Third World Congress of Neuroscience, IBRO. N P31.31, p213. Montréal, QC, August 7, 1991.
90. **BRADWEJN J**, KOSZYCKI D, SHRIQUI C. Comparison of the action of cholecystokinin in panic and agoraphobia. Third World Congress of Neuroscience, IBRO. N P31.32, p213. Montréal, QC, August 7, 1991.
91. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BORTHWICK H. Study of the repetition of action of CCK-4 in panic disorder. Third World Congress of Neuroscience, IBRO. N P31.33, p213. Montréal, QC, August 7, 1991.
92. **BRADWEJN J**, KOSZYCKI D, BOURIN M. Comparison of the panicogenic effects of CCK-4 and CO<sub>2</sub> in normal controls. IV<sup>th</sup> Congress of the European College of Neuropsychopharmacology (ECNP), Monte Carlo, Monaco, October 6-7, 1991, P-39, pp. 424.
93. BOURIN M, **BRADWEJN J**, KOSZYCKI D. Cholecystokinin and panic disorders. Invited Speaker, IV<sup>th</sup> Congress of the ECNP, Monte Carlo, Monaco, October 6-7, 1991, S-19-4, pp. 389-391.
94. PALMOUR RE, ERVIN FR, **BRADWEJN J**, HOWBERT JJ. The anxiogenic and cardiovascular effects of CCK-4 are blocked by the CCK-B antagonist LY262,691. Abstracts of the 21<sup>th</sup> Annual Meeting of the Society for Neuroscience, New Orleans, LA, No. 637.1 p. 1602, November 21, 1991.
95. **BRADWEJN J**, KOSZYCKI D, BOURIN M. Cholecystokinin-panic: a comparison to carbon dioxide-panic in panic disorder and normals. Association of Anxiety Disorders of America annual meeting. NR 405R. Houston, TX, April 12, 1992.
96. **BRADWEJN J**, KOSZYCKI D, PAYEUR R, BOURIN M, BORTHWICK H. Study of repeated administrations of cholecystokinin-tetrapeptide in panic disorder. Association of Anxiety Disorders of America annual meeting. P4. Houston, TX, April 10, 1992.
97. COUETOUX-DUTERTRE A, **BRADWEJN J**, KOSZYCKI D, PARADIS M, BOURIN, M. Lack of effect of

- flumazenil on CCK-4-panic. New Research Program and Abstracts, 145th Meeting of the APA, Washington, DC, NR138, p.81, May 4, 1992.
98. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260: A CCK-B antagonist blocks CCK-4-panic. New Research Program and Abstracts, 145th Meeting of the APA, Washington, DC, NR475, p.164, May 6, 1992.
  99. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, ANNABLE L, REINES S, KARKANIAS C. A dose-ranging study of CCK-4 in panic disorder. New Research Program and Abstracts, 145th Meeting of the APA, Washington, DC, 476, p.164, May 6, 1992.
  100. CHOUINARD G, SAXENA BM, NAIR NPV, KUTCHER SP, BAKISH D, **BRADWEJN J**, KENNEDY SH, SHARMA V, REMICK RA, KUKHA-MOHAMAD SA, SNAITH J, D'SOUZA J. Efficacy and safety of brofaromine in depression: A Canadian multi-centre placebo controlled trial and a review of comparative controlled studies. 18th CINP Congress, Nice, France, vol.15, suppl.1, part A, p.426, June 28, 1992.
  101. **BRADWEJN J**. CCK agonists and antagonists in clinical studies of panic and anxiety. 8th CINP Congress, Nice, France, vol.15, suppl.1, part A, p.481, July 1, 1992.
  102. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260: A CCK-B antagonist blocks CCK-4-panic disorder. 18th CINP Congress, Nice, France, vol.15, suppl.1, part B, p.59, June 30, 1992.
  103. BENKELFAT C, **BRADWEJN J**, MEYER E, ELLENBOGEN M, MILOT S, GJEDDE A, EVANS A. Neuro-anatomical correlates of CCK-4-induced-panic in normals. 18th CINP Congress, Nice, France, vol.15, suppl.1, part B, p.233, July 2, 1992.
  104. SHRIQUI C, ANNABLE L, **BRADWEJN J**, JONES B. Lack of correlation between vitamin E plasma levels and improvement in tardive dyskinesia. 18th CINP Congress, Nice, France, vol.15, suppl.1, part B, p.262, June 29, 1992.
  105. PALMOUR R, **BRADWEJN J**, ERVIN F. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. 18th CINP Congress, Nice, France, vol.15, suppl.1, part B, p.489, July 1, 1992.
  106. KOSZYCKI D, **BRADWEJN J**, CAMPBELL J, BOURIN M. Psychometric profile of users and nonusers of benzodiazepines in a panic disorder population. 18th CINP Congress, Nice, France, vol.15, suppl.1, part B, p.536, July 1, 1992.
  107. **BRADWEJN J**. The CCK Hypothesis of panic disorder. EBPS Meeting, Cambridge, England, J Psychopharmacology. August 7, 1992.
  108. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260: A CCK-B antagonist blocks CCK-4-panic disorder. 42nd Annual Meeting of the CPA, p. 120, September 16, 1992.
  109. PALMOUR R, **BRADWEJN J**, ERVIN F, HOWBERT JJ. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists. 42nd Annual Meeting of the CPA, p. 120, September 16, 1992.
  110. **BRADWEJN J**. The cholecystokinin hypothesis of panic disorder. 42nd Annual Meeting of the CPA, p. 118, September 16, 1992.
  111. PALMOUR RM, **BRADWEJN J**, ERVIN FR. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. 5th Congress of the ECNP, Marbella, Spain, Vol 2, No 3, p. 193, October 18-21, 1992.
  112. **BRADWEJN J**. The role of CCK receptors in panic disorders: Clinical studies. 5th Congress of the ECNP, Marbella, Spain, Vol 2, No 3, Pg 195, October 18-21, 1992.
  113. **BRADWEJN J**, KOSZYCKI D, COUETOX-DUTERTRE A, VAN MEGEN H, DEN BOER J,



- WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260, a CCK-B receptor antagonist, blocks CCK-4 panic. Oral presentation. Abstracts of the 22<sup>nd</sup> Annual Meeting of the Society for Neuroscience, Anaheim, CA, 324.12, October 28, 1992.
114. **BRADWEJN J**, KOSZYCKI D, COUETOUX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260, a CCK-B receptor antagonist, blocks CCK-4 panic in panic disorder. 5<sup>th</sup> Congress of the ECNP, Marbella, Spain, Vol. 2, No 3, p. 193, October 18-21, 1992.
115. **BRADWEJN J**, KOSZYCKI D, COUETOUX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260, a CCK-B receptor antagonist, blocks CCK-4 panic. Oral presentation. Abstracts of the 22<sup>nd</sup> Annual Meeting of the Society for Neuroscience, Anaheim, CA, 324.12, October 28, 1992.
116. **BRADWEJN J**, KOSZYCKI D, COUETOUX-DUTERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, KARKANIAS C, HAIGH J. L-365,260, a CCK-B receptor antagonist, blocks CCK-4 panic. Oral presentation. Annual meeting of the Association of Anxiety Disorders of America. NR 235. Charleston, NC, March 20, 1993.
117. COUETOUX-DUTERTRE A, **BRADWEJN J**, KOSZYCKI D, PARADIS M, BOURIN, M. Lack of effect of flumazenil on CCK-4-panic. Association of Anxiety Disorders of America annual meeting. NR 235. Charleston, NC, March 20, 1993.
118. KOSZYCKI D, COX B, **BRADWEJN J**. Anxiety sensitivity and response to CCK-4 challenge in healthy volunteers. New Research and Abstracts, 146<sup>th</sup> Annual meeting of the American Psychiatric Association. Washington, DC, May 1993.
119. **BRADWEJN J**. The CCK hypothesis of panic disorder. Annual Meeting of the Scandinavian Physiological Society. Tartu, Estonia, May 11, 1993.
120. **BRADWEJN J**. CCK in anxiety and panic disorders. CCK '93. Chatham, MA, May 22, 1993.
121. **BRADWEJN J**, KOSZYCKI D. Imipramine antagonizes the effects of CCK-4 in panic disorder. New Research Program and Abstracts, 146<sup>th</sup> Meeting of the APA, San Francisco, CA, May 25, 1993.
122. KOSZYCKI D, COX B, **BRADWEJN J**. Cognitive determinants of CCK-4-induced panic attacks. New Research Program and Abstracts, 146<sup>th</sup> Meeting of the APA, San Francisco, CA, May 25, 1993.
123. LANE C, PALMOUR R, **BRADWEJN J**, BOULENGER JP. Familial study of panic disorder in Québec. New Research Program and Abstracts, 146<sup>th</sup> Meeting of the APA, San Francisco, CA, May 25, 1993.
124. **BRADWEJN J**. The CCK hypothesis of panic and anxiety: a review of clinical and animal data. 16<sup>th</sup> Annual Scientific Meeting, CCNP, S2.3, Montréal, QC, May 31, 1993.
125. KOSZYCKI D, COX B, **BRADWEJN J**. Anxiety sensitivity and response to CCK-4 challenge in healthy volunteers. 16<sup>th</sup> Annual Scientific Meeting, CCNP, M5, Montréal, QC, May 31, 1993.
126. KOSZYCKI D, ZACHARKO R, **BRADWEJN J**. The relationship between personality variables and response to CCK-4 in patients with panic disorder. 16<sup>th</sup> Annual Scientific Meeting, CCNP, M4, Montréal, QC, May 31, 1993.
127. **BRADWEJN J**. The role of CCK in panic: clinical research. 9<sup>th</sup> World Congress of Psychiatry, 880, p. 224, Rio de Janeiro, Brazil, June 9, 1993.
128. PALMOUR R, **BRADWEJN J**, ERVIN F. Neuropharmacological studies of cholecystokinin- 4-induced anxiety and panic in a non-human primate model. 9<sup>th</sup> World Congress of Psychiatry, 882, p. 225, Rio de Janeiro, Brazil, June 9, 1993.
129. KOSZYCKI D, ZACHARKO RM, **BRADWEJN J**. The relationship between personality variables and response to CCK-4 challenge in patients with panic disorder. 16<sup>th</sup> Annual meeting of the Canadian College of Neuropsychopharmacology (in association with the British Association of Pharmacology). Montréal,

- QC, June 1993.
130. CHOUINARD G, SAXENA B, NAIR NPV, KUTCHER SP, BAKISH D, **BRADWEJN J**, KENNEDY S, SHARMA VS, REMICK RE, KUKHA-MAHAMAD SA, BEAUCLAIR L, SNAITH J, D'SOUZA J. Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled study. 9<sup>th</sup> World Congress of Psychiatry, 490, p. 124, Rio de Janeiro, Brazil, June 8, 1993.
  131. **BRADWEJN J**. The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. Summer Neuropeptide Conference, Martha's Vineyard, MA, June 23, 1993.
  132. **BRADWEJN J**. Neuropeptides and Behavior: an Overview. Planery Speaker, First Congress of Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece, September 16, 1993.
  133. **BRADWEJN J**. Cholecystokinin and anxiety: invited Panel speaker. American College of Neuropsychopharmacology. Honolulu, HI, December 17, 1994.
  134. **BRADWEJN J**, BOURIN M. Chairman, Symposium: "Drug Approval Process". CCNP 17<sup>th</sup> Annual Meeting, QC, May 30, 1994.
  135. BOULENGER JP, **BRADWEJN J**. Drug approval process in Canada. CCNP 17<sup>th</sup> Annual Meeting, S 1.1, p. 23, QC, May 30, 1994.
  136. KOSZYCKI D, ZACHARKO R, LE MELLEDO JM, YOUNG S, **BRADWEJN J**. The effects of acute tryptophan depletion on behavioral, cardiovascular and hormonal responses to CCK infusions in healthy males. CCNP 17<sup>th</sup> Annual Meeting, T. 10, p. 18, QC, May 31, 1994.
  137. **BRADWEJN J**, PARADIS M, KOSZYCKI D, REECE P, SEDMAN A. The effects of CI-988 on CCK-4-panic in healthy volunteers. CCNP 17<sup>th</sup> Annual Meeting, T. 11, p. 18, QC, May 31, 1994.
  138. **BRADWEJN J**. Symposium Speaker. Panic induction with cholecystokinin. XIX CINP Congress, Washington, DC, S-218-929, June 1994.
  139. **BRADWEJN J**, PARADIS M, KOSZYCKI D, REECE P, SEDMAN A. The effects of CI-988 on CCK-4-panic in healthy volunteers. XIX CINP Congress, Washington, DC, O-27-42, June 1994.
  140. KOSZYCKI D, ZACHARKO R, LE MELLEDO JM, YOUNG S, **BRADWEJN J**. The effects of acute tryptophan depletion on CCK-4-anxiety. XIX CINP Congress, Washington, DC, O-27-44, June 1994.
  141. BOULENGER JP, JOLICOEUR F, CADIEUX A, JERABEL I, LAVALLEE YJ, **BRADWEJN J**. Are peripheral mechanisms involved in CCK-4-induced panic attacks? XIX CINP Congress, Washington, DC, pp. 117-174, June 1994.
  142. BOULENGER JP, JOLICOEUR F, CADIEUX A, JERABEL I, LAVALLEE YJ, **BRADWEJN J**. Are peripheral mechanisms involved in CCK-4-induced panic attacks? Annual meeting of the Canadian Psychiatric Association (CPA), Ottawa, ON, September 22, 1994.
  143. **BRADWEJN J**, PARADIS M, KOSZYCKI D, REECE P, SEDMAN A. The effects of CI-988 on CCK-4-panic in healthy volunteers. American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 1994.
  144. **BRADWEJN J**. Clinical and research issues in the psychopharmacology of depression: Pharmacology & Toxicology. Tartu, Estonia, May 1995.
  145. VASAR E, VOLKE V, KOKS S, **BRADWEJN J**. Cholecystokinin and regulation of emotional behaviour in rats. Pharmacology & Toxicology. Tartu, Estonia, May 1995.
  146. KOSZYCKI D, ZACHARKO RM, LE MELLEDO JM, **BRADWEJN J**. The effects of CCK-4 in normal individuals: comparison of panickers and nonpanickers. CCNP & JSNP. Vancouver, BC, June 1995.
  147. LE MELLEDO JM, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET DG, HALBREICH U, STEINBERG S, LEGRAND JM. Enhanced sensitivity to CCK-4 in women with severe premenstrual symptoms (PDD). CCNP & JSNP. Vancouver, BC, June 1995.

148. LE MELLEDO JM, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, STEINBERG S, HALBREICH U, LEGRAND JM, BICHET DG. The effects of CCK-4 on plasma arginine-vasopressin levels in women. CCNP & JSNP. Vancouver, BC, June 1995.
149. JERABEK I, BOULENGER JP, JOLICOEUR FB, **BRADWEJN J**, DRUMHELLER A, LAVALLEE YJ. Peripheral monoamines and CCK-4-induced panic attacks in healthy volunteers. VIII<sup>th</sup> Congress of the ECNP, Volume 5, n. 5, pp. 5-33, Venice, Italy, September 30-October 5, 1995.
150. KOSZYCKI D, ZACHARKO RM, LE MELLEDO J-M, **BRADWEJN J**. A comparison of CCK-4 panickers and non-panickers. 149<sup>th</sup> Annual Meeting of the APA, New York, NY, pp. 259, May 4-9, 1996.
151. LE MELLEDO, J-M, **BRADWEJN J**, KOSZYCKI D, JERABEK I, JOLICOEUR F, CADIEUX A, BOULENGER J-P, BELLAVANCE F, BICHET DG. The role of beta-noradrenergic system in CCK-4 induced panic symptoms. 149<sup>th</sup> Annual Meeting of the APA, New York, NY, pp. 257, May 4-9, 1996.
152. FLINT A, **BRADWEJN J**, VACCARINO FJ, KOSZYCKI D. The effect of aging on cholecystokinin-induced panic. 149<sup>th</sup> Annual Meeting of the APA, New York, NY, pp. 258, May 4-9, 1996.
153. **BRADWEJN J**, VACCARINO FV. Chairman of Symposium: role of cholecystokinin in mood and anxiety disorders. CCNP, 19<sup>th</sup> Annual Meeting, Toronto, ON, June 2-5, 1996.
154. PALMOUR RM, ERVIN FR, **BRADWEJN J**. Cholecystokinin and anxiety: A non-human primate model. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 9, June 2-5, 1996.
155. LYDIARD, RB, BRAWMAN-MINTZER O, **BRADWEJN J**, EMMANUEL N, JOHNSON MR, WARE MR, BALLENGER JC. Human CSF-CCK in anxiety disorders and CCK agonist challenge in GAD. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 10, June 2-5, 1996.
156. JERABEK I, BOULENGER JP, **BRADWEJN J**, LAVALLEE YJ, JOLICOEUR FB. CCK4 challenge II: Catecholamine time course in plasma and platelets after CCK4 administration? CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 41, June 2-5, 1996.
157. LE MELLEDO, J-M, **BRADWEJN J**, KOSZYCKI D, JERABEK I, JOLICOEUR F, CADIEUX A, BOULENGER J-P, BELLAVANCE F, BICHET DG. The role of beta adrenergic system in CCK-4 induced panic symptoms. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 44, June 2-5, 1996.
158. LE MELLEDO, J-M, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET DG. Effect of major depressive episode history on the CCK-4 response in women. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 45, June 2-5, 1996.
159. VASAR E, VOLKE V, SOOSAAR A, KOKS S, **BRADWEJN J**, BOURIN M. Evidence that cholecystokinin (CCK) and nitric oxide (NO) interact in regulation of anxiety. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 49, June 2-5, 1996.
160. KOSZYCKI D, **BRADWEJN J**. Cognitive and non-cognitive panic attacks induced by CCK-4. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 50, June 2-5, 1996.
161. JOSSELYN SA, FRANKLAND PW, YEOMANS JS, **BRADWEJN J**, VACCARINO FJ. CCK and anxiety: Intra-amygdala infusion of pentagastrin, a CCKB agonist, produces facilitation of acoustic startle reflex in rats. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 52, June 2-5, 1996.
162. DESOUSA NJ, **BRADWEJN J**, VACCARINO FJ. The effects of frontal cortex CCKB receptor activation on anxiety-like responses in the elevated plus-maze. CCNP 19<sup>th</sup> Annual Meeting, Toronto, ON, pp. 54, June 2-5, 1996.
163. LYDIARD RB, **BRADWEJN J**. Chairman of Symposium: CCK in anxiety: overview and update. XX<sup>th</sup> CINP, Melbourne, Australia, June 23-27, 1996.
164. LYDIARD, RB, BRAWMAN-MINTZER O, **BRADWEJN J**, EMMANUEL N, JOHNSON MR, WARE MR, BALLENGER JC. Human CSF-CCK in anxiety disorders and CCK agonist challenge in GAD. XX<sup>th</sup> CINP, vol. 6, S3, p. 213, Melbourne, Australia, June 23-27, 1996.

165. **BRADWEJN J**, KOSZYCKI D. CCK-B agonists and panic induction in humans. XX<sup>th</sup> CINP, vol. 6, S3, Melbourne, Australia, June 23-27, 1996.
166. LE MELLEDO, J-M, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET DG. Effect of a major depressive episode history on the CCK-4 response in women. XX<sup>th</sup> CINP, vol. 6, S3, pp. 113-114, Melbourne, Australia, June 23-27, 1996.
167. LE MELLEDO, J-M, **BRADWEJN J**, KOSZYCKI D, JERABEK I, JOLICOEUR F, CADIEUX A, BOULENGER J-P, BELLAVANCE F, BICHET DG. The role of beta adrenergic system in CCK-4 induced panic symptoms. XX<sup>th</sup> CINP, vol. 6, S3, p. 114, Melbourne, Australia, June 23-27, 1996.
168. KOSZYCKI D, ZACHARKO RM, LE MELLEDO J-M, **BRADWEJN J**. The effects of CCK-4 in normal individuals: comparison of panickers and non-panickers. XX<sup>th</sup> CINP vol. 6, S3, p. 206 Melbourne, Australia, June 23-27, 1996.
169. KOSZYCKI D, **BRADWEJN J**. Cognitive and Non-Cognitive Panic Attacks Induced by CCK-4 Challenge. X World Congress of Psychiatry p. 85, Madrid, Spain, August 23-28, 1996.
170. LE MELLEDO J, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET D. Effect of a Major Depressive Episode History on CCK-4 Response in Women. X World Congress of Psychiatry p. 87, Madrid, Spain, August 23-28, 1996.
171. LE MELLEDO J, **BRADWEJN J**, KOSZYCKI D, BOULENGER J, BICHET D. The Role of the B Adrenergic Systems in CCK-4 Induced Panic Symptoms. X World Congress of Psychiatry p. 92, Madrid, Spain, August 23-28, 1996.
172. **BRADWEJN J**, KOSZYCKI D, LE MELLEDO J. Cholecystokinin and Anxiety. X World Congress of Psychiatry p. 57, Madrid, Spain, August 23-28, 1996.
173. LE MELLEDO J-M, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET D. Effect of a Major Depressive Episode History on the CCK-4 Response in Women Suffering from Premenstrual Dysphoric Disorder. 46<sup>th</sup> Annual Meeting. Psychiatry: Opening the Doors, P21, p. 78, QC, October 1-4, 1996.
174. LE MELLEDO J-M, **BRADWEJN J**, KOSZYCKI D, BELLAVANCE F, BICHET D. The Role of the  $\beta$ -Adrenergic System in CCK-4-Induced Panic Symptoms. 46<sup>th</sup> Annual Meeting. Psychiatry - Opening the Doors, P22, p. 79, QC, October 1-4, 1996.
175. PLAMONDON J, REYNOLDS C, SHEEHAN D, DUNNER D, CLAYTON P, ROSENBAUM J, **BRADWEJN J**. Case Forum: Clinical Experiences in Depression and Panic Disorder. 46<sup>th</sup> Annual Meeting. Psychiatry - Opening the Doors, SS3, p. 126, QC, October 1-4, 1996.
176. LE MELLEDO JM, **BRADWEJN J**, KOSZYCKI D, BOULENGER JP, CADIEUX A, JERABEK I, JOLICOEUR F, BELLAVANCE F, BICHET D. The role of the beta-noradrenergic system in CCK-4-induced symptoms. Society for Neurosciences Meeting, Program # 95.16, Washington, DC, November 17, 1996.
177. ZHOU Y, ARIFUZZAMAN AI, JOSSELYN SA, FRANKLAND PW, **BRADWEJN J**, VACCARINO FJ. Effects of intraperitoneal administration of CCK agonists and antagonists on acoustical startle response, an anxiety model, in rats. Society for Neurosciences Meeting, Program # 455.8, Washington, DC, November 19, 1996.
178. FLINT AJ, **BRADWEJN J**, VACCARINO FJ, KOSZYCKI D. The effect of aging on cholecystokinin-induced panic. Department of Psychiatry, University of Toronto Research Day, Toronto, ON, 1996.
179. KATZMAN, MA, **BRADWEJN, J**, KOSZYCKI, D, VACCARINO, F, RICHTER MA. The effect of CCK-4 in social phobia and OCD. 150<sup>th</sup> Annual Meeting of the APA, San Diego, CA, p. 105, May 17-22, 1997.
180. SHLIK, J, ALUOJA, A, VASAR, V, VASAR, E, PODAR, T, **BRADWEJN, J**. Effects of citalopram treatment on behavioral, cardiovascular and neuroendocrine response to CCK tetrapeptide challenge in panic disorder patients. 150<sup>th</sup> Annual Meeting of the APA, San Diego, CA, p. 105, May 17-22, 1997.
181. LE MELLEDO J-M, ARTHUR H, **BRADWEJN J**, DALTON D, LIPSON N, WOO C, KOSZYCKI D,

- BELLAVANCE F, BOULENGER J-P, CADIEUX A, BICHET DG Influence of type A behaviour pattern on response to CCK-4. World Biological Psychiatry Conference, Nice, France, June 1997 Biological Psychiatry, 1997; 42: 297S.
182. LE MELLEDO J-M, **BRADWEJN J**, KOSZYCKI D, BOULANGER J-P, CADIEUX A, BELLAVANCE F, BICHET DG The role of the beta-adrenergic system in behavioral and neuroendocrine response to CCK-4. NCDEU Annual Meeting, May 1997.
183. KOSZYCKI, D, **BRADWEJN, J**. Personality correlates of response to CCK-4 in healthy males. 150<sup>th</sup> Annual Meeting of the APA, San Diego, CA, p. 216, May 17-22, 1997.
184. **BRADWEJN, J**, LEGRAND J-M, KOSZYCKI, D, BATES JHT, BOURIN, MS. Respiratory response to CCK-4 in healthy subjects. 150<sup>th</sup> Annual Meeting of the APA, p. 216, May 17-22, 1997.
185. KENNEDY, JL, KOSZYCKI, D, KATZMAN, MA, KING, NA, **BRADWEJN, J**. CCK-B receptor gene alleles associated with panic disorder. 150<sup>th</sup> Annual Meeting of the APA, San Diego, CA, p. 233, May 17-22, 1997.
186. KOSZYCKI D, **BRADWEJN J**. Personality correlates of response to CCK-4 in healthy males. 6<sup>th</sup> World Congress of Biological Psychiatry, Nice, France, June 1997; Biological Psychiatry (Supp), 42, 1997, p. 18S.
187. **BRADWEJN J**, KOSZYCKI D. Therapeutics of panic disorder. 6<sup>th</sup> World Congress of Biological Psychiatry, Nice, France, June 1997; Biological Psychiatry (Supp), 42, 1997, p. 18S.
188. BOULENGER, JP, JERABEK, I, **BRADWEJN, J**, LAVALLEE, YJ, CADIEUX, A. Plasma neuropeptide Y reactivity to cholecystokinin challenge in panic disorders and normal controls. 6<sup>th</sup> World Congress of Biological Psychiatry, Nice, France, June 1997, Biological Psychiatry, 42:IS-297S. 1997.
189. KOSZYCKI, D, **BRADWEJN, J**. The relationship between neuroticism and extraversion and sensitivity to CCK-4 in healthy volunteers. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, Supplement to Journal of Psychopharmacology, 11:A24, July 13-17, 1997.
190. JERABEK, I, BOULENGER, J-P, **BRADWEJN, J**, LIZOTTE, ME, LAVALLE, YJ, JOLICOEUR, FB. CCK4 challenge and differences between panic disorder patients and healthy subjects. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, Supplement to Journal of Psychopharmacology, 11:A25, July 13-17, 1997.
191. LE MELLEDO, J-M, ARTHUR, H, **BRADWEJN, J**, DALTON, J, LIPSON, N, WOO, C, KOSZYCKI, D, BELLAVANCE, F, BOULENGER, J-P, CADIEUX, A, BICHET, DG. Influence of type A behaviour pattern on response to CCK-4. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, Supplement to Journal of Psychopharmacology, 11:A25, July 13-17, 1997.
192. DESOUSA, NJ, WUNDERLICH, GR, **BRADWEJN, J**, VACCARINO, FJ. Individual differences in sugar intake predicts behaviour in animal models of anxiety. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, Supplement to Journal of Psychopharmacology, 11:A49, July 13-17, 1997.
193. JAVANMARD, M, SHLIK, J, KENNEDY, SH, VACCARINO, FJ, **BRADWEJN, J**. Neuroanatomical correlates of CCK-4 panic in healthy volunteers. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, Supplement to Journal of Psychopharmacology, 11:A88, July 13-17, 1997.
194. LE MELLEDO J-M, **BRADWEJN J**, BOULENGER J-P, CADIEUX A, KOSZYCKI D, BELLAVANCE F, BICHET DG Influence of propranolol pretreatment on the neuroendocrine response to CCK-4. British Association for Psychopharmacology and the Canadian College for Neuropsychopharmacology, Cambridge, England, July 1997.
195. JERABEK, JP, BOULENGER, JP, **BRADWEJN, J**, LIZOTTE, ME, LAVALLÉE YJ, JOLICOEUR, FB.

- CCK4 effects on plasma catecholamines, psychological and cardiovascular indices in panic disorder patients is different from healthy controls. Society for Neuroscience 1997 Program. 425.15.
196. LE MELLEDO, J-M, ARTHUR, A, **BRADWEJN, J**, DALTON, J, LIPSON, N, WOO, C, KOSZYCKI, D, BELLAVANCE, F, BOULENGER, J-P, CADIEUX, A, LIZOTTE, M-E, JOLICOEUR, F, BICHET, DG. Influence of type A behaviour pattern on response to CCK-4. Society for Neuroscience 1997 Program. 630.7.
  197. VACCARINO, FJ, ARIFUZZAMAN, AI, SABIJAN, SM, WUNDERLICH GR, DESOUSA, NJ, BUSH, DEA, **BRADWEJN, J**. CCKB receptor activation and anxiogenic behavior: a neuroanatomical analysis. Society for Neuroscience 1997. 630.8.
  198. MERANI, S, GUTKOWSKA, J, ERVIN, FR, **BRADWEJN, J**, VACCARINO, F, PALMOUR, RM. Intravenous caffeine elevates plasma CCK levels in healthy adults and in vervet monkeys. Society for Neuroscience 1997 Program. 630.9.
  199. JAVANMARD, M, SHLIK, J, KENNEDY, SH, VACCARINO, FJ, **BRADWEJN, J**. Positron emission tomography study of cholecystokinin-4-induced panic attacks in healthy volunteers. Society for Neuroscience 1997 Program. 714.2.
  200. SHLIK, J, ZHOU, Y, KOSZYCKI, D, **BRADWEJN, J**. Effects of cholecystokinin-tetrapeptide infusion on the acoustic startle response in healthy volunteers. 18<sup>th</sup> Annual Conference of the Anxiety Disorders Association of America 1998 Program. March 1998, NR04.
  201. **BRADWEJN, J**, ZHOU, Y, VACCARINO, F. From CCK to Herbal Medicine in Anxiety: Research with Centella Asiatica. Anxiety Disorders Association of America 1998 Program. March 1998, 306R.
  202. KING N A, KOSZYCKI D, **BRADWEJN J**, KENNEDY J. Molecular genetics studies of panic disorder. New Research and Abstracts (NR 383), American Psychiatric Association Annual Meeting, Toronto, ON, June 1998.
  203. JAVANMARD M, SHLIK J, KENNEDY S, **BRADWEJN J**. Neuroanatomical correlates of anticipatory anxiety: A PET study of CCK-4-induced anxiety. New Research and Abstracts (NR 369), American Psychiatric Association Annual Meeting, Toronto, ON, June 1998.
  204. SHLIK J, KOSZYCKI D, **BRADWEJN J**. CCK-4-induced effects on the acoustic startle reflex in humans. 38<sup>th</sup> NCDEU Annual Meeting, Boca Raton, FL, June 9-13, 1998.
  205. SHLIK J, ZHOU Y, KOSZYCKI D, VACCARINO FJ, **BRADWEJN J**. Effects of CCK-4-infusion on the acoustic startle reflex and stress hormones in healthy volunteers. 21<sup>st</sup> Annual Meeting CCNP, Montréal, QC, June 14-17, 1998.
  206. **BRADWEJN J**, ZHOU YP, KOSZYCKI D, SHLIK J, KATZMAN M, VACCARINO F. Effect of acute administration of gotu-kola on acoustic startle response in healthy volunteers. XXI<sup>st</sup> Colloquium Internationale Neuropsychopharmacologicum Congress. Glasgow, Scotland, NRW001, pg 171, July 15, 1998.
  207. SHLIK J, ZHOU Y, KOSZYCKI D, VACCARINO FJ, **BRADWEJN J**. The effects of CCK-4 infusion on the acoustic startle reflex. XXI<sup>st</sup> CINP Congress, Glasgow, Scotland, July 12-16, 1998.
  208. KING NA, KOSZYCKI D, **BRADWEJN J**, KENNEDY JL. Molecular genetic studies of panic disorder. The American Society of Human Genetics Annual Meeting. Denver, CO, October 1998.
  209. KOSZYCKI D, APPELTON D, **BRADWEJN J**. Predictors of illness intrusiveness in anxiety disorders (NR 334). American Psychiatric Association Annual Meeting, Washington, DC, May 1999.
  210. KATZMAN M, **BRADWEJN J**, KOSZYCKI D, VACCARINO F. The effect of cholecystokinin-tetrapeptide in social phobia and OCD. New Research and Abstracts (NR 215). American Psychiatric Association Annual Meeting, Washington, DC, May 1999.
  211. KOSZYCKI D, **BRADWEJN J**. Response to CCK-4 in patients with major depression and panic disorder.

- Canadian College of Neuropsychopharmacology. Halifax, NS, June 12-15, 1999.
212. **BRADWEJN J**, SHLIK J, KOSZYCKI D. Effects of acute pretreatment with RWJ-51204-000, a partial agonists of the GABA<sub>A</sub> receptor, on CCK-4-induced panic anxiety in healthy volunteers. Canadian College of Neuropsychopharmacology. Halifax, NS, June 12-15 1999.
  213. FLINT AJ, KOSZYCKI D, **BRADWEJN J**, VACCARINO FJ. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy volunteers. Ninth Congress of the International Psychogeriatric Association. Vancouver, 1999
  214. KOSZYCKI D, COPEN J, **BRADWEJN J**. Neuroendocrine response to CCK-4 in panic and major depressive disorders. 23<sup>rd</sup> Annual Meeting Canadian College of Neuropsychopharmacology, Marrakech, Morocco, April 10-13, 2000.
  215. **BRADWEJN, J**. Le rôle de la CCK dans l'éthiopathogénie des trouble panique. Canadian College of Neuropsychopharmacology (Joint meeting with the French and Moroccan College of Neuropsychopharmacology), Casablanca, Morocco, April 2000.
  216. **BRADWEJN J**, KOSZYCKI D. CCK and panic disorder. 13<sup>th</sup> Annual Meeting of the European College of Neuropsychopharmacology. Munich, Germany, September 9-13, 2000, p. S124.
  217. FLINT AJ, **BRADWEJN J**, VACCARINO FJ, KOSZYCKI D. Effect of aging on the cholecystokinin system. American Psychiatric Association Meeting, New Orleans, LA, May 2001.
  218. KOSZYCKI D, SWAIN J, **BRADWEJN J**. Effect of CCK-4 in patients with irritable bowel syndrome. Canadian College of Neuropsychopharmacology, Banff, AB, June 19-20, 2001.
  219. **BRADWEJN J**, KOSZYCKI D. The role of CCK in panic disorder: From behavior to genes. 8<sup>th</sup> World Congress of Biological Psychiatry, Berlin, Germany, July 1-6, 2001.
  220. **BRADWEJN J**, KOSZYCKI D. Cholecystokinin and anxiety disorders. European Psychiatry, Vol. 17 (suppl. 1), May 2002, 51S.
  221. KOSZYCKI D, **BRADWEJN J**. Effect of CCK-4 in Irritable Bowel Syndrome. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 21, 2002. New Research Abstracts, p. 47.
  222. **BRADWEJN J**. The CCK System and Anxiety: From Genes to Therapeutics. The International Journal of Neuropsychopharmacology, Volume 5, Abstract No. S.39.2, p. S37, June 2002.
  223. **BRADWEJN J**, KOSZYCKI D, SEGAL Z. Efficacy of Self-Administered Cognitive-Behavior Therapy and Sertraline in Panic Disorder, APA, San Francisco, CA, May 17-22, 2003.
  224. **BRADWEJN J**, EMILIEN G, WHITAKER T. Treatment of Panic Disorder with Venlafaxine Extended Release, Abstract No. NR214, APA, San Francisco, CA, May 17-22, 2003.
  225. **BRADWEJN J**, EMILIEN G, WHITAKER T. Treatment of Panic Disorder with Venlafaxine XR, Poster No. Panic 391, NCDEU conference, Boca Raton, FL, May 27-30, 2003.
  226. AHOKAS A, **BRADWEJN J**, EMILIEN G, WHITAKER T. Treatment of panic disorder with venlafaxine XR, Poster No. P.3.057, 16<sup>th</sup> ECNP Congress, Prague, Czech Republic, September 20-24, 2003.
  227. **BRADWEJN J**, EMILIEN G, WHITAKER T, AHOKAS A. Treatment of Panic Disorder with Venlafaxine XR, Poster No. 121, American College of Neuropsychopharmacology Meeting in Puerto Rico, December 8, 2003.
  228. **BRADWEJN J**, EMILIEN G, AHOKAS A, WHITAKER T. Treatment of Panic Disorder with Venlafaxine XR, International Congress of the World Federation of Societies of Biological Psychiatry (WFSBP), Sydney, Australia, February 9-13, 2004.
  229. KOSZYCKI D, ZWANZGER P, MERALI Z, **BRADWEJN J**. Heart rate variability and cortisol response to a stressor in children at high and low genetic risk for panic disorder. The International Journal of Neuropsychopharmacology, Volume 7, Supplement 1, Abstract No. P01.247, June 2004.

230. ZWANZGER P, KOSZYCKI D, MARSHALL R, MERALI Z, **BRADWEJN J**. Identification of Possible neurobiological trait markers in High-Risk subjects for Panic Disorder. The International Journal of Neuropsychopharmacology, Volume 7, Supplement 1, Abstract No. SP.22.01, June 2004.
231. **BRADWEJN J**, KOSZYCKI D. The Genetics of panic disorder, The International Journal of Neuropsychopharmacology, Volume 7, Supplement 1, Abstract No. SP.22.04, June 2004.
232. THARMALINGAM S, KING N, ROTHE C, KOSZYCKI D, **BRADWEJN J**, MACCIARDI F, KENNEDY J. Association between the C-45T polymorphism of the cholecystokinin gene and panic disorder. Meeting of the American Society of Human Genetics. October 29, 2004.
233. KOSZYCKI D, ZWANZGER P, MERALI Z, **BRADWEJN J**. Heart rate variability and cortisol response to a stressor in children at high and low genetic risk for panic disorder. American Society for Psychosomatic Medicine. Vancouver, BC, March 2005.
234. **BRADWEJN J**, KOSZYCKI D, SEGAL Z. Randomized controlled trial of acute and extension treatment with sertraline and self-administered cognitive behaviour therapy, alone or in combination, in panic disorder. ECNP Meeting, Amsterdam, The Netherlands, October 2005.
235. **BRADWEJN J**. Invited Speaker, Brainstorming Session "Update on clinical and genetic aspects of CCK research". ECNP Meeting, Amsterdam, The Netherlands, October 22, 2005.
236. KOSZYCKI D, SHLIK J, **BRADWEJN J**. Influence of personality on behavioral and cardiovascular response to cholecystokinin-tetrapeptide in healthy volunteers. ECNP Meeting, Amsterdam, The Netherlands, October 23, 2005.
237. KOSZYCKI D, SHLIK J, **BRADWEJN J**. Personality correlates of response to low dose CCK-4 in healthy volunteers. American Society for Psychosomatic Medicine, Denver , CO, March 2006.
238. KOSZYCKI D, **BRADWEJN J**. Personality and clinical correlates of response to a laboratory stress in patients with social anxiety disorder. 9th World Congress of Biological Psychiatry, Paris, France, June 30<sup>th</sup>, 2009.
239. KEATING L, TASCA GA, MAXWELL H, HARES S, TRINNEER A, BARBER A, **BRADWEJN J**, BISSADA H Predicting acceptance of intensive treatment and participation in a randomized control trial of medication among women with anorexia nervosa. International Conference on Eating Disorders, April 28-30, 2011 Miami, Florida.

#### **Invited Conferences (Selected):**

1. **BRADWEJN J**. Tardive dyskinesia: Practical aspects for the physician. Royal Victoria Hospital, Academic Seminar for Emergency Room Physicians, QC, July 28, 1982.
2. CHOUINARD G, ANNABLE L, **BRADWEJN J**, LABONTE A, JONES BD, MERCIER P, BELANGER MC. An early phase II clinical trial of tomoxetine (LY 139603) in the treatment of newly admitted depressed patients. Free Communications Session, Rockville, MD, March 16, 1984.
3. **BRADWEJN J**. Mode d'action des psychotropes. Continuing Medical Education, Fleury Hospital, March 7, 1984.
4. **BRADWEJN J**. La depression réfractaire. Continuing Medical Education, Louis-H. Lafontaine Hospital, Montréal, QC, March 6, 1985.
5. **BRADWEJN J**. Un nouveau mode d'action des benzodiazepines. Hotel-Dieu Hospital, Montréal, QC, March 15, 1985.
6. **BRADWEJN J**. La lithothérapie. Journée de Toxicologies. Santa-Cabrini Hospital, October 3, 1985.
7. **BRADWEJN J**. Les benzodiazepines. Department of Psychiatry, Université de Montréal, QC, October 9, 1985.
8. **BRADWEJN J**. Receptors in Psychiatry. Lecture to neurologists, Montréal Neurological Institute, QC, January 22, 1986.
9. **BRADWEJN J**. A new mode of action of benzodiazepines. Invited speaker, department of Psychiatry,



- Montréal General Hospital, QC, January 24, 1986.
10. **BRADWEJN J.** La recherche avec les benzodiazepines. Invited speaker, Department of Psychiatry, Hotel-Dieu de Levis, QC, April 30, 1986.
  11. **BRADWEJN J.** Le role de la cholecystokinine dans les troubles d'anxiété. Invited speaker, department of Psychiatry, Hôpital Maisonneuve-Rosemont, Montréal, QC, November 6, 1986.
  12. **BRADWEJN J.** Research with Cholecystokinin. Invited speaker, Neuroscience Group, Research and Training Building, McGill University, QC, November 14, 1986.
  13. **BRADWEJN J.** Attaques de panique. Invited speaker, Continuing medical education, Hôpital de Chicoutimi, QC, January 17, 1987.
  14. **BRADWEJN J.** Attaques de panique. Invited speaker, Continuing medical education (F.M.O.Q.), Trois Rivières, QC, January 31, 1987.
  15. **BRADWEJN J.** Les désordres affectifs saisonniers. Monthly meeting of psychiatrists of Québec City. Clinique Roy-Rousseau, Québec City, QC, March 11, 1987.
  16. **BRADWEJN J.** Research with cholecystokinin. Invited speaker, Veterans Hospital, St. Anne de Bellevue, QC, April 24, 1987.
  17. **BRADWEJN J.** Study on the treatment of major depressive episodes refractory to treatment with antidepressants, Kingston Memorial Day. St. Mary's Hospital, ON, May 6, 1987.
  18. **BRADWEJN J.** Les désordres affectifs saisonniers. Department of Psychiatry, Veterans Hospital, St. Anne de Bellevue, QC, October 3, 1987.
  19. **BRADWEJN J.** Le tryptophane et les troubles affectifs. Louis-H. Lafontaine Hospital, QC, October 23, 1987.
  20. **BRADWEJN J.** Les benzodiazepines, nouveaux usages. Pharmacotherapy Symposium, St. Jérôme Hospital meeting, L'Estérel, QC, October 1987.
  21. **BRADWEJN J.** New antidepressants. Department of Psychiatry, Queen Elizabeth Hospital, Montréal, QC, March 8, 1988.
  22. **BRADWEJN J.** La psychopharmacologie. Département de psychiatrie, Hôpital St. François d'Assises, La Sarre, QC, March 23, 1988.
  23. **BRADWEJN J.** Nouvelles indications des benzodiazepines. Département de psychiatrie, Hôpital Jean Talon, Montréal, QC, April 21, 1988.
  24. **BRADWEJN J.** New indications for benzodiazepines. Department of Psychiatry, Lakeshore General Hospital, Point Claire, QC, April 27, 1988.
  25. **BRADWEJN J.** Technique d'induction des crises de panique. Département de psychiatrie, Hôpital de Granby, Granby, QC, May 4, 1988.
  26. **METERISSIAN G, BRADWEJN J.** Comparative studies on the efficacy of psychotherapy, pharmacotherapy and their combination in depression: Was adequate pharmacotherapy provided? Department of Psychiatry, St. Mary's Hospital, QC, May 5, 1988.
  27. **BRADWEJN J.** Le tryptophane et les troubles affectifs. Journée psychiatrique régionale annuelle (AMOIP). Chicoutimi, QC, May 20, 1988.
  28. **BRADWEJN J.** The use of tryptophan. Department of Psychiatry, St. Anne de Bellevue, QC, May 27, 1988.
  29. **BRADWEJN J.** Les nouveaux antidépresseurs. Département de médecine, Hôpital George Dumont, Moncton, NB, June 1, 1988.
  30. **BRADWEJN J.** Research in panic disorder. Department of Psychiatry. Moncton Hospital, Moncton, NB, June 2, 1988.
  31. **BRADWEJN J.** Panic disorder. Workshop leader, McGill University, Clinical Day, Montréal, QC, June 10, 1988.
  32. **BRADWEJN J.** Depression: Acute pharmacological treatment. Canadian Consensus Symposium on Depression. University of Ottawa, ON, September 9, 1988.
  33. **BRADWEJN J.** Nouveaux antidépresseurs. Maisonneuve-Rosemont Hospital, Montréal, QC, September 15, 1988.

34. **BRADWEJN J.** New antidepressants. Montréal General Hospital, Montréal, QC, September 16, 1988.
35. **BRADWEJN J.** Panic disorder: Psychological and psychopharmacological aspects. Department of Psychiatry, Jewish General Hospital, Montréal, QC, October 4, 1988.
36. **BRADWEJN J.** Cholecystokinin and anxiety disorders. Department of Psychiatry, Allan Memorial Institute, Montréal, QC, November 3, 1988.
37. **BRADWEJN J.** The use of benzodiazepines. Continuing Medical Education. Santa Cabrini Hospital, Montréal, QC, November 26, 1988.
38. **BRADWEJN J.** Panic disorder in the emergency room. Royal Victoria Hospital, Montréal, QC, November 30, 1988.
39. **BRADWEJN, J.** Les nouveaux antidépresseurs. Département de Psychiatrie, Hôpital Pierre-Janet, Hull, QC, December 6, 1988.
40. **BRADWEJN, J.** Le traitement des depression résistantes. Centre Hospitalier Régional de Lanaudière, Joliette, QC, January 11, 1989.
41. **BRADWEJN, J.** Neurobiologie des attaques de panique. Département de Psychiatrie, Hôpital Pierre-Janet, Hull, QC, January 19, 1989.
42. **BRADWEJN, J.** Les troubles affectifs saisonniers (SAD). Département de Psychiatrie, Cite de la Santé, Laval, QC, February 8, 1989.
43. **BRADWEJN J.** Cholecystokinin and panic disorder research. Merck, Sharp and Dohme, West Point, PA, March 16, 1989.
44. **BRADWEJN J.** Research in panic disorders. Department of Psychiatry, Lakeshore Hospital, Point Claire, QC, March 22, 1989.
45. **BRADWEJN J.** Review of new antidepressants. Department of Psychiatry, Robert Giffard Hospital, QC, April 6, 1989.
46. **BRADWEJN J.** Fluoxetine and selective MAOI. Meeting for psychiatrists. Delta hotel, Montréal, QC, April 10, 1989.
47. **BRADWEJN J.** The role of tryptophan in affective disorders. Hotel Dieu de St. Jérôme, QC, April 12, 1989.
48. **BRADWEJN J.** Neurobiology of panic disorder. Department of Psychiatry, Queen Elizabeth Hospital, Montréal, QC, May 2, 1989.
49. **BRADWEJN J.** Aspects psychosociaux des benzodiazepines. 23ieme Congrès Annuel de l'Association des Psychiatres du Québec, Montebello, QC, May 25, 1989.
50. **BRADWEJN J.** Le tryptophane et les maladies affectifs. Département de Psychiatrie, Hôpital Enfant Jesus de Québec, QC, May 29, 1989.
51. **BRADWEJN J.** Main Speaker, Clinical Day in Psychiatry. Dr. Everett Chalmers Hospital Center, Fredericton, NB, June 5, 1989.
52. **BRADWEJN J.** Diagnosis and treatment of anxiety disorders. Montréal Chinese Hospital, Continuing Medical Education, QC, June 17, 1989.
53. **BRADWEJN J.** Recherche neurobiologique dans les troubles panique. Département de Psychiatrie, Hôpital Maisonneuve Rosemont, QC, September 14, 1989.
54. **BRADWEJN J.** Les nouveaux antidépresseurs. Département de Psychiatrie. Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, October 6, 1989.
55. **BRADWEJN J.** Cholecystokinin as a panic inducer. Department of Psychiatry, St. Mary's Hospital, Montréal, QC, October 12, 1989.
56. **BRADWEJN J.** La psychopharmacologie des troubles affectifs et anxieux. Département de Psychiatrie, Centre Hospitalier Universitaire de Laval (CHUL), QC, October 26, 1989.
57. **BRADWEJN J.** La recherche psychiatrique à l'Université McGill. Hôpital Enfant Jesus de Québec, QC, October 26, 1989.
58. **BRADWEJN J.** Cholecystokinin and panic disorder. Third Annual Research Day in Psychiatry. McGill University, Montréal, QC, November 10, 1989.
59. **BRADWEJN J.** Les peptides et les troubles de panique. Département de Psychiatrie, Centre Hospitalier

- St. Jean sur le Richelieu, QC, December 12, 1989.
60. **BRADWEJN J.** The role of cholecystokinin in the neurobiology of panic disorders. Invited Speaker, Lilly Research Laboratories, Indianapolis, IN, December 19, 1989.
  61. **BRADWEJN J.** Panic Disorders. 40<sup>th</sup> Annual Refresher Course for Family Physician. Royal Victoria Hospital Continuing Medical Education, QC, November 27, 1989.
  62. **BRADWEJN J.** The neurobiology of anxiety. Symposium on Anxiety Disorders, University of Laval, St. Anne de Beaupré, QC, January 24, 1990.
  63. **BRADWEJN J.** The CCK-4 hypothesis of panic disorders. Department of Psychiatry, Veterans Hospital, Ste.-Anne de Bellevue, QC, March 16, 1990.
  64. **BRADWEJN J.** Le role de la cholecystokinine dans la neurobiologie de l'anxiété. Département de Psychiatrie, Hôpital Ste-Anne, Paris, France, April 2, 1990.
  65. **BRADWEJN J.** Video demonstration of cholecystokinin-induced panic attacks. International Symposium on New Concepts in Anxiety. Castre, France, April 1990.
  66. **BRADWEJN J, KOSZYCKI D.** CCK receptors and panic attacks in man. An International Symposium on Multiple Cholecystokinin Receptors: Progress Towards CNS Therapeutic Targets. Terlings Park, England, September 22, 1990.
  67. **BRADWEJN J.** CCK and research in panic disorders. Clark Institute of Psychiatry, Toronto, ON, September 11, 1990.
  68. **BRADWEJN J.** Les troubles de panique. Rencontre de l'Association des Agoraphobes, Haute- Rivère, QC, September 30, 1990.
  69. **BRADWEJN J.** Panic Disorders. 41st Annual Refresher Course for Family Physician. Royal Victoria Hospital Continuing Medical Education, QC, November 28, 1990.
  70. **BRADWEJN J.** Anxiety Disorders. Continuing Medical Education, Thursday Evening Lectures, McGill University, QC, December 6, 1990.
  71. **BRADWEJN J.** La cholecystokinine et le trouble panique; le traitement des trouble panique. Département de Psychiatrie, Université de Nantes, France, February 8, 1991.
  72. **BRADWEJN J.** Diagnosis and treatment of panic disorder. Continuing Medical Education for Family Physicians. University of Ottawa, Ottawa, ON, February 19, 1991.
  73. **BRADWEJN J.** Le trouble panique et l'agoraphobie. Education Médicale Continue pour le Généraliste, Montréal, QC, February 21, 1991.
  74. **BRADWEJN J.** Panic disorder: diagnosis and treatment. Department of Psychiatry, Jewish General Hospital, Montréal, QC, March 12, 1991.
  75. **BRADWEJN J.** The process of grant application. Child Psychiatry Research Seminar, Department of Child Psychiatry, McGill University, Montréal, QC, March 22, 1991.
  76. **BRADWEJN J.** Clinical issues in panic disorder. Department of psychiatry, Lakeshore Hospital, Pointe Claire, QC, April 10, 1991.
  77. **BRADWEJN J.** Les troubles de panique. Département de Psychiatrie, Hôpital Saint Vincent, Sherbrooke, QC, April 10, 1991.
  78. **BRADWEJN J.** Aspects cliniques des troubles de panique et de l'agoraphobie. Education Médicale Continue. Sherbrooke, QC, April 11, 1991.
  79. **BRADWEJN J.** CCK, CCK antagonists and panic disorders. Parke-Davis, Ann Arbor, MI, April 17, 1991.
  80. **BRADWEJN J.** Etats de panique, agoraphobie, diagnostique et traitement. Clinique Médicale de Laval, QC, April 18, 1991.
  81. **BRADWEJN J.** CCK Research in panic disorders. Département de Psychiatrie, Centre Hospitalier Universitaire de Sherbrooke, QC, May 3, 1991.
  82. **BRADWEJN J.** Les troubles panique: phénoménologie et traitements. Education Médicale Continue. Hôpital St. Michel, QC, May 4, 1991.
  83. **BRADWEJN J.** Trouble panique: perspectives pour la recherche. 25e Congrès Annuel de l'Association des Médecins Psychiatres du Québec, Chicoutimi, QC, June 6, 1991.

84. **BRADWEJN J.** Research with cholecystokinin in panic disorders. Young Investigator Award Lecture, Canadian College of Neuropsychopharmacology, Hamilton, ON, June 5, 1991.
85. **BRADWEJN J.** La cholecystokinine et le trouble panique. Jouveinal Recherche, Fresne, France, June 17, 1991.
86. **BRADWEJN J.** Le trouble panique, diagnostique et traitement. Upjohn Canada, Grandview, ON, September 9, 1991.
87. **BRADWEJN J.** Séminaire sur les méthodes de recherches en psychiatrie, Hôpital Pierre Janet, Hull, QC, September 13, 1991.
88. **BRADWEJN J.** Treatment of refractory depression. Department of Psychiatry, Lakeshore Hospital, QC, September 21, 1991.
89. **BRADWEJN J.** La cholecystokinine: une nouvelle théorie du trouble panique. Département de Psychiatrie de l'Institut Albert Prévost, QC, October 1, 1991.
90. **BRADWEJN J.** Typologie des maladies affectifs et développement récent des recherches. Colloque: "Les maladies affectifs majeures". Département de Psychiatrie, Université de Montréal, Hôpital Sacré-Coeur, QC, October 25, 1991.
91. **BRADWEJN J.** Conférencier Invite. Colloque: "Le Trouble Panique... Vous connaissez?". Hôpital St Francois d' Assises, QC, November 1, 1991.
92. **BRADWEJN J.** Le trouble panique et l'agoraphobie. Centre Hospitalier Saint Laurent, QC, November 9, 1991.
93. **BRADWEJN J.** Le trouble panique, nouvelles hypothèses étiologiques et diagnostiques. Hôpital Enfant Jesus de Québec, QC, November 13, 1991.
94. **BRADWEJN J.** Perspective futures de traitement pharmacologique des troubles panique. Centre Hospitalier de l' Université Laval, QC, November 14, 1991.
95. **BRADWEJN J, KOSZYCKI D.** Role of CCK in panic disorders. CI-988 Symposium, Parke-Davis Neuroscience Research Center, Cambridge, England, November 18, 1991.
96. **BRADWEJN J, KOSZYCKI D.** The CCK-4 Model for panic. Symposium, Parke-Davis Neuroscience Research Center, Cambridge, England, November 19, 1991.
97. **BRADWEJN J.** Panic Disorders. 42<sup>nd</sup> Annual Refresher Course for Family Physician. Royal Victoria Hospital Continuing Medical Education, QC, November 21, 1991.
98. **BRADWEJN J.** La cholecystokinine et l'anxiété. Département de Psychiatrie. Hôpital Maisonneuve Rosemont, QC, November 28, 1991.
99. **BRADWEJN J.** Le trouble panique et son traitement. Conference pour généralistes, Vaudreuil, QC, November 30, 1991.
100. **BRADWEJN J.** L'hypothèse cholecystokinine de l'anxiété. Téléconférence, AMPQ, December 4, 1991.
101. **BRADWEJN J.** Le trouble panique aux urgences: diagnostique et intervention. Urgence Santé. December 4, 1991.
102. **BRADWEJN J.** L'hypothèse cholecystokinine de l'anxiété. Département de Psychiatrie. Hôpital Notre Dame, QC, December 5, 1991.
103. **BRADWEJN J.** The CCK hypothesis of panic disorder. Department of Psychiatry, Medical University of South Carolina, Charleston, SC, January 7, 1992.
104. **BRADWEJN J.** Clinical research with CCK. Invited Speaker, Lilly Research Laboratories, Indianapolis, IN, January 15, 1992.
105. **BRADWEJN J.** Nouvelles données sur les benzodiazepines. Deuxième congrès du Conseil d'études et de recherches cliniques du Québec. Montréal, QC, January 24, 1992.
106. **BRADWEJN J.** Le trouble panique: diagnostique et traitement. Centre Hospitalier Regional de l'Outaouais. Hull, QC, March 5, 1992.
107. **BRADWEJN J.** Le trouble panique et agoraphobie: diagnostique et traitement. CLSC du Plateau Mont Royal, Montréal, QC, March 26, 1992.
108. **BRADWEJN J.** Le trouble panique et l'agoraphobie: traitements et recherche. Journée sur l'agoraphobie et la panique, Haute-Rive et CHUS, Sherbrooke, QC, April 4, 1992.

109. **BRADWEJN J.** Le trouble panique: question et réponses. Teleconference, Clinique Médicale, Hull, QC, April 14, 1992.
110. **BRADWEJN J.** Le trouble panique et agoraphobie: diagnostique et traitement. Département de psychiatrie, Hôpital Fleury, QC, April 22, 1992.
111. **BRADWEJN J.** Animal and clinical research with cholecystokinin in anxiety disorders. Anxiety Section, National Institute of Mental Health, Bethesda, MD, May 8, 1992.
112. **BRADWEJN J.** Chairman, Symposium: Cholecystokinin: a spectrum of action in the CNS. 18<sup>th</sup> CINP Congress, Nice, France, vol.15, suppl.1, part A, p. 481, July 1, 1992.
113. **BRADWEJN J.** The CCK Hypothesis of panic disorder. EBPS Meeting, Cambridge, England, J Psychopharmacology. August 7, 1992.
114. **BRADWEJN J.** Chairman of Symposium: The CCK Hypothesis of Panic Disorders. 42<sup>nd</sup> Annual Meeting of the CPA, September 16, 1992.
115. **BRADWEJN J.** Invited Speaker. The multiplicity of use of benzodiazepines. 42<sup>nd</sup> Annual Meeting of the CPA, September 17, 1992.
116. **BRADWEJN J.** New MAOIs, Department of Psychiatry, Montréal General Hospital, QC, September 25, 1992.
117. **BRADWEJN J.** New MAOIs, Department of Psychiatry, Allan Memorial Institute, QC, October 1, 1992.
118. **BRADWEJN J.** Research with CCK in anxiety. McGill University Affective Disorders Meetings, Allan Memorial Institute, QC, October 13, 1992.
119. **BRADWEJN J.** La neurobiologie du trouble panique. Congrès de la Fédération des Omnipraticiens de Québec. Hotel Ritz-Carlton, Montréal, QC, October 16, 1992.
120. **BRADWEJN J.** Le trouble panique: biologie ou psychologie? Conférence pour public et intervenants. ATAQ. Hotel le Méridien, October 17, 1992.
121. **BRADWEJN J.** The RIMAS. Cours de psychopharmacologie clinique. Hôpital Louis H. Lafontaine, QC, October 23, 1992.
122. **BRADWEJN J.** Les RIMAS. Département de Psychiatrie. Centre Hospitalier Universitaire de l' Université Laval, QC, November. 12, 1992.
123. **BRADWEJN J.** Le Trouble Panique et l'Agoraphobie. Réunion du Groupe Phobie-Zero. Hotel Lord Cartier, Longueuil, QC, November 23, 1992.
124. **BRADWEJN J.** Clinical studies with CCK agonists and antagonists. 15<sup>th</sup> Anniversary of the Academic Hospital of Utrecht (AZU-PKU), Utrecht, The Netherlands, December 4, 1992.
125. **BRADWEJN J.** The Cholecystokinin hypothesis of panic disorders. Neurobiology Research Center (Prof. M Hamon), Hôpital Pitié-Salpêtrière, Paris, France, December 11, 1992.
126. **BRADWEJN J.** La psychopharmacologie des troubles anxieux. 3ieme Congrès du Conseil d'Etude et de Recherche Clinique. Hotel Sheraton, Montréal, QC, March 26, 1993.
127. **BRADWEJN J.** Le trouble panique. Hôpital Regional de Lanaudière, Joliette, QC, March 30, 1993.
128. **BRADWEJN J.** Le trouble panique. Hôpital St Michel, Montréal, QC, April 3, 1993.
129. **BRADWEJN J.** Le trouble panique: neurobiologie et traitement. St. Rose, Laval, QC, April 15, 1993.
130. **BRADWEJN J.** The CCK hypothesis of panic disorder. Main Speaker at the Annual Meeting of the Scandinavian Physiological Society, Tartu, Estonia, May 11, 1993.
131. **BRADWEJN J.** CCK in anxiety and panic disorders. CCK '93. Chatham, MA, May 22, 1993.
132. **BRADWEJN J.** Le trouble panique: clinique, neurobiologie et traitement. Congrès de la Corporation des Psychologues du Québec, Montréal, QC, May 28, 1993.
133. **BRADWEJN J.** The CCK hypothesis of panic disorder. 16<sup>th</sup> Annual Scientific Meeting, CCNP, Montréal, QC, May 31, 1993.
134. **BRADWEJN J.** Clinical research with CCK in panic disorder. World Congress or Psychiatry, Rio de Janeiro, Brazil, June 9, 1993.
135. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. Planery Speaker at the Summer Neuropeptide Conference, Martha's Vineyard, MA, June 23, 1993.
136. **BRADWEJN J.** CCK-panic and drug development. Pfizer Pharmaceuticals, Groton, CT, July 23, 1993.

137. **BRADWEJN J.** Le trouble panique à l'urgence. Urgentologues de l'hôpital de Jonquière. Téléconférence. September 3, 1993.
138. **BRADWEJN J.** Symposium Chairman. Affective disorders. 50<sup>th</sup> anniversary meeting department of Psychiatry, McGill University. Montréal, QC, September 10, 1993.
139. **BRADWEJN J.** Neuropeptides and Behavior: an Overview. Planery Speaker, First Congress of Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece, September 16, 1993.
140. **BRADWEJN J.** Le trouble panique. Téléconférence for family physicians. October 4, 1993.
141. **BRADWEJN J.** Le trouble panique. Département de médecine, Hôpital Hotel-Dieu de Québec, QC, October 5, 1993.
142. **BRADWEJN J.** Les attaques de panique à l'urgence. Conference pour urgentologues. Auberge des Gouverneurs, QC, October 5, 1993.
143. **BRADWEJN J.** CCK and panic disorder. Department of Psychiatry, Toronto General Hospital. Toronto, October 18, 1993.
144. **BRADWEJN J.** CCK and anxiety. Department of Psychology, University of Toronto, Toronto, ON, October 18, 1993.
145. **BRADWEJN J.** Trouble panique: perspectives cliniques. Département de Psychiatrie, Hôpital Pierre Boucher, QC, October 20, 1993.
146. **BRADWEJN J.** La Biologie du Trouble Panique. Colloque département de Psychiatrie, Baie Comeau, QC, October 29, 1993.
147. **BRADWEJN J.** Le Traitement du Trouble Panique. Colloque département de Psychiatrie, Baie Comeau, QC, October 29, 1993.
148. **BRADWEJN J.** Le Trouble Panique: Perspective d'Avenir. Colloque département de Psychiatrie, Baie Comeau, QC, October 29, 1993.
149. **BRADWEJN J.** L'hypothèse CCK des trouble anxieux. Département de psychologie, Université Laval, QC, November 11, 1993.
150. **BRADWEJN J.** Le trouble panique. Colloque de Médecins de l'Outaouais, QC, November 13, 1993.
151. **BRADWEJN J.** Téléconférence, presentation du video:" Le trouble panique, un trouble caché". November 15, 1993. Repeated November 16, 17, 18, 19, 1993.
152. **BRADWEJN J.** Public Conference on Panic Disorder and Agoraphobia (French), St. Mary's Hospital, November 30, 1993. Repeated in English on December 6, 1993.
153. **BRADWEJN J.** "CCK and anxiety: current perspectives" Department of Psychiatry, Douglas Hospital, Montréal, QC, January 27, 1994.
154. **BRADWEJN J.** "CCK and anxiety: current perspectives" Rotta Pharmaceuticals, Milan, Italy, February 15, 1994.
155. **BRADWEJN J.** Trouble panique: perspectives cliniques. Conference pour Médecins et pharmaciens. St. Agathe, QC, February 23, 1994.
156. **BRADWEJN J.** Téléconférence, presentation du video:" Le trouble panique, un trouble caché". March 1, 1994. Repeated March 7, 11, 14, 16, 1994.
157. **BRADWEJN J.** Trouble panique: perspectives cliniques. Conference pour Médecins et pharmaciens. Côte des Neiges, Montréal, QC, March 16, 1994.
158. **BRADWEJN J.** La Biologie du Trouble Panique. Colloque, département de Psychiatrie. Sept-Îles, QC, March 19, 1994.
159. **BRADWEJN J.** Le Traitement du Trouble Panique. Colloque département de Psychiatrie. Sept-Îles, QC, March 19, 1994.
160. **BRADWEJN J.** Le Trouble Panique: Perspective d'Avenir. Colloque département de Psychiatrie. Sept-Îles, QC, March 19, 1994.
161. **BRADWEJN J.** Trouble panique: perspectives cliniques. Département de Psychiatrie, Hôpital Fleury, QC, March 22, 1994.
162. **BRADWEJN J.** La Biologie du Trouble Panique. Colloque, département de Psychiatrie. Chicoutimi, QC, April 8, 1994.

163. **BRADWEJN J.** Le Traitement du Trouble Panique. Colloque département de Psychiatrie. Chicoutimi, QC, April 8, 1994.
164. **BRADWEJN J.** Téléconférence Baie des Chaleurs, presentation du video:" Le trouble panique, un trouble caché". April 18, 1994.
165. **BRADWEJN J.** Téléconférence, présentation du vidéo:" Le trouble panique, un trouble caché". April 20-21, 1994.
166. **BRADWEJN J.** Invited Speaker, Skitch Conference: Biologie Psychiatrique, Douglas Hospital, April 22, 1994.
167. **BRADWEJN J.** CCK-panic and drug development. Phone-Poulenc Rhorer, Paris, France, April 29, 1994.
168. **BRADWEJN J.** Dimensional approach to research in psychiatry: the CCK example. Toronto Hospital, ON, May 2, 1994.
169. **BRADWEJN J.** La Biologie du Trouble Panique. Colloque. Laval, QC, May 6, 1994.
170. **BRADWEJN J.** Le Traitement du Trouble Panique. Colloque. Laval, QC, May 6, 1994.
171. **BRADWEJN J.** Le Trouble Panique: Perspective d'Avenir. Colloque. Laval, QC, May 6, 1994.
172. **BRADWEJN J.** The CCK hypothesis of panic disorder. Department of Pharmacology and Toxicology, University of Helsinki, Helsinki, Finland, May 23, 1994.
173. **BRADWEJN J.** Diagnosis of anxiety disorders. Department of Psychiatry, Tartu University, Tartu, Estonia, May 25, 1994.
174. **BRADWEJN J.** Panic Disorder. Department of Psychiatry, Tartu University, Tartu, Estonia, May 25, 1994.
175. **BRADWEJN J.** Depression and anxiety disorders. Department of Psychiatry, Tartu University, Tartu, Estonia, May 26, 1994.
176. **BRADWEJN J.** Nouveaux développements dans la psychopharmacologie des troubles anxieux. 4è Congrès du Conseil d'Etude et de Recherche Clinique. Hotel Sheraton, Montréal, QC, March 3, 1994.
177. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. University of British Columbia, Department Psychiatry Academic Lecture Series. Vancouver, BC, June 9, 1994.
178. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. British Columbia Medical Association, Psychiatry Academic Lecture Series. Vancouver, BC, June 9, 1994.
179. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. University of British Columbia, UBC Site, Department of Psychiatry Academic Lecture Series. Vancouver, BC, June 9, 1994.
180. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. University of British Columbia, St Paul Hospital, Psychiatry Grand Rounds. Vancouver, BC, June 10, 1994.
181. **BRADWEJN J.** The cholecystokinin hypothesis of panic and anxiety: a review of clinical and animal data. Yale University, Department of Psychiatry, New Haven, CT, June 13, 1994.
182. **BRADWEJN J.** Trouble panique: perspectives cliniques. CLSC Candiac, QC, June 15, 1994.
183. **BRADWEJN J.** Public Conference. Panic Disorder. Agoraphobia Foundation. Montréal, QC, June 20, 1994.
184. **BRADWEJN J.** Panic disorder. Public Information Lecture. St Mary's Hospital, Montréal, QC, June 20, 1994.
185. **BRADWEJN J.** Recherche en Anxiété. Département de Psychologie, Université Laval, QC, October 17, 1994.
186. **BRADWEJN J.** Symposium sur le Trouble Panique AMOQ, QC, October 21, 1994.
187. **BRADWEJN J.** Panic disorder. Public Information Lecture, Fondation des Agoraphobes du Canada. Cité de la Santé, Laval, QC, November 28, 1994.
188. **BRADWEJN J.** Symposium sur le Trouble Panique AMOQ, Trois-Rivières, QC, December 9, 1994.
189. **BRADWEJN J.** Cholecystokinin and anxiety. Medical University of South Carolina, Charleston, SC, February 14, 1995.
190. **BRADWEJN J.** Panic disorder and child psychiatry. Child Psychiatry Department, Douglas Hospital,

- McGill University, Montréal, QC, December 8, 1995
191. **BRADWEJN J.** Invited Speaker, Symposium on Psychopharmacology. Clinical and research issues in the psychopharmacology of anxiety. Tartu University, Estonia, May 23, 1995.
  192. **BRADWEJN J.** Invited Speaker, Symposium on Psychopharmacology. Clinical and research issues in the psychopharmacology of depression. Tartu, Estonia, May 23, 1995.
  193. **BRADWEJN J.** Nouveaux développements dans les troubles anxieux. Vè Congrès de Psychogériatrie et Psychopharmacology. Montréal, QC, June 2, 1995.
  194. **BRADWEJN J.** Chairperson's opening remarks. Exploratory targets of anxiety: beyond benzodiazepines. IBC's International Symposium on novel systems and therapeutic targets for depression and anxiety. Philadelphia, PA, June 22, 1995.
  195. **BRADWEJN J.** The cholecystokinin system and anxiety disorders. IBC's International Symposium on novel systems and therapeutic targets for depression and anxiety. Philadelphia, PA, June 22, 1995.
  196. **BRADWEJN J.** Panic disorder and OCD. Presentation to Smith Kline Beecham representatives. Sheraton Hotel, Hamilton, ON, November 1, 1995.
  197. **BRADWEJN J.** Panic disorder and OCD. Presentation to Smith Kline Beecham representatives. Prince Hotel, York Mills, ON, November 2, 1995.
  198. **BRADWEJN J.** Panic Disorder. Doctors Hospital, Toronto, ON, December 1995.
  199. **BRADWEJN J.** Panic Disorder. Women's College. Toronto, ON, February 9, 1995.
  200. **BRADWEJN J.** Panic Disorder. Brantford Hospital Physicians, Brantford, ON, February 28, 1995.
  201. **BRADWEJN J.** Développement de nouveaux anxiolytiques. Séminaire de formation aux essais cliniques. Centre Hospitalier Universitaire de Nantes. Nantes, France, March 11, 1996.
  202. **BRADWEJN J.** CCK and CNS research. Département de Pharmacie, Université Rene Descartes, Paris, France, March 12, 1996.
  203. **BRADWEJN J.** CCK et l'anxiété. Hôpital Pitié-Salpêtrière-INSERM, Paris, France, March 13, 1996.
  204. **BRADWEJN J.** Equipe de recherche sur la CCK à l'Institut Clarke de Toronto. Unité de Recherche INSERM (Pf LeMoal), Bordeaux, France, March 15, 1996.
  205. **BRADWEJN J.** La neurobiologie de l'anxiété. 25è Séminaire de Biologie Psychiatrique de Nantes, Nantes, France, March 17, 1996.
  206. **BRADWEJN J.** Générer un projet de recherche de la lecture de la littérature à l'évaluation clinique. Valoriser Votre Recherche-Research Seminar organized by ERASMUS Institute, Paris, France, March 18, 1996.
  207. **BRADWEJN J.** Treatment of Panic Disorder. Presentation to psychiatrists from North York Hospital and Scarborough, ON, March 20, 1996.
  208. **BRADWEJN J.** Management of Panic Disorder. Presentation to Peel Memorial Hospital physicians, Brampton, ON, March 27, 1996.
  209. **BRADWEJN J.** Diagnosis and treatment of panic disorder. Presentation to Simcoe family physicians. Simcoe, ON, April 9, 1996.
  210. **BRADWEJN J.** Neurobiology of anxiety disorders: new findings and future models, New York, NY, May 3, 1996.
  211. **BRADWEJN J.** Panic Attacks? Don't Panic..., Church of the Holy Trinity, Toronto, ON, May 6, 1996.
  212. **BRADWEJN J.** Panic disorder and social phobia. Grand Rounds, Queen Street Mental Health Centre, Toronto, ON, May 31, 1996.
  213. **BRADWEJN J.** Panic disorder and social phobia. Grand Rounds, Toronto General Hospital, ON, June 14, 1996.
  214. **BRADWEJN J, KOSZYCKI D.** The role of CCK in anxiety. Invited Speaker, Symposium: "Brain Peptides: Arousal, Anxiety and Depression". XXVII<sup>th</sup> Congress of the International Society of Psychoneuroendocrinology. Cascais, Portugal, August 19, 1996.
  215. **BRADWEJN J, KOSZYCKI D, LE MELLEDO J.** Cholecystokinin and anxiety. Invited Speaker, Symposium on: "Neuropeptides in the CNS: From Molecular Biology to Clinical Studies" World Congress of Biological Psychiatry, Barcelona, Spain, August 28, 1996.



216. **BRADWEJN J.** Case Presentation Panic Disorder. Case Forum: Clinical Experiences in Depression and Panic Disorder. 46<sup>th</sup> Annual Meeting. Psychiatry - Opening the Doors, SS3, p. 126, QC, October 1-4, 1996.
217. **BRADWEJN J.** The Psychobiology of Anxiety and Alternative Medicine. Seminar to York University psychology students. Toronto, ON, November 5, 1996.
218. **BRADWEJN J.** La depression, anxiété et phobies. Sensibilisation aux maladies mentales, élèves de 11<sup>e</sup> année. Institut Clarke, November 13, 1996.
219. **BRADWEJN J.** Panic disorder: diagnosis and treatment. Lakeshore West Medical Clinic. Etobicoke, ON, January 8, 1997.
220. **BRADWEJN J.** Integration of Conventional and Complementary Medicines in Psychiatric Treatment and Research. Invited Speaker, Symposium: "Complementary and Conventional Medicines...Working Together" Toronto East General Hospital, ON, January 18, 1997.
221. **BRADWEJN J.** Research on panic disorder with CCK. Department of Psychiatry and Biochemistry, Rigshospitalet, University of Copenhagen, Denmark, January 27, 1997.
222. **BRADWEJN J.** The CCK hypothesis of panic disorder and anxiety. Department of Psychiatry, University of Linköping, Sweden, January 28, 1997.
223. **BRADWEJN J.** Lecture on Research Hypotheses, "Valoriser votre recherche", Erasmus Institute, Paris, France, January 30, 1997.
224. **BRADWEJN J.** Workshop on Research Methodology, "Valoriser votre recherche", Erasmus Institute, Paris, France, January 30, 1997.
225. **BRADWEJN J.** Panic disorder, diagnosis and treatment. Centenary Hospital, Scarborough, ON, February 5, 1997.
226. **BRADWEJN J.** Panic disorder, diagnosis and treatment. Toronto Hilton Hotel Conference, ON, February 12, 1997.
227. **BRADWEJN J.** Brain peptides, anxiety and alternative medicine. Professor's Series, Department of Psychiatry, University of Toronto, ON, February 12, 1997.
228. **BRADWEJN J.** Panic disorder, diagnosis and treatment. Chinatown Physician Association, Blue Mountain Resort, ON, February 15, 1997.
229. **BRADWEJN J.** Psychiatry and Alternative Medicines. Holy Blossom Temple, Toronto, ON, February 19, 1997.
230. **BRADWEJN J.** Integration of Conventional and Alternative Approaches in Psychiatric Treatment. Oshawa, Ajax and Pickering psychiatrists, Pickering, ON, February 25, 1997.
231. **BRADWEJN J.** Integration of Conventional and Alternative Approaches in Psychiatric Treatment. COTA conference, Toronto, ON, February 26, 1997.
232. **BRADWEJN J.** Integration of Conventional and Alternative Approaches in Psychiatric Treatment. Conference for physicians and pharmacists. Toronto, ON, March 2, 1997.
233. **BRADWEJN J.** Elaboration of a project of integrated conventional and alternative medicine treatment team in psychiatry. Across Boundaries Ethnoracial Mental Health Care Group, Toronto, ON, March 6, 1997.
234. **BRADWEJN J.** Integration of conventional and alternative medicine in psychiatric practice. Ontario Medical Student Weekend, Ottawa, ON, April 5, 1997.
235. **BRADWEJN J.** Diagnosis and Treatment of Panic Disorder. Scarborough Grace Hospital, ON, April 18, 1997.
236. **BRADWEJN J.** Multidisciplinary Research in Anxiety Disorders. Department of Psychiatry, University of British Columbia, UBC site, BC, April 22, 1997.
237. **BRADWEJN J.** Psychiatry and Complementary Medicines. Canadian Mental Health Association, Peterborough Branch, ON, May 6, 1997.
238. **BRADWEJN J.** Panic Disorder: Etiology and Treatment. St. Catherines Hospital Day in Psychiatry, Niagara on the Lake, ON, May 9, 1997.
239. **BRADWEJN J.** Panic Disorder: Etiology and Treatment" Meet-the- Expert Presentation, International

- Delegates, APA Annual Meeting, San Diego, CA, May 22, 1997.
240. **BRADWEJN J.** Panic Disorder: Diagnosis and Treatment. Family Physicians Meeting, Unionville, ON, May 28, 1997.
241. **BRADWEJN J.** Psychiatry and Complementary Medicines. Canadian Mental Health Association, St. Catherines Branch, ON, May 29, 1997.
242. **BRADWEJN J.** Panic Disorder: Diagnosis and Treatment. Family Medicine Department, Dalhousie University, Queen Elizabeth II Hospital, Halifax, NS, June 4, 1997.
243. **BRADWEJN J.** Panic Disorder: Detection and Treatment. Family Physicians of Halifax, NS, June 4, 1997.
244. **BRADWEJN J.** CCK and the Etiology of Panic Disorder. Department of Psychiatry, Dalhousie University, Queen Elizabeth II Hospital, NS, May 5, 1997.
245. **BRADWEJN J.** CCK and the Etiology of Panic Disorder. Department of Psychiatry, Nova Scotia Hospital, Dartmouth, NS, May 5, 1997.
246. **BRADWEJN J.** Detection and Treatment of Anxiety Disorders. Psychiatric Disorders, Contemporary Understanding & New Horizons. Department of Medical Education and Research, North Bay Psychiatric Hospital, ON, October 3, 1997.
247. **BRADWEJN J.** Integrating Alternative and Traditional Approaches in the Treatment of Mental Illness. Canadian Mental Health Association- for the Mental Illness Awareness Week. Burlington, ON, October 16, 1997.
248. **BRADWEJN J.** Psychiatry & Alternative Medicine - Building Bridges. The Learning Network. Sponsored by the Canadian Psychiatric Awareness Committee for the Mental Illness Awareness Week. First Canadian Place, ON, October 28, 1997.
249. **BRADWEJN J.** The CCK hypothesis of panic disorder: clinical studies. Symposium "New Medications for an Anxious World", Pasteur Institute, Paris, France, November 24-26, 1997.
250. **BRADWEJN J.** The CCK Hypothesis of panic. Presentation at the Ontario Psychiatric Association annual meeting, Toronto, ON, January 1998.
251. **BRADWEJN J.** Workshop in research methodology in Neurobiology. Erasmus Institute- Servier Research Seminars. Paris, France, March 27, 1998.
252. **BRADWEJN J.** Les troubles d'anxiété. Conférence publique. Université du Québec à Hull, QC, April 27, 1998.
253. **BRADWEJN J.** Plenary speaker, CCK and anxiety, Swedish Psychiatric Association, Linköping, Sweden, May 7, 1998.
254. **BRADWEJN J.** Psychiatry and Alternative Medicine, Is it time for Integration? Keynote speaker at a Canadian Psychiatric Awareness Committee "Open Mind" luncheon, Toronto, ON, May 12, 1998.
255. **BRADWEJN J.** Anxious depression. CME presentation to community-based psychiatrist, Ottawa, ON, July 7, 1998.
256. **BRADWEJN J.** Anxiety and Depression. CME Symposium for Family Physicians. Mont Tremblant, QC, August 23, 1998.
257. **BRADWEJN J.** RO Jones Memorial Lecture. "How Should We Intergrate Psychobiological Research Findings with Clinical Practice? 48<sup>th</sup> Annual Meeting of the Canadian Psychiatric Association, Halifax, NS, September 18, 1998.
258. **BRADWEJN J.** St. John's Wort: what to tell patients? Workshop, 48<sup>th</sup> Annual Meeting of the Canadian Psychiatric Association, Halifax, NS, September 18, 1998.
259. **BRADWEJN J, APPLETON S, BASSON D.** "Integration of conventional and complementary medicine in the treatment of psychiatric disorders", Workshop Leader, Psychiatry and Alternative/Complementary Medicine: Building Bridges, The Royal Ottawa Hospital, Ottawa, ON, November 13-14, 1998.
260. **BRADWEJN J.** "Symposium on Generalized Anxiety Disorder", Wyeth-Ayerst, Ottawa, ON, April 10, 1999.
261. **BRADWEJN J.** "Quality of Worklife and The Status of Human Health", Canadian Healthcare Association, Ottawa, ON, April 20th, 1999.
262. **BRADWEJN J.** Ethics Workshop, National Defence of Canada, Ottawa, ON, April 15th, 1999.
263. **BRADWEJN J.** Health Systems, Intramural Session presentation, Canadian Health Education,

- April 20, 1999.
264. **BRADWEJN J.** Clinical Management Overview on Social Anxiety Disorder, SmithKline Beecham Course for Canadian Residents, Muskoka, ON, May 1st, 1999.
265. **BRADWEJN J.** Mental Health and Complementary Medicines, Canadian Mental Health Association, Ottawa, ON, May 6th, 1999.
266. **BRADWEJN J.** CCNP Abstracts, June 11-12, 1999.
267. **BRADWEJN J.** 1999 Summer Neuropeptide Conference, June 28, 1999.
268. **BRADWEJN J.** Review Course, July 1999.
269. **BRADWEJN J.** Social Anxiety Disorder: Case Study: A 23 year-old Female with Probable Social Anxiety Disorder, SmithKline Beecham, Toronto, ON, September 15, 1999.
270. **BRADWEJN J.** Chairman, University of Ottawa and Queen's University Departments of Psychiatry joint presentation, Mont Tremblant, QC, October 2-3, 1999.
271. **BRADWEJN J.** Video presentation, "The future Integrated Mental Health System of Ottawa", University of Ottawa and Queen's University Departments of Psychiatry joint presentation, Mont Tremblant, QC, October 2-3, 1999.
272. **BRADWEJN J.** Video presentation, "The CCK Hypothesis of panic disorder", University of Ottawa and Queen's University Departments of Psychiatry joint presentation, Mont Tremblant, QC, October 2-3, 1999.
273. **BRADWEJN J.** Chairman of Neuropsychopharmacology Congress Symposium, "CCK and Panic from Behaviour to Genes", Hungarian Association of Psychopharmacology, Hungary, October 7-9, 1999.
274. **BRADWEJN J.** Invited Speaker, Donor Recognition Evening, October 19, 1999.
275. **BRADWEJN J.** Invited Speaker, Abnormal CCK Function: "A Pathophysiological Model for Panic Disorder and Gastrointestinal Disorders" International Meeting on Gastro-Intestinal Functional Disorders, Key Biscayne, FL, October 21, 1999.
276. **BRADWEJN J.** "Mental Health and Spirituality", Plenary Speaker, Whitby Mental Health Center, ON, October 29, 1999.
277. **BRADWEJN J.** "Multidimensional Evaluation of Anxiety Disorders, Mood Fair, Montréal, QC, October 31, 1999.
278. **BRADWEJN J.** Chairman, "From Worried to Well: Effective Therapy for Generalized Anxiety", Montréal, QC, November 5-7, 1999.
279. **BRADWEJN J.** Speaker, "Genetics of Mental Illness: the CCK example. Into the Next Millenium : The Post-Genomic Era: Ottawa Life Sciences Council, Ottawa, ON, November 2, 1999.
280. **BRADWEJN J.** Speaker, "Operations, Risk Factors and Ethics", Conference of Ethics in Canadian Defence, Ottawa, ON, November 3, 1999.
281. **BRADWEJN J.** Speaker, Multidimensional Evaluation of GAD, "From Worried to Well: Effective Therapy for Generalized Anxiety", Montréal, QC, November 5-7, 1999.
282. **BRADWEJN J.** Speaker, Expert Advisory Board "The Spectrum of Depression and Anxiety Disorders: Advances in Management and Treatment Outcomes" Lake Louise, AB, March 3, 2000.
283. **BRADWEJN J.** Speaker, "The Generalized Anxiety Disorder Program" Diagnosis & Prevalence, Case Study, Calgary, AB, March 18-19, 2000.
284. **BRADWEJN J.** Organizer, "Tools & Strategies to Improve Patient Outcomes in the Treatment of Depression" Montebello, QC, March 24, 2000.
285. **BRADWEJN J.** Presenter, "Pharmacological Treatment of Anxiety Disorders", Mood Fair, Halifax, NS, April 2, 2000.
286. **BRADWEJN J.** Presenter, "Principles of Evaluation and Treatment of Anxiety Disorders" Mood Fair, Halifax, NS, April 2, 2000..
287. **BRADWEJN J.** Chair, Symposium on "Étiopathologie des troubles anxieux" Joint Meeting in Casablanca, Morocco, April 13-15, 2000.
288. **BRADWEJN J.** Presenter, "Le rôle de la CCK dans l'étiopathogénie des troubles panique", Casablanca, Morocco, April 13-14, 2000.
289. **BRADWEJN J.** Presenter, Congrès International du Jubile, Association mondiale de psychiatrie,

- “Psychopharmacology of Anxiety Disorders”, Paris, France, June 26-30, 2000.
290. **BRADWEJN J.** Presenter, Congrès International du Jubile, Association mondiale de psychiatrie, “Le système académique intégré de santé mentale à Ottawa” Paris, France, June 26-30, 2000.
291. **BRADWEJN J.** Organizer, 10<sup>th</sup> Annual Summer Neuropeptide Conference, Ste. Adele, QC, July 23-27, 2000.
292. **BRADWEJN J.** 2000 Gordon Research Conference on Neuronal Cholecystokinin, “CCK in Anxiety”, Oxford, UK, August 13-18, 2000.
293. **BRADWEJN J.** Speaker, 13<sup>th</sup> ECNP Congress, “CCK and panic disorder”, Munich, Germany, September 9-13, 2000.
294. **BRADWEJN J.** Introductory Remarks “Using Telehealth for Continuing Education”, Royal Ottawa Hospital, Ottawa, ON, November 22, 2000.
295. **BRADWEJN J.** Plenary Speaker, “Complementary Medicines & Psychiatry: A General Orientation”, CPA International Conference, Cancun, Mexico, February 26 - March 2, 2001.
296. **BRADWEJN J.** Workshop Presenter, “Use of Herbal Products in Psychiatric Practice”, CPA International Conference, Cancun, Mexico, February 26 - March 2, 2001.
297. **BRADWEJN J.** Workshop Presenter, “Explanatory Models from Complementary Medicines & Psychiatric Practice”, CPA International Conference, Cancun, Mexico, February 26-March 2, 2001.
298. **BRADWEJN J.** Presenter, “Valoriser Votre Recherche Seminar”, France, March 2001.
299. **BRADWEJN J.** Investigators’ Meeting “Venlafaxine ER Panic Study”, Protocol 0600B5-354, Sorrento, Italy, May 22, 2001.
300. **BRADWEJN J.** Chair, Peptide Receptors Symposium, “From Gene to Therapy”, Montréal, QC, July 29-August 2, 2001.
301. **BRADWEJN J.** Presenter, Peptide Receptors Symposium, “From Gene to Therapy” Montréal, QC, July 29-August 2, 2001.
302. **BRADWEJN J.** Organizer, Peptide Receptors Symposium, “From Gene to Therapy”, Montréal, QC, July 29-August 2, 2001.
303. **BRADWEJN J.** Presenter, Rehfeld 60 Conference, “The CCK System and Anxiety: From genes to Therapeutics”, Stockholm, Sweden, October 2001.
304. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, France, December 2001.
305. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, France, March 2002.
306. **BRADWEJN J.** Presenter, “The CCK Hypothesis of Panic Disorder”, Université de Lausanne, Switzerland, May 15, 2002.
307. **BRADWEJN J.** Presenter “The CCK Hypothesis of Panic Disorder”, Pfizer Expert Panel, Berne, Switzerland, May 16, 2002.
308. **BRADWEJN J.** Presenter, “The CCK System and Anxiety: From Genes to Therapeutics”, XXIII CINP Congress, Montréal, QC, June 26, 2002.
309. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, France, March 2003.
310. **BRADWEJN J.** Presenter, “Hypothesis -Based Genetic Approaches to Research in Anxiety Disorders”, 16<sup>th</sup> ECNP Congress, Prague, Czech Republic, September 20-24, 2003.
311. **BRADWEJN J.** Presenter, “Comparison of Self Administered CBT and Sertraline and Their Combination in Panic Disorder”, 53<sup>rd</sup> Annual CPA Meeting, Halifax, NS, October 30-November 2, 2003.
312. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, France, March 2004.
313. **BRADWEJN J.** Chair, “Panic disorder: brain mechanisms and treatment outcome” CINP Congress, Paris, France, June 20-24, 2004.
314. **BRADWEJN J.** Presenter, “The Psychobiology of Anxiety Disorders in the Older Adult” Geriatric Anxiety Disorders, October 16, 2004.
315. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, France, March 2005.
316. **BRADWEJN J.** Presenter, “The CCK Hypothesis of Panic Disorder”. Department of Psychiatry, Queen’s University, Kingston, ON, May 20, 2005.
317. **BRADWEJN J, WISEMAN L.** “Mindsets to Mastery”. Wharton School of Business, University of

- Pennsylvania, Philadelphia, PA, February 1, 2006.
318. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2006.
  319. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2007.
  320. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2008.
  321. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2009.
  322. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2010.
  323. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2011.
  324. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 2012.
  325. **ROY J, BRADWEJN J.** Medical Education at University of Ottawa. Jiao Tong University. Shanghai, China, October 30, 2012.
  326. **BRADWEJN J.** The CCK Hypothesis of Panic Disorder. Shanghai Mental Health Center, Jiao Tong University, Shanghai, China, October 31, 2012.
  327. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 21, 2013.
  328. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, March 27, 2014.
  329. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, April 27, 2015.
  330. **BRADWEJN J.** Presenter, Valoriser Votre Recherche Seminar, Chantilly, France, January 9, 2016.
  331. **BRADWEJN J.** Presenter, The Shanghai Health International Complex : « Musée de la médecine et de la culture », Université de Lyon, Lyon, France, April 12, 2016.
  332. **BRADWEJN J.** Quality assurance and accreditation in Canadian Medical Education. 60th Anniversary of the Shanghai University of Traditional Chinese Medicine, Shanghai, China, May 27, 2016.
  333. **BRADWEJN J.** Canadian Medical Education. Karamay General Hospital, Karamay, China, June 8, 2016.
  334. **BRADWEJN J.** The Impact of Neurobiological Research on the Treatment of Anxiety Disorders. Forum on "Aspects of Anxiety Disorders", Chinese Society for Psychosomatic Medicine, Shanghai, China, November 16, 2018.
  335. **BRADWEJN J.** Anxiety Disorders. Presentation to Shanghai Canadian Consulate Human Resources Group. Shanghai, China, November 22, 2018.
  336. **BRADWEJN J.** Quality assurance in Canadian Medical Education. The 2<sup>nd</sup> Oriental Medical Education Forum (OCME 2018), Shanghai, China, November 30, 2018.
  337. **BRADWEJN J.** Health Systems and Medical Education in Canada. Course to TCM Physicians, Shanghai University of Traditional Chinese Medicine. Shanghai, China, December 7, 2018.
  338. **BRADWEJN J.** Leadership, wellness et coaching pour la transformation en milieux medical. Atelier, programme de formation au leadership médical. Université Claude Bernard Lyon1, Université d'Ottawa et Université de Montréal. April 26 & 27, 2019. Lyon, France.
  339. **BRADWEJN J.** The Intrinsic Practice. Invited speaker, Shanghai Renji Hospital Department of Psychological Medicine. May 27, 2019. Shanghai, China.
  340. **BRADWEJN J.** The Intrinsic Practice. Invited speaker, Shanghai University of Traditional Chinese Medicine. June 12, 2019. Shanghai, China.
  341. **BRADWEJN J.** The International Medical Leadership and Wellness training program of Universities of Lyon, Ottawa and Montréal. Innovation Presentation. Toronto International Summit on Leadership Education for Physicians. September 25, 2019. Toronto, Canada.
  342. **BRADWEJN J.** Anxiety Disorders as Psychosomatic Disorders Causes and Treatments. Keynote speaker. 25<sup>th</sup> Annual Meeting of the China Society of Psychosomatic Medicine & International Psychosomatic Medicine Forum. October 18, 2019. Ningbo, China.
  343. **BRADWEJN J.** La francophonie médicale en Chine, santé, éducation, recherche et la nouvelle route de la soie (OBOR). Séance plénière. 7<sup>ième</sup> Réunion Annuelle Sino-Française sur l'Enseignement Médical. October 19, 2019. Shanghai, China.
  344. **BRADWEJN J.** Canadian Medical Education. Course to Physicians. Shanghai University of TCM. October 28, 2019. Shanghai, China.

### **Symposia and Conferences Organized (Selected):**

- 1996 Organizer/Chairman for Symposium: "Psychiatry and Alternative Medicine: Building Bridges" First Canadian Symposium on psychiatry and alternative medicines (Traditional Chinese Medicine, Homeopathy, Ayurvedic Medicine, Spirituality, Herbology, Shamanism, Aromatherapy). Toronto, ON, November 1-2, 1996.
- 1997 Organizer, Community Partner and Moderator: "Treating Depression: Assessing Alternative Therapies" St. Lawrence Center for the Arts. Toronto, ON, March 25, 1997.
- 1998 Organizer/Chairman for Symposium: "Psychiatry and Alternative/Complementary Medicine: Building Bridges". Second Canadian Symposium on psychiatry and alternative/complementary medicines (Traditional Chinese Medicine, Homeopathy, Ayurvedic Medicine, Spirituality, Herbology, Shamanism, Aromatherapy). The Royal Ottawa Hospital, Ottawa, ON, November 13-14, 1998.
- 2000 Chair, Organizing Committee, CCNP 2000 Annual Meeting, Marrakech, Morocco, April 10-13, 2000.
- 2000 Co-Chair, Organizing Committee, Joint Meeting Association Francaise de Psychiatrie Biologique, Association Marocaine de Psychiatrie, Casablanca, Morocco, April 14-15, 2000.
- 2000- Gala Patron, The Annual Ottawa Evening in Support of the Canadian Institute of Health Research, Ottawa, ON
- 2000 Co-organizer, Tenth Annual Summer Neuropeptide Conference, Sainte-Adele, QC, July 23-27, 2000.
- 2002 Co-Chair, International Conference on Spirituality and Mental Health, Ottawa, ON, December 3, 2002.
- 2004 Co-Chair, International Conference on Spirituality and Mental Health, Ottawa, ON, December 5, 2004.
- 2014 Co-Chair, Academic Health Sciences Network Symposium: "The Sustainability of Health Research in Canada", Ottawa, ON, March 12<sup>th</sup>-13<sup>th</sup>, 2-14.
- 2016 Canadian Bureau for International Education. Wang Jay and Bradwejn Jacques. "Transformational Internationalization in Practice: The Ottawa-Shanghai Joint School of Medicine. November 16, Ottawa.
- 2019 Co-organizer, programme de formation au leadership medical. Université Claude Bernard Lyon1, Université d'Ottawa et Université de Montréal. First cohort enrolled in 2019.

### **Media interventions (Selected):**

1. Panelist, Impact, Radio-Canada TV, March 31, 1984.
2. Invited scientist, Sciences Réalité, Radio-Canada TV, March 14, 1984.
3. Panelist, Droit de Parole, Radio-Québec TV, May 2, 1984.
4. Interview : "Psychopharmacologie et traitements alternatifs en psychiatrie", Video, Le Regroupement des Alternatives, July 19, 1984.
5. Interview : "Recherche en psychiatrie", Video, Congrès et Exposition de l'AMLFC, October 24-27, 1984.
6. Interview : "La Clinique de la Dépression de Louis-H. Lafontaine", Radio-Canada TV News, November 19, 1984.
7. Invited scientist, Sciences et Technologies, "Le lithium", Télé-Métropole, February 4 & July 20, 1985.
8. Invited speaker, ALPABEM, "La schizophrénie", April 23, 1985.
9. Interview: "Seasonal Affective Disorders", Canadian Broadcasting Corporation (CBC) Radio, March 6, 1986.
10. Seasonal Affective Disorder. CTV network, Today's Magazine, December 23, 1987.
11. Interview: "Seasonal Affective Disorders" CBC Radio, February 25, 1987.
12. Interview: "Panic Disorder", CHLT Radio, Ottawa, ON, May 18, 1988.
13. National news release (USA), Associated Press, "Brain Chemical Linked to Panic Attacks", May 12, 1988.
14. National Cable News Release, ABN "Cholecystokinin and Panic Disorder", May 13, 1988.
15. International news release (36 languages) British Broadcasting Corporation (BBC), Cholecystokinin and Panic Disorder", June 1988.
16. Interview: "Panic Disorder and Cholecystokinin", BBC Radio 2, July 25, 1988.
17. Invited speaker, Radio Canada: "La maladie manico-dépressive". Émission "Présente", December 18, 1988.
18. Canadian News Release, Southam Press, Science/Medicine: "Cholecystokinin and Panic Attacks",

- January 14, 1989.
19. Interview: "Research in Panic Disorder", Canadian Broadcasting Corporation. Radio-noon, January 26, 1989.
  20. Interview: "Anxiety and Phobias", CKUT Radio, February 3, 1989.
  21. Interview: "Research at St. Mary's in Anxiety Disorders", CKO Radio, March 23, 1989.
  22. Interview: "La recherche psychiatrique à l'Université McGill", CKAC Radio, June 7, 1989.
  23. Interview: "Les troubles d'anxiété et la recherche psychiatrique", À Votre Service, Radio Canada CBF 690, March 2, 1990.
  24. Interview: "Un nouvel antidépresseur", Information du Midi, CJMS Radio, April 10, 1990.
  25. Information "Recherche à St. Mary's", À Votre Service, Radio-Canada CBF 690, July 10, 1990.
  26. Interview: "La cholecystokinine: impliquée dans l'étiologie des attaques de panique". Information Radio Canada AM, August 9, 1991.
  27. La Presse: "Des chercheurs de McGill auraient percé le mystère des attaques de panique". August 9, 1991.
  28. Interview: "Cholecystokinine and the medical cause for panic attacks". CJAD AM, August 9, 1991.
  29. Television program: "Le trouble panique". Dr. Lapointe, TVA Network, January 7, 1992.
  30. Television Interview: "Les phobies". Le match de la vie, TVA, April 21, 1992.
  31. Interview: Ce jour à Montréal. Entrevue: l'agoraphobie. Télé-Métropole, TVA. September 28, 1992.
  32. Interview: Les Phobies. Télé-métropole, TVA. October 5, 1992.
  33. La Presse, Cahier Santé: "La Panique". October 18, 1992.
  34. Interview: "En Direct", Radio Canada Radio. "Les Phobies", December 17, 1992.
  35. Invited expert: Claire Lamarche: "Le trouble panique", TVA, January 18, 1993
  36. Interview: "Research on panic disorder at St. Mary's Hospital" Pulse News, CTV, February 2, 1993.
  37. Interview: "Panic disorder and its treatments", CFRB Radio, February 8, 1993.
  38. The Montréal Gazette Women's Section "Panic disorder", March 7, 1993.
  39. Interview: "What is panic disorder", CIQC Radio, March 22, 1993.
  40. Video appearance: "Panic disorder", Channel TV3, Germany, May 5, 1993.
  41. Interview: "Exercise and mood" Pulse News, CTV Television, September 22, 1993.
  42. Press Conference, St Mary's Hospital: "Le trouble panique", November 8, 1993.
  43. Radio Interview: CJMS, Montréal: "Le trouble panique", November 8, 1993
  44. La Presse, Montréal, "Des médicaments traitent le trouble panique", November 9, 1993.
  45. Radio Interview: Radio Canada AM, Montréal: "Le trouble panique", November 8, 1993.
  46. TV News, Quatre Saisons: "Le trouble panique", November 8, 1993.
  47. CIBL Radio: "La panique et l'agoraphobie", November 23, 1993.
  48. CJAD Radio, Montréal: "Phobias", December 21, 1993.
  49. Chatelaine magazine: "High Anxiety", January 1994.
  50. Magazine 7 Jours: "La Panique", February 1994.
  51. Television Radio Canada: "Usage non medical du Prozac", Le Point, June 16, 1994.
  52. Canadian Press: Prozac and depression, July 1994.
  53. Chatelaine: "Les antidépresseurs", November 1994.
  54. Réseau de télévision médical Educational Channel. Trouble Panique: Trouble Caché. Run twice daily from October 3 to 23, 1994.
  55. CBC Radio-Canada (French), Enjeu: "Prozac". December 7, 1994.
  56. TV Quatre Saisons, La médecine apprivoisée. March 13, 1995.
  57. SRC Radio: Les dépressions. April 3, 1995.
  58. Globe and Mail front page article: "Protein Sensitivity May Cause PMS." August 3, 1995.
  59. Rocky Mountain News article: "Protein Sensitivity Linked to premenstrual syndrome". August 1995.
  60. City TV News: "PMS and CCK" August 2, 1995.
  61. CRFB Radio: "PMS and CCK" August 2, 1995.
  62. News Radio: "PMS and CCK" August 2, 1995.

63. HRBC and KCLV Radios (Andre Arthur): "PMS and CCK" August 2, 1995.
64. RDI TV (French CBC): "PMS and CCK" August 3, 1995.
65. KR77 Radio: "PMS and CCK" August 4, 1995.
66. CBC Montréal Newswatch (TV): "PMS and CCK" August 5, 1995.
67. Hospital News: "Clarke research targets PMS". September 1995.
68. Ontario Medical Review: "Clarke Institute researchers receive awards, grants". September 1995.
69. The Toronto Sun: "PMS protein found". August 4, 1995.
70. The Daily News: "Protein sensitivity linked to PMS". August 3, 1995.
71. Medicine Hat News: "PMS linked to substance". August 2, 1995.
72. PMAC News: "Research links PMS to altered biology". August 1995.
73. The Ottawa Citizen: "Study suggests PMS link to stress-sensitive protein". August 3, 1995.
74. The Observer: "Study links severe PMS to anxiety attacks". November 18, 1995. Pembroke, ON.
75. The Times: "New weapon against panic attacks". November 25, 1995. Moncton, NB.
76. The Globe and Mail: "Panic disorder common, help is available." November 27, 1995. Sarnia, ON.
77. The Nuggett: "One more weapon available to combat panic attacks". November 24, 1995. North Bay, ON.
78. Kitchener-Waterloo Record: "New drug will fight panic causes". November 24, 1995. Kitchener, ON.
79. The Sudbury Star: "When anxiety attacks strike". November 24, 1995. Sudbury, ON.
80. The Whitehorse Star: "Panic attacks disabling up to million Canadians". November 25, 1995. Whitehorse, YT.
81. Times-Colonist: "Panic attacks disabling up to million Canadians". November 1995. Victoria, BC.
82. Daily Free Press: "Panic attacks disabling up to million Canadians". November 25, 1995. Nanaimo, BC.
83. Chronicle-Journal: "Panic attacks disabling up to million Canadians". November 24, 1995. Thunder Bay, ON.
84. The Recorder & Times: "New weapon available to combat panic attacks". November 25, 1995. Brockville, ON.
85. The Sun Times: "Doctors using anti-depressant to fight panic". November 29, 1995. Owen Sound, ON.
86. The Calgary Herald: "Doctors reveal new treatment for disorder". November 29, 1995. Calgary, AB.
87. Daily News: "Fighting the illness of panic attacks". December 18, 1995. Amherst, NS.
88. The Toronto Star: "Pinpointing the panic button". December 31, 1995. Toronto, ON.
89. The Edmonton Sun: "The panic plague". January 5, 1996. Edmonton, AB.
90. The Daily Gleaner: "Anxiety disorders problem for many". January 5, 1996.
91. The Western Star: "Pinpointing panic buttons". January 6, 1996. Corner Brook, NL.
92. The Medical Post: "Drug may help in Rx, education of panic disorder". January 2/9, 1996.
93. The Toronto Star: "Understanding why Canadians panic". January 8, 1996. Toronto, ON.
94. The Province: "Key to panic found". January 8, 1996. Vancouver, BC.
95. The Edmonton Journal: "Pinpointing people's panic buttons". January 9, 1996. Edmonton, AB.
96. Record Health: "Panic attacks. Chemical linked to disorder that affects 600,000 Canadians". January 12, 1996.
97. Chatham Daily Newspaper: "Pinpointing people's panic buttons". January 1996. Chatham, ON.
98. Journal Pioneer: "Pinpointing people's panic buttons". January 29, 1996. Summerside, PE.
99. Packet and Times: "Victims suffer in silence". January 29, 1996. Orillia, ON.
100. Family Practice: "Graduated drug regimens needed in treating panic disorder". February 19, 1996. Scarborough, ON.
101. Dayton Daily News: "Study links PMS to protein hypersensitivity". 1996.
102. Women's Health Matters: "Women especially vulnerable to panic disorder". March 1996.
103. Le Métropolitain: "La panique". April 19, 1996. Toronto, ON.
104. The Leader Post: "Pinpointing those panic buttons". February 10, 1996. Regina, SK.
105. 106 CBC Toronto Radio Interview: "La semaine de la santé mentale". Noon News, May 8, 1997.
106. CBC Toronto Radio Interview (French): "Le Congrès du CCNP", June 3, 1996.



107. Toronto Star, full length article. Herbal medicine get psychiatric work out at the Clarke. November 1, 1996.
108. CIUT Radio. "Well Street" program. Psychiatry and Alternative Medicine" November 13, 1996.
109. Network Winnipeg Mental Health. Alternative Health Practices and Mental Health. November 1996.
110. CTV Canada AM. Psychiatry and Alternative Medicine. November 20, 1996.
111. Sin Tao magazine. Herbs and Psychiatry. December 8, 1996.
112. Network Magazine. Alternative Remedies. Fall 1996.
113. The Globe and Mail Newspaper. Alternative treatments gaining ground. December 28, 1996.
114. The Penticton Herald. Alternative medicine growing in popularity. January 6, 1997. Penticton, BC.
115. The Examiner. Alternative healing gains followers. January 7, 1997. Peterborough, ON.
116. Welland-Port Colborne Tribune. Alternative medicine growing in popularity. January 7, 1997.
117. The Daily Gleaner. Canadians want medical choices. January 7, 1997. Fredericton, NB.
118. The Western Star. Alternative medicine growing in popularity. January 7, 1997. Corner Brook, NL.
119. The Intelligencer. Alternative medicine growing in popularity. January 7, 1997. Belleville, ON.
120. Chronicle-Journal. Alternative medicine grows in popularity. January 7, 1997. Thunder Bay, ON.
121. Reformer. Alternative medicine growing in popularity. January 8, 1997. Simcoe, ON.
122. Amherst Daily News: "Remarkable advances: Alternative medicine growing more popular daily" January 10, 1997.
123. Cape Breton Post. Canadians trying alternative treatments. January 11, 1997. Sydney, NS.
124. The Sun Times. Numbers tell tale. Alternative therapy gaining respect. January 14, 1997. Owen Sound, ON.
125. The Mail Star. Canadians turn to alternative medicine in record numbers. January 15, 1997. Halifax, NS.
126. The Chronical-Herald. Canadians turn to alternative medicine in record numbers. January 15, 1997. Halifax, NS.
127. The Times. Alternative medicine growing in popularity. January 16 1997. Moncton, NB.
128. Discovery TV Channel: "Hostages of Anxiety". The Body Series. February 19, 1997.
129. Kingston This Weekend. "Panic attacks triggered by levels of carbon dioxide". March 1, 1997.
130. CBC National TV: "Les depressions saisonnières". RDI News Channel, March 10, 1997.
131. CBC National TV: "A Psychiatrist Does Research with Herbs". The Health Show, March 12, 1997.
132. CKLW Radio News (Windsor): "A study on panic disorder". March 13, 1997.
133. CFTO TV Channel: "A national study on panic disorder". News Release, March 13, 1997.
134. CBC National TV: "A Psychiatrist Does Research with Herbs". News World, March 15, 1997.
135. WTN TV Channel: "A national study on panic disorder". Doctor on Call, March 14, 1997.
136. The Edmonton Sun. "Toronto clinic to study panic attack". March 19, 1997. Edmonton, AB.
137. The Prince George Citizen. "Panic disorder target of new study". March 19, 1997.
138. The Penticton Herald. "BC part of panic study". March 19, 1997.
139. Daily Miner and News. "Study aims to nail down best therapy for panic disorder". March 20, 1997. Kenora, ON.
140. The Nugget. "Study aims to nail down best therapy for panic disorder". March 20, 1997. North Bay, ON.
141. Daily Press. "Study aims to find best therapy for panic disorder". March 20, 1997. Timmins, ON.
142. The Lethbridge Herald. "Panic attacks may be linked to carbon-dioxide". March 20, 1997.
143. Times-Journal. "New study launched into panic attacks". March 21, 1997. St. Thomas, ON.
144. The Observer. "Study hopes to discover therapy for panic attacks". March 22, 1997. Pembroke, ON.
145. Star Phoenix. "New therapy for panic disorder". March 24, 1997. Saskatoon, SK.
146. The Standard. "Study seeks treatment alternatives for panic attacks". March 24, 1997. St. Catharines, ON.
147. The Medical Post. "A cassette a day may help keep panic at bay". March 25, 1997. Toronto, ON.
148. The Province. "What causes panic?" March 31, 1997. Vancouver, BC.
149. Médecin du Québec: "L'unité des soins prolongés devient la résidence Urgel Pelletier". April 1997.
150. Canadian Healthcare Manager: "Panic disorder often goes undetected". April/May 1997.

151. Welland-Port Colborne Tribune. "Study aims to nail down best therapy for panic disorder". April 2, 1997.
152. TVO: "Panic Disorder and Anxiety". Life Skills, April 4, 1997.
153. The Guardian: "Panic disorder focus of study". April 9, 1997. Charlottetown, PE.
154. Review: "Study aims to nail down best therapy for panic disorder". April 9, 1997. Niagara Falls, ON.
155. Review: "Study takes aim at panic disorder". April 11, 1997. Niagara Falls, ON.
156. Review: "Facts about panic disorder". April 11, 1997. Niagara Falls, ON.
157. The Beacon Herald: "Study aims to nail down best therapy for panic attack". April 17, 1997. Stratford, ON.
158. The Toronto Sun: "Study aims to find the best therapy for panic disorder". April 21, 1997.
159. L'Actualité Médicale. "Zolof pour le trouble panique: seul ou avec une autopsychothérapie?" April 23, 1997.
160. Winnipeg Free Press: "Panic-attack study to judge best help". April 29, 1997.
161. The Leader Post: "Study aims to find best panic disorder therapy". May 3, 1997. Regina, SK.
162. Maclean's: "Doctors and fitness". May 5, 1997.
163. The Evening Telegram "Mental Medicine". May 8, 1997. St. John's, NL.
164. The Expositor: "Study aims to nail down best therapy for panic disorder". May 13, 1997. Brantford, ON.
165. The Toronto Star: "Panic attacks cured by drug, study says". May 16, 1997. Toronto, ON.
166. The Calgary Herald: "Drug cures panic attacks". May 17, 1997. Calgary, AB.
167. Times-Colonist: "Research holds out hope for victims of panic attack". May 18, 1997. Victoria, BC.
168. The Daily News: "New therapy offers relief from panic attacks". May 20, 1997. Halifax, NS.
169. The Evening News: "No time to panic". May 20, 1997. New Glasgow, NS.
170. Fort McMurray Today: "Patients cured of panic attacks". May 20, 1997.
171. The Sudbury Star: "Patients in drug study cured of panic attacks". May 21, 1997.
172. Observer: "Patients cured of panic attacks". May 21, 1997. Sarnia, ON.
173. Review: "Patients in drug study cured of panic attacks". May 23, 1997. Niagara Falls, ON.
174. The Toronto Star: "Drug-free therapy effective treatment for panic attacks". June 3, 1997.
175. L'Omnipraticien: "Un projet pancanadien sur le traitement du trouble panique". June 4, 1997.
176. WTN TV. Doctor On Call: "Herbal Medicine and Homeopathy" TV Interview, June 6, 1997.
177. The Leader Post: "Drug helps patients with panic attacks". June 6, 1997. Regina, SK.
178. 640 Radio, Toronto. Larry Solvay Talk Show: St John's Wort. September 30, 1997.
179. CFOF Radio, Owen Sound: "Panic Disorder: Recognition and Treatment". October 10, 1997.
180. Modern Woman Magazine: "Don't Panic". Pages 71-73, October 1997.
181. Parkhurst Exchange: St. John's Wort, the people's antidepressant. Pages 64-67, January 1998.
182. Le Droit: Des psychologues au secours des sinistrés. January 17, 1998.
183. Global TV Toronto Here & Now: Ice Storm '98. January 14, 1998.
184. CBOFT Ce Soir en Couleurs: Entrevue concernant la tempête de verglas. January 14, 1998.
185. La télévision communautaire Rogers: Entrevue concernant la tempête de verglas. January 21, 1998.
186. The Ottawa Citizen: "Breaking down myths". A letter to the Editor. March 22, 1998.
187. Radio Canada: "Les troubles anxieux". April 27, 1998.
188. CBC Radio Here & Now: "Alternative Medicine". Toronto, ON, May 12, 1998.
189. News On TV: "St. John's Wort and Depression". June 1, 1998.
190. CBC News: "St. John's Wort and Depression". June 1, 1998.
191. Global News: "St. John's Wort and Depression". June 1, 1998.
192. "St. John's Wort and Depression". June 1, 1998 broadcast in: Ottawa, ON; Charlottetown, NL; Calgary, AB; Halifax, NS; Regina, SK; Edmonton, AB; Montréal, QC; Sudbury, ON; Québec, QC.; Toronto, ON; Winnipeg, MB; Windsor, ON.
193. La radio de Radio Canada: "Le millepertuis et la dépression". June 3, 1998.
194. CTV Ottawa Canada AM: "St. John's Wort and Depression". June 9, 1998.
195. CIQC Radio (Montréal): "St. John's Wort and Depression". June 10, 1998.
196. The Ottawa Citizen: "Treating depression the natural way". Ottawa, ON, June 30, 1998.

197. SRC Radio FM 102.5, entrevue: "Le huitieme jour", national program, Toronto, ON, July 5, 1998.
198. CHRO TV. "The use of antidepressants", Ottawa, ON, July 15, 1998.
199. Hospital News. Alternative Medicine being studied by mainstream psychiatrists. Page 21, July 1998.
200. Hospital News. The role of spirituality in health care. Page 14, July 1998.
201. The Medical Post. St. John's Wort shows promise against depression, but still early. Page 6, September 15, 1998.
202. Le Melledo, J-M, **Bradwejn, J**, Koszycki D, Bichet D, Bellavance F. The role of the  $\beta$ -adrenergic system in CCK-4-induced panic symptoms (1998). *Biological Psychiatry*. 44, 364-366.
203. Nutrition Action Health Letter, Herbs for Nerves, Page 8, October 1998.
204. New RO TV. "World Mental Health Day", January 20, 1999.
205. CBC News. "World Mental Health Day", January 20, 1999.
206. CJOH TV, Ottawa - "World Mental Health Day", January 22, 1999.
207. CJOH TV, Ottawa - Workplace stress is a major cause of depression, January 25, 1999.
208. CKCO-TV, Kitchener-Waterloo - Work related stress causes depression, January 25, 1999.
209. BCTV-TV, British Columbia - Workplace stress is a major cause of depression in Canada, January 25, 1999.
210. The Varsity, Health Supplement- Consumer, heal thyself, - January 26, 1999.
211. Carp News, An alternate route to mental health, Page 34 - February 1999.
212. Radio Canada Radio, Au Nord des Sentiers Battus, Les Saisons et la santé mentale, April 6, 1999.
213. CBC TV News, "Mass murder in Ottawa" National News, April 7, 1999.
214. CJOH TV "Mass Murder in Ottawa" Evening News, April 7, 1999.
215. Ottawa Citizen Newspaper interview: "OC Transpo shootings", April 8, 1999.
216. CBC Radio "Research with a Ayurvedic Herb, Centella Asiatica" Québec City, Montréal, Ontario Morning, Winnipeg, Regina, Ottawa, Calgary, Victoria, Sudbury, Whitehorse, Kelowna, Vancouver, May 20, 1999.
217. CBOT-TV, Ottawa Newsday, "CHEO to Take Over Treatment of Mentally Ill", July 6, 1999.
218. National Post, "Use of Beta Blockers in the Treatment of Performance Anxiety", July 7, 1999.
219. Ottawa Citizen, "Impact of Movies on People Who Are Prone to Anxiety", August 3, 1999.
220. CBC News World, "Children's Program at ROH", August 13, 1999.
221. CBS News - 48 Hours, "Profile of Dr. Bradwejn's Work on Panic Disorder", November 5, 1999.
222. CBC Newsworld, "Dr. Bradwejn on new IMHR", November 15, 1999.
223. Clinical Call, "Generalized Anxiety Disorder", 2000.
224. The Ottawa Citizen, "End the Stigma", June 1, 2000.
225. The Ottawa Citizen, "Crisis: Stress of hospital restructuring", June 14, 2000.
226. Brockville Recorder & Times, "Governance of BPH changing October 16", August 8, 2000.
227. Ottawa Sun, "Royal Ottawa to govern services", August 9, 2000.
228. TVA, "Les urgences psychiatriques et la pénurie de psychiatres à Ottawa", September 24, 2000.
229. CBC AM Radio, "Psychiatry Emergency Services", October 4, 2000.
230. National Post, "Be afraid, it is good for your health" October 30, 2000.
231. CBC Radio, Windsor, Newfoundland, "Fear and Phobias", October 31, 2000.
232. Ottawa Citizen "Highly addictive" Ativan under fire from long-term British patients", November 3, 2000.
233. The Globe & Mail, "When depression turns deadly", April 21, 2001.
234. Canadian Press, Toronto: "St. John's wort not effective against major depression, large study shows" April 9, 2002.
235. CKTB Radio, St. Catherines, Ontario: "Use of Hypericum in Depression", April 10, 2002.
236. National Post, "Post-trauma stress linked to gene mutation" September 2002.
237. TVA - Les Productionss Rivard, "Entre les murs de la panique" January 10, 2003.
238. The Ottawa Citizen, "The lure of a miracle pill for mental illness" June 21, 2003.
239. TFO, Panorama, "Santé mentale", November 4, 2003.
240. CFRA-The Ottawa Business Journal, "Workplace Stress, Depression and How Mental Health affects

- Business and the Economy", May 2, 2004.
241. Radio-Canada - "Onde Aubaine", Les troubles de panique, May 5, 2004.
  242. The Ottawa Citizen - Nurse files complaint after she was refused hospital care, November 16, 2004.
  243. Ottawa Citizen City Desk Rogers 22 . TV interview. The Statistics Canada study on panic disorder. November 30 and December 1, 2004.
  244. National Post, Canadians Prone to Panic Attacks, November 30, 2004.
  245. CTV National News television interview, "Statistics Canada Study on Panic Disorder", December 4, 2004.
  246. CFRA Ottawa Radio interview, "Statistics Canada Study on Panic Disorder", December 5, 2004.
  247. Le Droit, "La construction du nouvel Hôpital Royal peut commencer", December 18, 2004.
  248. Canadian Press (Helen Branswell). "Antidepressants May be Tied to More Suicide Tries". National press release, February 18, 2005.
  249. CBC News, "Antidepressants increase risk of suicidal behaviour" February 18, 2005.
  250. Globe and Mail article. "Antidepressants and Suicide" February 19, 2005.
  251. The Nature of Things (David Suzuki). Passion and Fury-The Emotional Brain. May 11 and 12, 2005. (Multiple broadcasts thereafter).
  252. TFO-TV Ontario "Moments anxieux II" Multipart documentary. Multiple broadcasts from November 5 to December 10, 2005.
  253. The Nature of Things (David Suzuki). Passion and Fury-The Emotional Brain. May 2006. (Multiple broadcasts).
  254. Radio Canada. Le monde selon Matthieu. Les Troubles Anxieux, August 10, 2007.
  255. TV-Rogers. Mosaique Francophone. 2008-2009. (Multiple Broadcasts)
  256. APTN TV Doctors get education in Indigenous culture. September 12, 2012.
  257. Globe and Mail, Canada. Interview "When fear holds you tightly in its grip" Martha Leung Article, October 30, 2012.
  258. Telequebec.tv. Emission: "Une pilule, petite granule", sujet: "le trouble panique". February 28, 2013.
  259. TFO TV. Emission Ruby "les troubles anxieux". February 24, 2014.
  260. Radio Canada Radio. Emission Carl Bernier, "l'anxiété". March 11, 2014.
  261. CFRA Radio. University of Ottawa welcomes new partners from Shanghai university to simulation centre. April 11, 2014.
  262. Globe and Mail uOttawa launches ground-breaking joint medical school with Shanghai Jiao Tong University. October 25, 2014
  263. La Presse L'Université d'Ottawa et l'Université Jiao-Tong de Shanghai inaugurent une nouvelle école de médecine. October 25, 2014
  264. Le Droit L'Université d'Ottawa et l'Université Jiao-Tong de Shanghai inaugurent une nouvelle école de médecine. October 25, 2014
  265. Hill Times uOttawa launches ground-breaking joint medical school with Shanghai Jiao Tong University (Web). October 25, 2014
  266. iPolitics uOttawa launches ground-breaking joint medical school with Shanghai Jiao Tong University (Web). October 25, 2014
  267. CMAJ Magazine uOttawa launches ground-breaking joint medical school with Shanghai Jiao Tong University. October 25, 2014
  268. Ottawa Citizen uOttawa launches ground-breaking joint medical school with Shanghai Jiao Tong University. October 25, 2014
  269. Ottawa Citizen Reevely: Research to be done, money to be made as Ottawa's medical brain trust heads out on trade mission to China. October 25, 2014
  270. Globe and Mail Norman Bethune's legacy endures as Canadian, Chinese medical schools partner up. October 25, 2014

271. [Le Devoir](#) Des médecins de famille chinois formés à la manière de l'Université d'Ottawa. [October 2014.](#)
272. [Radio-Canada](#) Une première formation en médecine de l'Université d'Ottawa en Chine. [October 2014.](#)
273. [La Presse](#) .La médecine canadienne exportée en Chine. [October 2014.](#)
274. [Radio-Canada](#) Pogramme conjoint d'études médicales Université d'Ottawa-Shanghai (Radio interview - Le midi trente). [October 2014.](#)
275. [Le Droit](#) Partenariat entre l'U d'o et une université chinoise. [October 2014.](#)
276. [CBC Ottawa](#) uOttawa medical partnership in China (Video). [October 2014.](#)
277. [Academica](#) uOttawa to launch first-in-China medical program. [October 2014.](#)
278. [Hong Kong Herald](#) Ottawa's medical brain trust goes on trade mission to China
279. [Xinming Weekly](#) 170-year-old Renji : Ancient and Modern. [October 2014.](#)
280. [Hong Kong Herald](#) Norman Bethune's legacy endures as Ottawa, China medical schools tie up. [October 2014.](#)
281. [People's Daily](#). Renji : "The Hospital Will go wherever the patients are"(Available in Chinese only). [October 2014.](#)
282. [China News](#). "Shanghai - Ottawa Joint Medicine School Launched," a fusion of Chinese and western medical training methods (Available in Chinese only). [October 2014.](#)
283. [Phoenix New Media](#) Shanghai - Ottawa Joint Medical School launched in Shanghai (Available in Chinese only). [October 2014.](#)
284. [Wenhui Daily](#). Shanghai - Ottawa Joint Medical School Launched (Available in Chinese only). [October 2014.](#)
285. [Shanghai TV News Comprehensive Channel](#) China - Canada cooperation to cultivate international medical talents: Shanghai - Ottawa Joint Medical School settled at Renji Hospital (Available in Chinese only). [October 2014.](#)
286. [Shanghai Daily](#) Medical school out to set new standards. [October 2014.](#)
287. [Jiefang Daily](#) Shanghai and Ottawa building a joint medical school (Available in Chinese only). [October 2014.](#)
288. [Shanghai Government](#) Shanghai - Ottawa Joint Medical School inaugurated at Renji Hospital (Available in Chinese only). [October 2014.](#)
289. [Shanghai Jiao Tong University of Medicine](#). Shanghai - Ottawa formally inaugurated the joint medical school (Available in Chinese only). [October 2014.](#)
290. [Tencent](#) 170<sup>th</sup> anniversary of the Shanghai Renji Hospital marks the establishment of the Shanghai-Ottawa Joint Medical School (Available in Chinese only). [October 2014.](#)
291. Brighter future for hearing disorder sufferers in city. [Shanghai Daily](#), May 25, 2017.